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Introduction
u
Blood coagulation n
Injury of the vascular endothelium is followed by a series of successive chemi-
cal and physical interactions resulting in the generation of thrombin at the site
of injury. Thrombin generation will finally lead to an increased platelet deposi-
tion and the formation of a stable haemostatic plug. This process has first been
described by MacFarlane in the "coagulation cascade" (l). The burst of enzymic
reactions is following two distinct routes: the intrinsic and the extrinsic pathway
(fig. 1). Formation of enzyme complexes on phospholipid surfaces is essential
for rapid delivery of products at the site of vascular injury (2). y-Carboxygluta-
mic acid (Gla) residues present in the amino terminal region of some coagulati-
on zymogens are a prerequisite in the Ca^-dependent interaction with negatively
charged phospholipid surfaces (3,4). These Gla-residues are formed during a
posttranslational modification, in which the enzyme y-glutamylcarboxylase and
vitamin K are of vital importance (5,6). The carboxylase is tightly bound to the
microsomal membranes. Its most important features, as well as the way in which
vitamin K fulfils its role as a coenzyme will be discussed below.
EXTRINSIC INTRINSIC
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History of vitamin K
More than 50 years ago the Danish scientist Henrik Dam discovered vitamin K
while measuring the effect of a cholesterol free diet on chickens (7). It turned
out that together with the cholesterol a second unknown fat soluble component
had been extracted, in the absence of which the animals developed haemorrha-
ges and their blood exhibited a prolonged coagulation time. This unknown factor
was identified as a fat soluble vitamin necessary for normal blood coagulation.
Therefore it was called "Koagulations vitamin", abbreviated as "Vitamin K".
Already in 1922 Schofield detected comparable bleeding symptoms in cattle on
feeding the animals improperly cured sweet clover hay (8). It is now known that
these symptoms were provoked by dicoumarol (9), a drug possessing vitamin K
antagonistic properties. These and related drugs are nowadays used both as
rodenticides, and for the treatment and prophylaxis of thrombo-embolic diseases.
In 1963 Hemker et al. (10) already suggested, that blood plasma of anticoagula-
ted patients contained abnormal coagulation factors. However, it lasted until
1974 before Gla was discovered and the real nature of the abnormality could be
elucidated.
Function of vitamin K
After protein biosynthesis secretory proteins undergo further post-translational
modifications, which in most cases are essential for their biological activity.
Subsequently they are transported via the Golgi apparatus and secreted into the
extra cellular environment (11). Nowadays many post-translational modifications
have been described in the literature (12). Examples are glycosylation, hydroxyla-
tion and disulphide bond formation and most of these reactions occur in the
rough endoplasmic reticulum of eukaryotic cells. Also v-glutamylcarboxylation,
subject of this thesis, belongs to this category.
Early theories had often postulated a general role for vitamin K in protein
biosynthesis, but until 1974 its only known function was being an essential
cofactor in the synthesis of the four vitamin K-dependent coagulation factors
prothrombin, factor VII, factor IX and factor X. In 1974 Stenflo et al. (5), Nel-
sestuen et al. (6) and Magnusson et al. (13) reported independently that vitamin K
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promotes a unique posttranslational modification of specific glutamic acid resi-
dues (Glu) into y-carboxyglutamic acid residues (Gla). During this conversion
an extra carboxyl group is introduced at the y-position of the glutamate residue
(fig. 2). The carboxylation reaction is catalysed by vitamin K-dependent y-
glutamylcarboxylase for which the requirements are the presence of reduced
vitamin K, COj, Oj and an appropriate protein precursor. Whereas during the
last two decades the mechanism of transcription and translation have been
elucidated to a molecular level in procaryotes as well as in eukaryotes, relatively
little is known about the mechanism and regulation of post-translational modifi-
cations. Especially because the enzymes involved are hydrophobic, membrane
bound proteins, their purification raises serious problems. Unfortunately this
holds also true for the enzymes involved in the carboxylation process, and only
recently y-glutamylcarboxylase has been purified to near homogeneity (14,15).
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Gla-containing proteins
Since vitamin K-dependent carboxylase has been found in almost all types of
eukaryotic cells (16), it was to be expected that a wide variety of Gla-containing
proteins would be discovered. Nevertheless, the number of well characterized
Gla-proteins has remained surprisingly low. They can be classified in three
groups:
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a. Gla-containing proteins in blood plasma
Gla was first discovered in prothrombin (5,6,13). At that time the high degree
of sequence similarity between prothrombin and the coagulation factors VII,
IX and X had already been established. As a logical consequence the latter
proteins were also subjected to Gla analysis and all appeared to contain 10-
12 Gla residues per molecule (17,18). Some years later three other Gla-con-
taining proteins in plasma were discovered on the basis of their similar
chemical properties (e.g. their absorption to and co-elution from insoluble
barium salts). The proteins involved were: Protein C (19), Protein S (20) and
Protein Z (21). The proteins C and S are known to play an important role in
the regulation of the blood coagulation process. Their function is to inac-
tivate the activated coagulation factors V and VIII by limited proteolytic
degradation (22,23). Although the function of protein Z has not yet been
elucidated there is some evidence that it mediates in the binding of thrombin
with phospholipid vesicles in a Ca^-independent way (24). All four classical
coagulation factors and the proteins C, S and Z are typical secretory glyco-
proteins with molecular masses ranging from 45,000 to 72,000 Da.
b. Gla-containing proteins in calcified tissues
Gla-containing proteins have been found in various calcified tissues such as
bone (25,26), dentin (27), renal stones (28), hardened atherosclerotic plaques (29)
and coral (30). Except for the two Gla-containing proteins in bone, these
proteins have not been well-characterized and their physiological function is
not known. Bone is the only extrahepatic tissue in which the products of
vitamin K-dependent carboxylation have been unequivocally characterized.
The proteins in question are matrix Gla-protein (MGP) and osteocalcin, also
known as bone Gla-protein (BGP). MGP was initially discovered in bone
(31), but its mRNA has now been detected in tissues varying as much as
lung, kidney and vessel wall (32). Hence it must be assumed that this protein
is expressed in all these tissues. Osteocalcin is the most abundant Gla-protein
in man. Its molecular mass is 5,700 Da. It is smaller than and does not share
substantial sequence similarity with the vitamin K-dependent coagulation
factors. It is exclusively synthesized by osteoblasts and odontoblasts and
after its secretion it is bound to the hydroxyapatite matrix of the bone. Des-
pite substantial knowledge of the bone Gla-proteins, their function remains
obscure. Initially it was thought that the coumarin induced bone abnormali-
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ties in human fetuses (33) and in young rats (34) were caused by the incom-
plete carboxylation of osteocalcin. Now these defects can also be explained
by assuming a role for MGP during early bone formation,
c. Other Gla-containing proteins
In spermatozoa (35), urine (36), lung surfactant (37), and snake (38) and snail
(39) venoms Gla-containing proteins have been found. Except for the snail
venom, which is a highly powerful neurotoxin (40) and which has been cha-
racterized to the level of aminoacid sequence, the proteins have not been
well-characterized and their physiological function is not known.
The vitamin K cycle
The active form of vitamin K during the carboxylase reaction is the hydroqui-
none (KHj). y-Glutamyl carboxylation is linked to a vitamin K epoxidase acti-
vity (41), which simultaneously converts vitamin KHj into vitamin K2,3-epoxide
(KO). In theory, the addition of COj to the y-carbon in a Glu-residue may occur
either via an activation of CO2 or via labilization of a y-hydrogen. Most eviden-
ce presently available supports a mechanism in which carboxylation proceeds by
the abstraction of the y-proton of the Glu-residue followed by a COj-attack at
the same position (42-44).
The role of vitamin K in this reaction is to act as a cofactor in the labilization of
the y-glutamyl hydrogen, either by an ion- (or radical-) mediated mechanism
(43,45). Although the carboxylase and epoxidase activities are not strictly coupled
(45-47), it is postulated that the same enzyme (carboxylase) is responsible for
both activities (48). It is also thought that the oxidation of KHj into KO by
molecular oxygen provides the energy required for the COj-fixation at the y-
position of a glutamate residue. Via two subsequent reduction steps KO may
then be recycled into KH2 (fig. 3).
The first step in the recycling of KO is the dithiol-dependent reduction of KO
into vitamin K-quinone (K) by the enzyme vitamin K epoxide reductase. The
cycle is completed by the reduction of K into KH2 which may be accomplished
by a dithiol-dependent as well as by an NADPH-dependent reductase. The
importance of this 'vitamin K-cycle' being operative in vivo may be demonstra-
ted by the fact that on a molar base the urinary Gla-excretion exceeds the dieta-
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ry intake of vitamin K 200-500 times. Since the intestinal absorption of dietary
vitamin K has been estimated to be 30-70% (li) each molecule of vitamin K
must be recycled many hundred (and probably several thousand) fold before it is
metabolized into inactive degradation products (49).
The enzymes operational in the vitamin K-cycle will be dealt with elsewhere.
NAD(P)H * H NAD(H)
dithiol-(SH),
dithiol-(SH) dithiol-S,
F/G. 3. TAe Wtamin K
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The carboxylase reaction
The cellular function of the enzyme y-glutamylcarboxylase has been mostly
studied using crude and partially purified microsomal liver preparations. In table
I the main properties are summarized.
An in vitro system for measuring vitamin K-dependent carboxylase activity was
developed by Esmon et al. in 1975 (66). Initial studies, performed in washed rat
liver microsomes (54,59,66,67), showed the possibility to incorporate '"COj into
endogenous precursor proteins. The incorporation was dependent on the presen-
ce of O2, vitamin K and HCO, and the system also required NAD(P)H and/or a
reduced pyridine nucleotide-generating system. This energy-generating system
seemed to be present in the postmicrosomal supernatant, but it was soon esta-
blished that it could simply be replaced by KHj (54,59). The carboxylase activity
was then extracted from the membrane by means of detergents or bile salts.
Initially Triton X-100 was frequently used (57,68), later it was replaced by 3-[(3-
cholamidopropyl)dimethyl-ammonio]-l-propane sulphonate (CHAPS) (69). The
solubilized system was shown to contain all activities necessary for carboxyla-
tion.
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Standard conditions
- Either phylloquinone (K,) or menaquinone (MK), both either in the presen-
ce of reducing agents (NAD(P)H or DTT) or in their hydroquinone form
- carboxylatable substrate (exogenous and/or endogenous).
Stimulating agents
- Mn* (50,51)
- DTT (52,53,54)
- (NHASO4 , (55)gyridoxal-5 -phosphate (52,56)
IMSO (51)
- ketones ' (51)
Inhibiting agents
- Chloro-K (2-Cl-3-phytyl-l,4-naphtoquinone) (57)
- coumarin derivates (58)
- 2,3,5,6-tetrachloro-4-pyridinol (TCP) (59, 60)
- CN" (47)
- sulfhydryl reagents (61, 62)
- peptide substrates analogs (63,64)
- naphtoquinones (65)
/or W/antin K-rfepe/K/enf cariojry/ase
Although the activity of carboxylase has been measured in the liver of a number
of species (70,71) vitamin K-dependent carboxylation has been studied most
extensively in microsomal preparations obtained from vitamin K-deficient or
warfarin-treated rats and from normal and warfarin- treated cows. During vita-
min K deficiency and during warfarin treatment the levels of the vitamin K-
dependent proteins in the plasma of the rat are decreased and endogenous pre-
cursor proteins accumulate in the liver (72). The hepatic microsomal fractions
thus prepared contain both carboxylase and an endogenous substrate (57,59,73). In
warfarin-treated cows, on the other hand, non-carboxylated coagulation factors
(descarboxy factors) appear in the blood plasma in concentrations similar to
those of the normal coagulation factors in untreated animals (10,74). Therefore it
was unexpected that warfarin treatment also caused an accumulation of endoge-
nous precursor proteins in bovine liver (75).
In solubilized microsomes the vitamin K- and Oj-requirement seems to be
higher than in intact microsomes. Concentrations used were mostly between 50-
500 uM for vitamin K. In intact microsomes K ^ values for Oj of 10-15 uM
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have been found (76) where in detergent-solubilized microsomes a K^'"" of 45
uM has been reported (49). Available data indicate that the active species in the
carboxylation reaction is COj and not HCO, (77). K ^ values for total
[COj/HCO, ] have been reported to be between 0.2 and 0.4 mM (77). Because
carboxylase is unstable at 37 °C, most studies were performed at temperatures of
20 °C or lower and at a pH of 7.2-7.4.
At this moment vitamin K-dependent carboxylase activity has been demonstrated
in many different tissues such as kidney (78-82), spleen (81-83), testes (82-84), lung
(81,83-85), pancreas (82,86), placenta (87,88), vessel wall (82), thyroid, thymus,
cartilage, tendon and uterus (82). Activity has also been shown to be present in a
wide variety of cultured cells (16,86,88,89) such as osteoblasts, hepatocytes, endo-
thelial cells and tumor cells of various origin.
Detection of Gla-residues
Since it is known that Gla is stable during alkaline hydrolysis, several methods
for its detection have been developed. Methods employed vary from a modified
aminoacid analysis described by Hauschka (90) to colorimetric methods (91),
gaschromatography (92) and mass-spectroscopy (93). Relatively simple procedures
have been developed which are based on high performance liquid chromatograp-
hy (HPLC) using anion exchange or reversed phase columns (94,95). Detection of
the amino acids is performed either by pre- or postcolumn derivatization using
ortho-phtalaldehyde (94) or phenylisothiocyanate (95). To verify whether the peak
eluting at the Gla-position is the correct one, parallel to the alkaline hydrolysis
acid hydrolysates of the same samples may be prepared. In the acid hydrolysates
the peak eluting at the Gla-position must be absent. By means of a specifically
incorporated radiolabel in the Gla-residues, the shift from the Gla- to the Glu-
position can also be checked (96).
Various forms of vitamin K
The two most important compounds found in nature having 'vitamin K activity'
are phylloquinone and the menaquinones. Active compounds all contain a
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naphtoquinone ring system substituted with a methyl group at position 2 and an
aliphatic side chain (R) of variable length at position 3 (fig. 4).
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In phylloquinone R is composed of 4 isoprenoid residues of which the first one
is unsaturated. In menaquinone R may vary from 1 to 13 residues, each contai-
ning one unsaturated bond. Phylloquinone (vitamin K,) is exclusively found in
green plants like spinach, kale, cabbage and broccoli. Also cows' milk contains
considerable amounts of phylloquinone, in concentrations between two and three
fold higher than those found in humans' milk (97). The phylloquinone content of
a wide range of products has been determined presently (98). Menaquinone (vita-
min Kj) is a group-name for a number of closely related products of microbial
origin. They are generally designated as MK-n, where n stands for the number
of isoprenoid residues in the aliphatic side chain. The hydrophobicity of the
various menaquinones strongly depends on their chain length, and will probably
influence the efficiency of their intestinal absorption, their transport and their
binding to carboxylase. Menaquinones occur in various (mainly fermented)
foods and also the bacterial flora in the colon produces significant amounts of
menaquinones, but the extent to which they are resorbed from the colon is still
subject of investigation.
Most data concerning dietary sources, intestinal absorption, plasma transport,
tissue concentrations, subcellular distribution and metabolism of vitamin K
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regard phylloquinone. The quantitation of menaquinones in food, plasma and
tissues has been a problem for many years and only recently detection techni-
ques are being developed which make their quantitation possible (99). The need
of a dietary supply of vitamin K has been demonstrated in most species, inclu-
ding man. Even a rather mild limitation of vitamin K-intake (no green vegeta-
bles) caused detectable alterations in some blood coagulation parameters after
three weeks, both in human volunteers (100) and in rats (101), in spite of the
menaquinones produced in the colon. Hence the physiological relevance of the
menaquinones is at least doubtful. However, recent evidence has demonstrated
that long chain menaquinones account for 80-95% of the total hepatic vitamin K
stores (99,101). Their origin, intracellular location and utilization for y-glutamyl-
carboxylation has still to be established. In vitro experiments have demonstrated
that like phylloquinone menaquinones may serve as a cofactor in the carboxyla-
se reaction, especially MK-3 and MK-4 (102,103). Because of the above mentio-
ned arguments it cannot be excluded that the hepatic menaquinone stores pre-
dominantly originate from the diet, and not from the intestinal flora. An elabo-
rate food analysis for menaquinones levels must be awaited to obtain more
conclusive support for this hypothesis.
Enzymes involved in the vitamin K cycle
Vitamin KO, formed during the carboxylation/epoxidase reaction, is recycled
into reduced vitamin K by the action of at least two reductases. KO and K
reductase require a dithiol as a cofactor; in vitro the synthetic product dithio-
threitol (DTT) is frequently used (104). In vivo a possible candidate to fulfil this
role is the dithiol protein thioredoxin (105). Thioredoxin abundantly occurs in
various subcellular fractions of calf liver, including nuclei, mitochondria and
microsomes (106). In vitro experiments demonstrated that the enzyme system
thioredoxin/thioredoxin reductase using NADPH as a cofactor, could replace
DTT during the reduction of KO and K (105). In a different assay system these
results were confirmed by Silverman & Nandi (107).
Two other enzymes require NAD(P)H as a reductant. One is the membrane-
bound NAD(P)H-dependent K reductase (108). This enzyme is relatively insensi-
tive to warfarin and during coumarin treatment it can utilize exogenous vitamin
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K to bypass the inhibited dithiol-dependent enzyme (109,110). Although unable to
complete the vitamin K cycle by itself, it is of vital importance in case of in-
toxication. This enzyme is membrane-bound and probably of more importance
than the other NAD(P)H-dependent reductase DT-diaphorase, an enzyme present
in both the microsomal fraction and the cytosol (60,108). It has been demonstra-
ted that DT-diaphorase is able to reduce vitamin K but the importance seems
questionable because of its low activity in the liver.
It has been well established that 4-hydroxy-coumarins inhibit the action of the
dithiol-dependent KO reductase (111-113). These drugs cause an accumulation of
KO in liver, thereby exhausting the supply of KHj and preventing further car-
boxylation events. Coumarins also inhibit the dithiol-dependent K reductase
(114,1 IS), but this enzyme may be bypassed by the NADH-dependent reductases
mentioned before (116). Therefore KO reductase is the most important chain in
the vitamin K cycle. The plasma accumulation of vitamin KO in humans on
anticoagulant treatment makes it plausible that indeed vitamin KO-reductase is
the target enzyme for warfarin. Recently direct evidence has been obtained for
the existence of a microsomal warfarin receptor with binding characteristics
specifically related to the activity of KO-reductase (117).
Whether or not the two microsomal DTT-dependent activities are generated by
the same protein is still a matter of debate, but the finding that the optimal
dithiol concentration (118) and the apparent Kj for warfarin (114) are closely
similar does not suggest the occurrence of two different dithiol-dependent reduc-
tases. Additionally Fasco et al. (114) brought up very strong arguments in favour
of only one reductase, since they found both enzymic activities to be decreased
in warfarin-resistant rats. The low probability of a genetic alteration affecting
two enzymes in a similar way argues against the presence of two different
enzymes.
Coumarin derivatives
The blockade of the vitamin K cycle by coumarins causes the hepatocellular
accumulation of coagulation factor precursors (descarboxyfactors).The extent to
which descarboxy-factors are excreted into the blood stream is species depen-
dent. The active compounds invariably act by inhibiting the dithiol-dependent
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reductases in the vitamin K cycle. In this way the recycling of vitamin K is
blocked and the supply of KH, is rapidly exhausted. Because only the dithiol-
dependent reductases are inhibited by coumarins, the blockade may be bypassed
by the administration of 10-125 mg/day of vitamin K, depending on the dose
and the kind of coumarin. Under these conditions all KHj formed by the action
of the NAD(P)H-dependent reductase can only be used once, leading to high
circulating KO levels in the plasma.
In 1974 a second generation of 4-hydroxycoumarins became available, which
are generally designated as 'super warfarins' (119). These compounds (difena-
coum, brodifacoum) are more hydrophobic than is warfarin, and they are charac-
terized by very long half-life times. Because of their extreme toxicity they are
only used as rodenticides, especially in areas where rats have become warfarin-
resistant (120). The production and application of these drugs include the risks of
accidents by human ingestion (121-123).
Several compounds, not being 4-hydroxycoumarins, have vitamin K-antagonistic
properties and have been shown to inhibit vitamin KO-reductase. These com-
pounds include salicylate (124-126), lapachol (127) and sulphaquinoxaline (128).
Substrate specificity
Most information available on the mechanism of substrate recognition has been
obtained via cDNA research. Initial attempts to find an amino acid sequence in
the Gla region of the vitamin K-dependent proteins, known at that time, were
not successful. It was demonstrated, however, that a peptide homologous with
amino acids 5 to 9 of bovine prothrombin could serve as a substrate in the
carboxylation reaction (129). The peptide in question, Phe-Leu-Glu-Glu-Val
(FLEEV) is one of the many low molecular-weight peptide substrates that have
been synthesised from that time (52,64,73,130). Because they are readily carboxy-
lated these pepides were useful as substrates in the carboxylation reaction, but
they all share the disadvantage of having a low affinity for the enzyme. K *^'"''
values reported were all in the millimolar range and it was demonstrated that
only the first of the two Glu residues was carboxylated (131,132). The same high
K^P values were found for high molecular weight proteins like decarboxylated
coagulation factors (55,136-138). The preparation of smaller protein substrates like
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decarboxylated osteocalcin (55) and descarboxyprothrombin fragment 13-29 (135)
indicated that some secondary or tertiary structure or some recognition site for
carboxylase could facilitate the carboxylation of these substrates.
All Gla-containing proteins are secretory proteins and need substantial post-
translational modification for full biological activity. They are synthesized in a
precursor form consisting of a signal sequence, a prosequence and the aminoacid
residues found in the mature protein. To enter the secretory pathway proteins
must be translocated into the endoplasmic reticulum membrane. Targeting to the
endoplasmic reticulum membrane occurs through the sequential actions of the
signal recognition particle (SRP) and its receptor (docking protein) (136). Shortly
after translocation the signal sequence is cleaved by a signal peptidase while the
propeptide stays attached to the mature protein probably until it reaches the
Golgi body (11). The presence of a propeptide in the Gla-containing proteins was
predicted from the cDNA clone of human factor IX by Kurachi and Davie (137).
Shortly afterwards Degen et al. demonstrated a propeptide after cloning human
prothrombin (138). By the proper alignment of these and other prosequences (139-
142) a substantial sequence homology was found indicating a possible important
role in y-carboxylation (see fig. 5).
-18 -10 -1 1 10 20 30 40
I I I I I I I I
h-PT HVFLAPCXJARSLLQRVRR-ANT-FLYYVRKGNLYRYCVYYTCSYYYAFTALYSSTATDVFW
b-PT HVFLAHQQASSLLQRARR-ANKGFLYYVRKGNLyRyCLYYPCSR-nAFYALYSLSATDAFW
h-FX SLFIRREQANNILARVTR-ANS-FLYYMKKGHLYRYCMYYTCSYYYARyVFYDSDKTNYFW
b-FX SVFLPRDQAHRVLQRARR-ANS-FLYYVKOGNLYRyCLYYACSLYYARYV-FYDAYQTDYFW
h-PC SVFSSSERAHQVLRIRKR-ANS-FLYYLRHSSLyRYCIYYlCDFYYAKYIFQNVDDTLAFW
F/G. 5. jY-ferm/na/ segue/ices in f/ie propeprides and Gto domains o/ some mamma/uin
vitamin K-rfependenf proteins. 77if se^Mewtrs are ;>j 7/ie one ta/er code, y stands /or G/a.
AoorenaH'ons are; n, numa/i; />, ftovi/ie; / T , pror/iromb/n; FX,/acror X; PC, profózn C
Additional data were obtained from the mutant forms of factor IX isolated from
patients suffering from haemophilia B (140,141,143-145). They were all shown to
be biological inactive and to have slightly higher molecular weights. Structural
analysis revealed that the propeptide was still attached and that a mutation had
occurred in the propeptide region. In all cases substitution had taken place in the
Arg-rich region near the cleavage site: Arg-4 —» Gin (141,143-145) and Arg-1 —> Ser
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(140). The importance of the propeptide was also demonstrated by the expression
of cDNA coding for human factor IX (146,147) and human protein C (148). When
expressed in heterologous mammalian cells the product showed a substantial
degree of carboxylation in both recombinant proteins. With the aid of site-spe-
cific mutagenesis it was subsequently shown that complete or partial removal of
the propeptide dramatically influenced carboxylation (148,149). Recently a rabbit
liver microsomal endopeptidase has been purified which cleaves synthetic pep-
tides that mimic the propeptide (150). Proteolytic cleavage was dependent on an
arginine residue at positions -4 and -1. Point mutations at position -16 (Phe —>
Ala) or -10 (Ala -» Glu) also severely affected the carboxylation of factor IX
(149). After synthesizing a 20-residue peptide homologous to the propeptide
region of human factor X, Knobloch & Suttie demonstrated that this peptide
stimulated the carboxylation of non-covalently linked small peptide substrates
(151). The stimulation was about 3-fold and these results were confirmed by
Ulrich et al. with a synthetic peptide homologous to the propeptide region of
human prothrombin (152). In the same paper these authors showed a further
improvement of the substrate by covalently binding it to the propeptide. A
synthetic peptide similar to the sequence -18 to +10 in human descarboxypro-
thrombin was characterized by a K ^ of 3.6 uM which is at least three orders
of magnitude lower than the synthetic peptides lacking the propeptide. These
results suggest that the propeptide plays a major role in the recognition of
substrates by carboxylase but at this moment it remains unclear whether other
sequences contribute to the regulation of carboxylation. It was proposed by Price
et al. (153) that also the highly conserved amino acid residues in the Gla-region
found in all known mammalian proteins may play a role in carboxylase recog-
nition. This sequence, Gla-X-X-X-Gla-X-Cys at the position +17 to +23 (see fig.
5), is also present in decarboxylated osteocalcin and descarboxyprothrombin
fragment 13-29, two low K „ ^ substrates lacking a prosequence (135,55). By the
same author it was suggested that the cysteine residue could be of importance
(153) during carboxylation, since carboxylase has been shown to contain an
essential thiol group (154).
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Introduction to this thesis
Since the discovery of y-carboxyglutamic acid (Gla) in 1974, the metabolic role
of vitamin K and its function in the carboxylation process has been subject of
many investigations. The involvement of the enzyme y-glutamylcarboxylase in
the formation of Gla-residues made it necessary to purify the enzymee for
proper analysis. However, purification of the enzyme has met with extreme
difficulties which make many details of the carboxylation reaction still to be
elucidated. Vitamin K-dependent carboxylase, an enzyme having all characteris-
tics of an integral membrane protein and located at the luminal side of the rough
endoplasmic reticulum, has been found in a wide variety of tissues. Although
initially blood coagulation seemed to be the only physiologically important
interest of y-carboxylation, Gla-containing proteins have been detected in many
other, non hepatic tissues and it is still a matter of debate which functions these
non-hepatic Gla-proteins might have. The discovery of the new proteins has
expanded the role of vitamin K and indicated the need to re-examine required
dietary vitamin K intake aside from its traditional role in blood coagulation.
Sensitive methods to detect Gla and vitamin K have become available during
recent years and will facilitate further research. The discovery of the propeptide
and its role in substrate recognition finally lead to the purification of carboxyla-
se to homogeneity. It should be considered, however, that the technique for this
purification could only be developed on the basis of data obtained in 15 years of
research performed by groups from the USA and Europe.
The work presented in this thesis started in 1975, the same year in which the
first carboxylating systems had been developed, and it ends with the complete
purification of the enzyme. This thesis describes the contribution of the Maas-
tricht vitamin K group in the discoveries leading to that success.
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CHAPTER 2
Methods for the preparation of artificial
Prothrombin and factor X reagents and improved
separation of descarboxy and normal coagulation
factors by HPLC
Based on:
- Vermeer, C , Soute, B.A.M., and Hemker, H.C. (1977). A new method for the
preparation of artificial factor II reagents from normal human and bovine
plasma. Thromb. Res. 10, 495-507.
- Vermeer, C , Soute, B.A.M., and Hemker, H.C. (1978). Improvements of the
method for the preparation of an artificial prothrombin reagent. Thromb. Res.
12, 713-716.
- Vermeer, C , Soute, B.A.M., and Hemker, H.C. (1979). A coagulation reagent
completely devoid of factor X: relation between clotting time and concentra-
tion of factor X. Thromb. Res. 14, 679-685.
- Soute, B.A.M., de Boer-van den Berg, M.A.G., and Vermeer, C. (1984). The
separation of bovine prothrombin and descarboxyprothrombin by HPLC.
Anal. Biochem. 137, 227-229.
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Historical background
In vivo there are two ways to retard the vitamin K-dependent carboxylation of
proteins. Firstly, a reduced nutritial intake of vitamin K will lead to the exhaus-
tion of the total body stores, and to the subsequent slowing down of all hepatic
and extrahepatic carboxylation reactions. Secondly, the recycling of vitamin K
may be blocked by the administration of coumarin derivatives. In both cases
non-carboxylated precursors of the Gla-containing proteins will accumulate in
the RER of a wide variety of cells (1). In a later stage these proteins are also
secreted into the extracellular environment, where they are known as descarboxy
proteins. Initially, it was thought that the endoplasmic precursor proteins were
similar to the circulating descarboxy proteins, but in the early '80s it became
clear that the endoplasmic precursors contain a "pro"-sequence directly prece-
ding the N-terminus of the mature protein. This pro-sequence is composed of 18
amino acids with a high degree of similarity for all Gla-containing proteins, and
it plays a major role in the substrate recognition by y-glutamylcarboxylase (2-4).
When we started our investigations on vitamin K-dependent carboxylase in 1976
there were two logical ways to set up an in vitro system in which the posttrans-
lational carboxylation reaction could be investigated:
a. From vitamin K-deficient rats a cell-free microsomal liver system had been
described by Esmon et al. (5), who used the accumulated endoplasmic precur-
sor proteins (mainly prothrombin and related coagulation factor precursors) as
a substrate for carboxylase. The system was absolutely dependent on vitamin
K, whereas NaH'^CO, could serve as a COj donor. By using the radiolabeled
CO;, the progress of the carboxylation reaction could be followed in time. An
additional advantage was that the bulk of the radiolabeled bicarbonate was
rapidly removed from the solution by adding trichloroacetic acid.
b. Methods had been developed for the purification of descarboxy prothrombin
and descarboxy factor X from the plasma of coumarin-treated cows. At that
time it seemed plausible that these purified proteins could serve as well
characterized substrates for carboxylase. The procoagulant activity of the
descarboxyfactors is extremely low, but it was thought that the carboxylation
reaction would convert them into normal coagulation factors, with at least
substantially improved procoagulant activity. Hence the progress of the Gla
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formation should be measurable as the generation of prothrombin and factor
X activity estimated by means of a coagulation assay.
For several reasons (one being the long history in blood coagulation of Hem-
ker's group) we decided to start by exploring the second line. New procedures
were developed for preparing one-stage prothrombin and factor X reagents,
which were essentially free of any prothrombin and factor X, respectively. With
these reagents the detection limit for both coagulation factors was decreased
several orders of magnitude. However, incubation of the descarboxy proteins
with bovine liver microsomes, vitamin K and COj did not lead to the generation
of 'normal' coagulation factors. Lateron it became clear that the failure of this
system was due to the absence of a pro-sequence in the descarboxy factors, and
that the descarboxy factors as such are very poor substrates for carboxylase (2,3).
Hence we changed to the system mentioned under a. Yet some positive outco-
mes of the initial period can be mentioned: i) two new coagulation factor rea-
gents had been developed which were superior to any of the existing ones, and
ii) with these reagents the coagulation kinetics initially worked out by Hemker
et al. (6) could be proven (7). Presently, chromogenic substrates provide more
sophisticated methods for measuring coagulation factor activity (8), but since the
one-stage coagulation assays are relatively simple and quick, they are still often
used in our lab and elsewhere.
Finally we were the first to demonstrate that normal and descarboxy prothrom-
bin could be separated by ion exchange chromatography. Obviously this was to
be expected on the basis of their different charge, but until the introduction of
high performance liquid chromatography (HPLC) the differences were too small
to form a basis for their chromatographic separation.
As a practical guide the preparation procedures of prothrombin and factor X
reagents and their charcterization as well as an HPLC-method for the separation
of bovine prothrombin and descarboxyprothrombin are summarized below.
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New methods for the preparation of artificial
prothrombin and factor X reagents: relation
between coagulation time and concentration
Introduction
For the determination of prothrombin generally two procedures are used:
a. The one-stage assay in which prothrombin deficient plasma and thromboplas-
tin constitute a medium in which all factors are present in excess, except
prothrombin. The prothrombin content of the sample added is rate limiting.
The clotting time upon recalcification thus indicates the prothrombin level (9).
b. The two-stage assay in which first the prothrombin present in the sample is
converted into thrombin. In a second stage the sample's thrombin content is
assessed by measuring the clotting time with a suitable source of fibrinogen
(10).
The disadvantage of the first method is that both artificial and congenital
prothrombin deficient plasmas usually contain residual amounts of prothrombin
which, in the absence of added piothrombin, are responsible for a rather short
coagulation time (the "buffer time", which is generally 50-90 s). Consequently
low prothrombin concentrations are difficult to assess. The two-stage method,
although more elaborate than the one-stage assay, is especially useful in the
determination of more or less purified prothrombin preparations. In plasma and
plasma dilutions, however, the assay is hampered by the presence of thrombin
inhibitors such as antithrombin III, which necessitates evaluation of the time-
course of thrombin generation and degradation (11,12).
An artificial prothrombin and factor X reagent was composed by supplementing
oxalate plasma with a concentrated solution, containing either factor VII and X
or prothrombin and factor VII. From the oxalate plasma all vitamin K-dependent
coagulation factors were first removed by adsorption with BaSC), and Al(OH),.
To this plasma then either a factor VII/X concentrate or a prothrombin/factor
VII concentrate was added. The factor VII/X concentrate was prepared from
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citrate plasma by activating prothrombin with Echis carinatus venom. After
removal of the clot the factors VII and X were isolated by adsorption on DEAE
Sephadex and subsequent elution. The prothrombin/factor VII concentrate,
required for the factor X reagent was prepared by purification of these factors
on DEAE Sephadex. •••••* ur.
In this way plasmas artificially deficient in either prothrombin (prothrombin
reagent) or factor X (factor X reagent) could be prepared (13,14). The resulting
reagents contained all coagulation factors of the extrinsic pathway in sufficient
amounts, except the factors to be tested. It was shown that no clot formation
occurred in a mixture in which prothrombin was completely absent and on
theoretical grounds neither should clot formation occur in a mixture deficient in
factor X. It was found, however, that all factor X-deficient plasma tested or
described so far would form a clot in the presence of calcium and thromboplas-
tin. This raised the question whether either trace amounts of factor X are diffi-
cult to remove, or other enzymes (c.q. coagulation factors) are able to shortcut
or bypass the factor X-dependent step. To solve this question the last traces of
factor X were removed from both the X-deficient reagent and thromboplastin
with solid-phase antifactor X. With the factor X-deficient coagulation system
thus prepared, a better insight was obtained in the relation between coagulation
time and factor X concentration.
The bovine prothrombin reagent
recovery o//actors VJ7 and X. It was shown that using oxalate
plasma for the preparation of the factor VII/X concentrate, reduced the recovery
of factor X. The most probable reason for this phenomenon is the partial adsorp-
tion of factor VII and X to the calcium oxalate, formed during the collection of
blood and after recalcification of the plasma (15). Therefore citrate plasma
should be used for the production of the factor VII/X concentrate.
77ie amou/i/ o/ £C/HS carina/us venom to Ae adrfed. Although the concentra-
tion of unreacted prothrombin was below the detection range it still impaired the
properties of the reagent (a buffer time of 5-15 min was observed). These last
traces of prothrombin were removed from the dialysed factor VII/X concentrate
by repeating the Echis carinatus treatment, followed by DEAE-Sephadex adsorp-
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tion and elution.
to/nova/ o/ anftï/trom6tri ƒ/ƒ. The BaSCVadsorbed plasma still contained
thrombin inhibitors, the major part of which consists of antithrombin III. As was
published earlier (6), a rectilinear curve should be obtained when the clotting
time is plotted against the dilution of clotting factor (t-D plot). However, the
presence of thrombin inhibitors caused longer coagulation times than expected,
especially at prothrombin concentrations lower than 3.10' U/ml. In the range
between 10' and 3.10""' U/ml hardly any deviation could be detected. Since
Al(OH), is known to bind antithrombin III (16), it was used to efficiently remove
the antithrombin activity from the BaSCVadsorbed plasma (5% w/v). The
prothrombin reagent prepared with this plasma was compared to the normal
reagent. This is shown in fig. 1. When plasma, adsorbed with both BaSC^ and
Al(OH), was used for preparing the prothrombin reagent the t-D plot was recti-
linear, whereas the reagent from plasma, adsorbed with only BaSO^ resulted in
a curved t-D plot notably at very low concentrations of prothrombin.
F/G. / . /te/erence curves o/ varying
raige/ifs. BaSO.,- adsorbed
(.see re.rrj was absorbed w/7/i
. 77ie p/flima to/ore f O - O j
/ j reamie/j/ ( • - • ) was
/o prepare a pro//ircwiton reagen/
Dilution factor of reference plasma (fold)
o/ ffo /vof/irom&in raigenf. Before freezing of the reagent,
the factors VII en X had been added in amounts of 2.5 and 1 U/ml, respectively.
The activity of these factors decreased substantially after freezing and thawing,
which should be taken into account when the reagent is composed. Up to very
low prothrombin concentrations a linear relationship existed between the coagu-
lation time and the dilution of the reference plasma. When the reference plasma
38
was replaced by a prothrombin preparation, purified according to ref. 17', very
short coagulation times were measured at high prothrombin concentrations. The
coagulation time of a sample containing 2 U/ml of prothrombin for instance,
was found to be 11.7 sec. showing that the reagent contained all other coagula-
tion factors in sufficient amounts (fig. 2). The prothrombin concentration of 0
U/ml in the reagents was concluded from the buffer time (more than 15 hours)
and from computer calculations as described in refs. 12 and 18. The samples
containing prothrombin were prepared by diluting reference plasma. Experiments
in which factor VII was tested with either bovine or human thromboplastin as
described by Hemker et al. (19) indicated that, by freezing, the activated fraction
of bovine factor VII had lost its activity. The partial activation of factor VII
could not be prevented by the omission of CaClj. Moreover, without CaClj the
prothrombin was removed less efficiently.
0 MO 1200 1800 2400
Dilution factor of reference plasma (fold)
F/G. 2. /-Z) /»/o< o/ Me re/iercnce curves
/or èovine /wof/iroméi/i in </ie coagiita/jo/i
assay.
• - • mige/;/ fl
O-O reagenr S /o w/i/c/i J./O"" I///n/ o/
Aas freen
77te />re/?arafio/j o//actor ƒƒ re/ierence curves. With the prothrombin reagent
prothrombin was tested in varying dilutions of bovine normal pool plasma.
When the coagulation time was plotted against the prothrombin concentration, a
convex curve (fig. 3) was obtained on double logarithmic scale (log C/log t
plot). Addition of small amounts of prothrombin to the reagent restored the
sigmoid shape, which is usual for reference curves of coagulation factors. Ob-
viously, the convex form of the curve was due to the fact that the prothrombin
Purified bovine factor II was kindly provided by Mrs. J.Govers-Riemslag.
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reagent was absolutely free of prothrombin: at very high dilutions of the referen-
ce plasma the prothrombin concentration in the coagulation mixture becomes
negligible and infinite clotting times were obtained. As was proposed by Hem-
ker et al. in 1965 (6) the quasi-linearity of a log-C log t plot is based on the
coincidence that most reagents are non-ideal, i.e. they contain traces of the
coagulation factor to be tested. In the case of the newly prepared prothrombin
reagent, which was not believed to contain even trace amounts of prothrombin,
the relation between coagulation time and prothrombin concentration could be
studied directly. The results obtained seem to support the hypothesis that a
linear relationship exists between the coagulation time and the inverse of the
prothrombin concentration (7,20). In a similar way as was described for the
bovine system, a reagent was prepared from normal human pooled plasma,
which had the same characteristics as the bovine reagent.
F/G. 3. DouWe-/og p/o/ o/ fne re/erence cur-
ves /or èovine /actor / / in Me coagulation
assay.
• - • reage/i/ B
O - O raj#e/i/ B /o w/iit7i 5. /CH [// m/ o/
pro//irawjfc/>i /ws fceen
ftw/fer //'me o/ reagen/ B
5. 70'"" (// m/ o/
0.1 1.0
Prothrombin (%)
The bovine factor X reagent
Separation of prothrombin and the coagulation factors VII and X on DEAE
Sephadex, resulted in the elution of prothrombin and factor VII at about 200
mM NaCl and factor X at 350 mM NaCl (fig. 4a). Nevertheless, the prothrom-
bin/factor VII concentrate (pooled as indicated) was not free from factor X ac-
tivity. This became clear after the concentrate had been added to
BaSCyAKOhOj-adsorbed plasma. The resulting factor X reagent showed a
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buffer time of 121 seconds, indicating that still 8.10"* U/ml factor X were pre-
sent in the reagent. Because the addition of small amounts of antifactor X resul-
ted in very long buffer times, it seemed clear that the buffer time of the reagent
was caused by contaminating factor X. Therefore the prothrombin/factor VII
concentrate was rechromatographed on DEAE Sephadex which resulted in the
separation of a small amount of factor X from prothrombin and factor VII (fig.
4b).
0 300
EFFLUENT VOLUME (ml)
F/G. 4. Separa/ion o//actors 77 ( • - • ) , V//
(O-Oj a/id A" (* -*) on D£4E Sepfaufex
A; 77ie SaSO^-e/uafe was adsorbed baftn-
wwe to D£4£ Sepftattet, ap/>/;'«/ to a
co/wmn W/H'C/I was e/wfed w/r/i a /inear
sa// gradien/. Frac/tons con/ai/iing /ac-
tors // ana" V7/ were poo/ed as indica-
ted and diaAysed aga/nsf ftwjffer C.
B: 77ie d/a/yred /attor //-V// /jreparar/o«
was app/ied to a D£A£ 5ep/iad« co-
/umn and c/iro/nato^rap/ied ar s/wjj'/ar
cond(V/o/is as descr/Aea' /n ƒ;#. 5A.
Fratr/ons con/a/w/'w^ /atrors // and V7/
were poo/ed as indicated and d/a/ysed
agains/ 0./5 M NaC/. For /Mtt/ier de-
/a/7s, see fej:/
If the prothrombin/factor VII concentrate thus obtained was used for the prepa-
ration of a factor X reagent, the buffer time was prolonged further (210 seconds)
but still factor X (4.10'' U/ml) was present in our coagulation system. In prin-
ciple the contaminating factor X might be present either in the prothrombin/fac-
tor VII concentrate, in the BaSO4/Al(OH),-adsorbed plasma, or in the throm-
boplastin used. To find the origin of the residual factor X, each of these com-
ponents was filtered separately through columns containing Sepharose-bound
antifactor X. Factor X reagents were constituted and the buffer times of com-
binations of antifactor X-treated and non-treated components were compared
(table I). It is clear that factor X is present in all three components, but mainly
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in BaSCyAKOH^-adsorbed plasma and thromboplastin. Therefore, the factor X
reagent and the thromboplastin were separately filtered through antifactor X-
Sepharose columns immediately before use and a t-D plot was constructed of a
number of plasma dilutions. As is shown in fig. 5, a straight line was obtained.
The interception with the abscissa (D=0) represents the minimal clotting time
and has the same value as that obtained with a prothrombin reagent (22 se-
conds). However, the slope of the factor X dilution curve was found to be ten
times smaller than that of the prothrombin curve. This explains why a small
amount of factor X will induce a rather short coagulation time, whereas the
same amount of prothrombin will fall below the detection limit.
Components treated
with antifactor-X
Sepharose
none
A
B
A B
A B
C
C
Components non-
treated with antifac-
tor-X Sepharose
A B
B
A
A B
none
C
C
c
c
Buffer time (s)
210
232
411
339
241
> 3600
Factor X left
(U/ml)
4.10"
3.10"
1.10"
2.10"
3.10"
< 2.10'
/. 77ie *KjQfer /ime o/ various /actor .Y reagents. £/7ner /ac/or //,V7/ concen/rafe f/4), or
fiaSO</y4/(CW,),-adsorbed p/asma Co), or r/iromoop/air//i (C) were /i/fered r/iroMgn anf//at7or
X-Sep/iarow (.o/wmn.s. Fat7or X reagent were prepared /rom /rea/ed or /ion-/rea/ed compo-
nent (71 and B,) and i«ed wi7/i rnrom/?op/a.sfin in //ie
1000 SCt» 500Ö Ï2SÖ0
Dilution factor reference plasma (fold)
F/G. 5. f-D pto/x o//actor X ( • - • ) am/
pro/nromèin (O—O).
Norma/ poo/ed p/aima was di/ufed wi7/i OM/-
/er (28.6 mM sod/wm ace/a/e, 2S.6 wiM sodi-
Mm fear/j/7«rafe, 7/6 mAf /VaC/, pW 7.4) and
fes/ed WI7/I /ac/or X reagenf and prof/iromöi/i
reagenr
42
Discussion
With the aid of Echis carinatus venom a prothrombin reagent was prepared
which did not contain any detectable prothrombin. The method differs from that
described by Koller et al. (9) in the serum preparation procedure. In the classical
method, whole blood is collected in thromboplastin, and at least all factors of
the extrinsic pathway are activated before prothrombin is converted into throm-
bin. We were never able to activate prothrombin completely and the best reagent
which was obtained contained 5.10"^  U/ml of prothrombin.
In this paper a method is described to convert all prothrombin enzymatically
into thrombin with only a moderate activation of the other factors. The method
is fit for the bovine as well as for the human system. Reasons why these rea-
gents are better than those prepared according to the classical procedures, are:
1. The classical reagents contain at least 5.10'U/ml (and usually 10"^  - 2.10"^ )
of prothrombin whereas the bovine reagent and the human reagent contained
0 and 10 * U/ml of prothrombin, respectively.
2. The factors I, V, VII and X may be added to the reagents in higher concen-
trations as compared to the classical ones. It should be noticed however, that
an excess of factors VII and X should be added because these factors are
partly lost during freezing of the reagent.
3. Since t-D plots of the reference curves are rectilinear, at least between all
prothrombin concentrations measured (10' - 4.10" U/ml ), the position of the
reference curves may be determined more accurately.
The hypothesis was proven to be correct in three cases: the one-stage determi-
nation of human and bovine prothrombin and that of bovine factor X. Secondly,
also a factor X reagent that was prepared completely devoid of factor X. The
fact that it was nearly impossible to reduce the buffer time by conventional
means raised the question whether a factor X-independent pathway exists in
coagulation. To exclude this possibility trace amounts of factor X were rigorous-
ly removed from the factor X reagent as well as from thromboplastin. Upon
recalcification, no signs of clot formation were observed in mixtures of the
factor X reagent and thromboplastin thus prepared. It was used to establish the
relationship between coagulation time and factor X concentration. It turned out
that, as a consequence of the ten times smaller slope of the factor X dilution
curve compared to that of prothrombin, small amounts of factor X will induce a
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rather short coagulation time, whereas the same amount of prothrombin rapidly
falls below the detection limit. For the same reason small contaminations of the
coagulation factor to be tested in the reagent or in thromboplastin will cause
considerable deviations in the factor X curve and none in the prothrombin curve.
These findings have been confirmed in systems containing purified coagulation
factors and phospholipid vesicles composed of phosphatidylcholine and phosp-
hatidylserine: in these systems it was found that at plasma concentrations of
prothrombin and factor X (1.4 and 0.17 umol/ 1), dissociation constants for the
protein-membrane interactions were 1.04 pmol/1 for prothrombin an 0.19 umol/1
for factor X respectively (19-23).
The reference curves presented in this paper strongly support the hypothesis that
a linear relationship exists between the coagulation time and the inverse concen-
tration of the coagulation factor and that the sigmoid form of the usual reference
curves is caused by the presence in the reagent of a residual amount of the
coagulation factor to be tested (20, 6, 7).
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The separation of bovine prothrombin and <-n«-
descarboxyprothrombin by high performance
liquid chromatography
Introduction
Vitamin K is required as a coenzyme for the post-translational carboxylation of
certain glutamic acid residues in proteins (1). The first protein found to be vita-
min K-dependent was prothrombin (24), and it could be demonstrated that in the
absence of vitamin K or in the presence of vitamin K antagonists (warfarin,
dicoumarol, etc.) descarboxyprothrombin is set free in the blood (25). Since each
y-carboxy-glumatic acid (Gla) residue contains an additional negative charge, it
might be expected that normal prothrombin (containing 10 Gla residues) can be
readily separated from its descarboxy form. It turned out, however, that in the
absence of divalent metal ions the electrophoretic mobility of both molecules are
closely similar. Only in the presence of Ca"*, prothrombin (which strongly binds
Ca^ *) is retarded whereas descarboxyprothrombin (which has a low affinity for
Ca**") is not (26-28). Therefore, the detection of descarboxyprothrombin requires a
two-dimensional electrophoresis technique, during which Ca^ * is present in the
first run and antibodies against prothrombin are present in the second dimension
(26). With this technique the analysis of a plasma sample usually takes 24 h,
which in many cases may be considered as too long. Moreover, it is a qualitati-
ve and not a quantitative method to detect descarboxyprothrombin. The concen-
tration of descarboxyprothrombin is generally estimated from the difference
between the concentration of prothrombin plus descarboxy-prothrombin and that
of prothrombin alone. The total amount of prothrombin-like material is measu-
red by converting it to thrombin with Echis carinatus venom (13). Prothrombin
alone is quantified with a coagulation assay (29). Obviously this is an indirect
test for descarboxyprothrombin and since plasma contains a number of proteins
(antithrombin III, descarboxyfactor X, etc.) which are known to inhibit these
coagulation assays, the accuracy of this method is low.
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HPLC analysis H o •*-{?•
Samples (100 ui) were analyzed with an LKB 2150 liquid chromatograph on a
Pharmacia Mono Q anion-exchange column. After the samples had been applied
to the column the adsorbed proteins were eluted with a linear gradient from 0.1
to 0.5 M NaCl in 20 mM Tris-HCl, pH 7.4. The effluent was recorded at 280
nm with an LKB 2158 Uvicord SD and fractions were collected with the aid of
the LKB 2211 SuperRac. The flow rate was 1 ml/min in all cases.
Results and discussion
For more than 15 years electrophoresis in the presence of Ca^ * has been the only
analytical technique by which prothrombin and descarboxyprothrombin could be
separated. Why Ca"* is required for this separation has always remained obscure.
Bivalent metal ions are unwanted in many cases because they induce a rapid
activation of the clotting factors.
F/G. <ï. £/ufJOR o/ pun/ïerf proteins.
in (A V.5 (/) and descar/jo.ryp-
ffl, 7.5 £/,) were arfsorfted Jo
r/ie Mono Q an/on-excna/ige co/um/i and
WM^O" w/r/i a //near ia/f grad/enr. 77ie
pea/t /ratr/ons were co//ected and
wif/i f/ie £cA/f car/na/us assay
souarei^ and WI7/I r/ie one-s/a^e pror-
nromo/n assay (open souares). C, c/o///n^
o/ f/ie /ratf/ons oo/a/ned /n /4; D,
acf/v/ry o/ f/ie /rac7/oni oofa/ned
/n B. Furr/ier de/a//i are descr/bed /n fte
rex/
We have tried, therefore, to separate the two proteins using a different techni-
que: high performance liquid chromatography (HPLC). In a first set of experi-
ments we measured the elution times of purified prothrombin (Fig. 6A) and
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descarboxyprothrombin (Fig. 6B). Prothrombin was eluted after 12.79 min (0.35
M NaCl) and descarboxyprothrombin after 10.56 min (0.29 M NaCl). The peaks
were collected and analyzed for prothrombin activity with the one-stage coagula-
tion assay and with the Echis carinatus assay (Fig. 6C and D). The recovery was
96% for prothrombin and 98% for descarboxyprothrombin. When the two pre-
parations were mixed, the elution time of each component remained unchanged
(Figs. 7A and C) and the recovery was 98% for both proteins. Finally, we
injected 100-ul samples of full plasma from a warfarin-treated cow. Before
injection this plasma contained 0.2 U/ml of prothrombin and 0.7 U/ml of descar-
boxy-prothrombin. Fractions of 0.5 ml were collected and analyzed as before
(Figs. 7B and D). Again the elution times of prothrombin and descarboxyp-
rothrombin remained unchanged and the recovery of these proteins was 95 and
98%, respectively.
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fa'a" ;n F;g. 7. Ö and D, ana/y.si.s o/
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in //ie o/ie-i
a«d 0.9 [///n/ I/I r/ie £cA/f
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iame sy/noo/5 ai in yï^. 6
These experiments demonstrate that prothrombin and descarboxyprothrombin
can be separated in the absence of Ca*\ The two proteins could be recovered at
nearly 100% from purified mixtures, but also from full plasma which was ap-
plied directly to the column. Therefore, this technique might be a helpful tool
for the screening of patients under anticoagulant therapy. When used for this
purpose, some minor adaptations (such as delipidation of the plasma) might be
required. In order to prevent obstruction of the column it may also be advisable
to dilute the plasma samples before use.
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Introduction 51 '
During the last 15 years many attempts have been made to purify vitamin K-
dependent carboxylase. The enzyme is located in the RER (1), and behaves as a
typical integral membrane protein, which probably is the reason why the purifi-
cation proved to be a difficult job. Although substantial amounts of work were
directed towards the understanding of its mechanism of action, the lack of
purified carboxylase preparations has often been an impediment to draw definite
conclusions. It was only recently that the enzyme has been purified to near
homogeneity (2,3) and that it even has been cloned (4). The strategies for purifi-
cation that have been employed during these years are summarized below.
a. Canfield et al.(5) developed a method with which they obtained a 150-fold
increase of specific carboxylase activity. The relatively high purification
factor was mainly due to the removal of an inhibitor in the microsomal pro-
teins in a rat system. The preparation thus obtained did not contain reductase
activity.
b. With ion exchange and size exclusion column chromatography, using CHAPS
as a detergent to solubilize the microsomes, Girardot described a method in
which a 400-fold purification was reported (6). The preparation had a M, less
than 350,000 Da, still contained an endogenous substrate for carboxylase, but
reductase activity was lost during purification.
c. With the aid of sepharose-bound antibodies against normal factor X, enzyme-
substrate complexes had been obtained, extracted from detergent-solubilized
microsomes (7). The procedure is based on the use of livers from warfarin-
treated animals. Microsomes thus obtained contain substantial amounts of
non-carboxylated precursors of blood coagulation factors (mainly factor X),
which accumulate during warfarin treatment, and at least part of which are
firmly cotnplexed to carboxylase. With this method a 100-fold purification
could be obtained. The resulting product remained strongly bound to the
sepharose beads and was therefore called "solid-phase carboxylase". Attempts
to elute the carboxylase from the sepharose in the bovine system have not
been successful, but Harbeck et al. (8) reported a method in a rat system in
which they were able to elute the carboxylase from an anti-prothrombin
antibody column with a synthetic propeptide. In this case the purification
achieved was 500-fold.
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d. Salt-washed microsomes from normal cow liver were used to obtain partly
purified carboxylase (9). This was accomplished by differential detergent
extraction followed by (NH^SC^ fractionation and gelpermeation chroma-
tography. By this procedure the enzymatic activity, expressed per mg of
protein, was increased up to 100 fold. The final product resulted in a tight
complex of at least 7 proteins and required very low detergent concentrations
for maximal activity. Sepharose-bound polyclonal antibodies raised against
the partly purified carboxylase have been used to prepare a solid-phase car-
boxylase. By incubating the sepharose-bound antibodies with detergent-solu-
bilized microsomes from normal bovine liver, a substrate-free solid-phase
enzyme system could be obtained. This complex is different from that men-
tioned under c) in its ability to carboxylate not only the pentapeptide FLEEL
but also large exogenous protein substrates like decarboxylated prothrombin
and factor X.
e. The propeptide consensus sequence preceding the amino terminus of the
vitamin K-dependent proteins, suggested by Pan and Price to be a recognition
site for carboxylase (10), was used for the development of an affinity proce-
dure leading to the purification of the vitamin K-dependent carboxylase to
near homogeneity (2) and even to homogeneity (3). By the first procedure a
7000-fold purification of carboxylase was obtained with an apparent M, found
by reducing SDS page gel electrophoresis of 94,000 Da. The second proce-
dure resulted in a purification of 350,000 fold and an apparent M, of 98,000
Da.
Although detailed mechanistic studies and physical characterization of the en-
zyme can only be reliably performed with the purified enzyme, numerous stu-
dies with the crude and partly purified carboxylase have yielded important
information about its properties and mode of action. Actually it turned out that
part of this knowledge was even essential for the successful strategy leading to
the purification of vitamin K-dependent carboxylase to homogeneity. Most of
the work presented in this thesis was performed with non-purified material,
notably with carboxylase preparations mentioned under c) and d). In this chapter
some detailed studies will be discussed in which attempts were made to improve
the specific activity of the enzyme, either by removing contaminating proteins or
by increasing the rate of the carboxylation events.
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Stimulation of the vitamin K-dependent carboxylase from bovine
liver by organic solvents
Research on the vitamin K-dependent carboxylation have mostly been performed
with liver microsomal fractions of anticoagulated or vitamin K-deficient rats. In
our group, however, vitamin K-dependent carboxylase from both non-treated and
anticoagulated cows has been used for most studies (li). The enzyme is mainly
found in the microsomal fraction from which it is readily solubilized with the
aid of detergents. With the livers of anticoagulated cows substantial purification
had been achieved by immunoadsorption of solubilized microsomes with sepha-
rose-bound antibodies against blood coagulation factor X. This immune response
was possible since precursors of coagulation factors (mainly factor X) had
accumulated in the endoplasmic reticulum during anticoagulation, where they
had formed tight complexes with the vitamin K-dependent carboxylase (7).
Addition
None
DMSO (20%, v/v)
Acetone (10%, v/v)
Acetonitrile (5%, v/v)
"CO2
incorporation
(% of control)
100
490
440
160
Formation of
vitamin K epoxide
(% of control)
100
500
350
150
/. Srimu/a/JOR o/ //je W/am/n K-aepe/iaen/ carfcoxyto/jort a/id epoxufti/ion in so/trf-
p/iase carftojryfose. 77/t' Wrami/i /f-aVp«ia£n/ //icorporaf/o/i o/ "CO2 <""' 'fl* /orwiafio/i »ƒ
vi7am;/i K ppaWaV M W »!«/««•«/ in ^ranrfarrf reac/ion mirtorw (/ nj/j, c°o/i/a/n/n^ 700 ,«M-
H'ar/ann. /l/ter inaz/wf/on/or /20 win. a/ 25 "C, a 0.4 m/ 5amp/e wa5 «ierf/o/- rfere/-mi>ii/jg
//ie a/now/» o/ j'ncorpora/ed CO^ and 0.4 m/ /or awew/n^ f/ie amounf o/ epox/rfe. 7"ne con/ro/
fivi/nou/ aa</<V/o/>) were 260,000 d.p.m. o/ i/Krorporared "COj per mg o/prore/n and 96
1>/ iv/am/n Ai cpo^/'de p^r wg o/ profc/n
The immuno-affinity procedure resulted in a 100-fold purification of the enzy-
me, which was designated as 'solid-phase carboxylase'. The properties of solid-
phase carboxylase are comparable to those of a non-purified solubilized micro-
somal preparation of bovine or rat liver (12-14). In our attempts to further purify
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carboxylase solid-phase carboxylase has been used as a starting material. A wide
variety of solvents, such as buffers with high or low pH, chaotropic reagents,
high ionic strength and most common detergents has been tested. To increase
hydrophobicity of the eluents, mixtures of low salt buffers and various organic
solvents have been used. Unfortunately none of these methods was successful in
eluting carboxylase from the solid-phase without irreversibly losing biological
activity. As an unexpected side-effect, however, we observed that during our
efforts to resolubilize the carboxylase some organic solvents stimulated the
vitamin K-dependent carboxylation without affecting the K^"'''' for the various
reaction components. The addition of dimethylsulfoxide (DMSO) and acetone to
the reaction mixture enhanced not only the vitamin K-dependent carboxylation
but also the epoxidation (Table I).
Kinetic analysis demonstrated that the stimulation was the result of a substantial
increase of the apparent V„„'^ of the carboxylase reaction. Notably ketones
(acetone) and DMSO were powerful stimulators of solid-phase carboxylase
activity. A time course of the reaction with and without either DMSO or acetone
is shown in fig. 1.
F/G. / . rime course o/ fne caréoxy/a/ion
reaction.
77ie /ncorporario/i o/ "CO^ i'n/o /ne penfapep-
r/de FL££L was wieaswrcd wi/n jo/iW-p/wse
car/wary/ase a/ter various incMftafton f/mes a/
25 °C w;7/!0K? a/ry adtf/ft'o/t (•,), ' " ' ^ presen-
ce o/ acetone (70%, v/v) fO,) and in f/ie pre-
sence o/ DM50 (20%, v/vj ( • )
30 60 90 120 ISO
Time (min)
It was demonstrated that the stimulatory effect of organic solvents could be
obtained with all vitamin K, intermediates and that it was independent of the
physical state of the phospholipid. At lower temperatures it was found that the
stimulation increased. In detergent solubilized microsomes the influence of
organic solvents was far less pronounced and possibly for that reason only
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detectable at low reaction temperatures (5 °C), where also in the solid-phase
system highest proportional stimulation was reached. The mechanism by which
organic solvents stimulate vitamin K-dependent carboxylase has never been
understood. It is known from the rat and bovine microsomal system that redu-
cing agents, pyridoxal phosphate and bivalent metal ions (especially Mn^)
stimulated vitamin K-dependent carboxylation (15-17). This is the first time that a
stimulation by organic solvents of the vitamin K-dependent carboxylation and
epoxidation reaction is reported. The stimulating solvents were all miscible or
partly miscible with water and were poor solvents for phospholipids. Solvents
like alcohols, which do solubilize phospholipids, may inhibit the carboxylation
reaction, because phospholipids are essential for enzyme activity (14). Although
the stimulating agents were miscible with water, experiments with ketones
having different chain length indicated that hydrophobicity seems to be relevant
for their action. With solid-phase carboxylase the stimulation by organic sol-
vents was highest at low temperatures, in detergent solubilized microsomal
preparations stimulation was only observed at low temperatures. It is possible
that in a non-purified preparation the proteins and lipids surrounding the car-
boxylase complex interact with the organic solvent and hence suppress the
stimulating effect on the carboxylase activity. On the other hand, the difference
between solid-phase carboxylase and a non-purified preparation might reflect a
difference in the state of the enzyme complex itself, i.e. the activity of solid-
phase carboxylase might be suboptimal. However, since most experimental
evidence is lacking until now, suggestions that organic solvents improve the
exchange of vitamin K between its solvent micelles and carboxylase, or increase
the mobility of vitamin K during its recycling remain speculative.
The preparation of partly purified carboxylase
After it had turned out that further purification steps with solid-phase carboxy-
lase were not successful, we returned to the detergent-solubilized microsomes,
from which we have tried to isolate protein fractions enriched in carboxylase
activity. The procedure comprises of the extraction of salt-washed microsomes
with 0.5% CHAPS, the solubilization of carboxylase from the membranes with
1% CHAPS + 1.5 M (NH^SCr, and subsequent fractionation by
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precipitation. The recovery of enzymatic activity after the various steps is sum-
marized in table II. The final (NHJjSC^ precipitation step resulted in a 70-fold
purification of carboxylase as compared with the salt-washed microsomes.
However, this figure is probably an overestimation of the real purification,
because in the (NH^SC^ precipitation step an inhibitor of carboxylase activity
(probably haemoglobin) is removed. This phenomenon has also been described
to occur during the partial purification of rat liver carboxylase (18).
Step
1.
2.
3.
4.
5.
Washed microsomes
CHAPS
supernatant (discard)
pellet
CHAPS (1%, w/v) +
(NH^SC^ (25% sat.)
pellet (discard)
supernatant (discard)
(NH4),SC>4 (50% sat.)
supernatant (discard)
pellet
Ultrogel A4
Protein
(mg)
3718
1871
1320
929
357
280
42
9
carboxylase
(dpm.lOVmg)
9.5
4.7
46.2
6.3
108
2.5
682
1756
recovery
(%)
100
25
175
17
109
2
81
45
purifica-
tion
(fold)
1
4.9
11.4
71
185
ƒƒ. Parria/ puny/co/ion o/ /iepa/ic tovi'/ie carftoxy/ase. Car/jary/ase ac/zv/ry IJ
as //ie flffloun; £>ƒ "CO^ '/itw/wafed info FL££L per mg o/ wi/croiowia/ profe/n ;'n 20 m/n
under rfa/ufarrf cond/7/ons. Sa//-wasAed m/crascwies /lad" feeen oft/a/ned /rom norma/ cow //ver.
77ie rfa/a ^i\'en in fn/j raWe are averages o/ a"«p//cafea' ana/y.se.r o/ a «ng/e, few/ represenfa/i've
The procedure developed for the partial purification of hepatic carboxylase is
equally well applicable for the enzyme from normal as well as from warfarin-
treated animals. Whereas microsomes from normal livers mainly contain sub-
strate-free carboxylase, a substrate-bound enzyme complex was obtained from
warfarin-treated animals. In the latter case the yields were slightly better, pro-
bably because of a stabilisation of carboxylase by the endogenous substrate
during the purification procedure. The preparation obtained after (NHJjSC^
precipitation has been used for most of our experiments until now, and has been
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designated as "partly purified carboxylase".
Further purification could be obtained if the (NH^SC^ step was followed by a
size exclusion chromatography column (Ultrogel A4). Carboxylase activity was
found in a fraction of which the apparent mass was estimated to be 670,000 Da
(fig. 2). Analysis on polyacrylamide gels in SDS showed that the preparation
still contained at least 7 proteins, ranging from 50,000-100,000 Da.
50 100
EFFLUENT VOLUME (ml)
150
F/G. 2. Frac/i'ona/i'on o/ carioxy/ase comp/ex o/i f/ttroge/ A4. 77ie prore/>i concenfraf/on in
r/ie ej§7uenr (so/id Wne,) was mom'/ored co/ifi/iuotu/y as rne op/i'ca/ de«sjY> ar 2<50 nm and r/ie
/ co/icenfraf/on in //if van'ous /rac/ions was venyied />^  //ie mefnod o/ Sednia/: and
f20^. /teatvio/t /nur/urei ton/a/n^d 60 ^/ o/ carAojry/aie. W/awiin ^//^ was used as a
co-cnzyiwe
Stimulation of carboxylase by
In (NHJjSC^ precipitation experiments it was found that high concentrations of
(NH^jSC^ may have a strong stimulating effect on the in vitro carboxylase
activity of bovine liver microsomes. However, the effect remained restricted to
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small peptide substrates lacking the pro-sequence, whereas no effect was mea-
surable on the carboxylation of pro-PT28, a synthetic peptide described by
Ulrich et al. (20) and endogenous precursor proteins (21) (table III). Kinetic
analysis demonstrated that the effect of ammonium sulphate was mainly the
result of an increase of the V ^ ^ , whereas the K „ ^ for a number of substrates
was not affected (fig. 3). -
Substrate
FLEEL
pro-PT28
d-osteocalcin
TFT
Concentration
(mM)
4
4.10'
4.10'
4
CO2 incorporated
+ (NH,),SO4
0.9
17.9
55.8
0.8
(mmol/mol of substrate)
- (NH^SO,
0.07
16.70
5.00
0.06
/ƒ/. Caréoxyto//on o/ various s«èsfra/es. /W/ reaction ma/Mrei were incufcafed /or JO
m/n af 20 "C under standard conditions. Pro-Pf2<S ij a synfnefic pep//de coni/5/e/i/ wi7/i //ie
ami'«o acid residues -Z8 /o +/0 /'n /iwma« prof/irowiftin m W/M'CA f/ie re5/'d«ei 6 and 7 are G/«
msfead o/ G/a; r / T « /«e yynr/ief/c ?r;pep»de
4 3 0.4 0.8 i l ?!ê
80
"I
O
• " 40
>
/
15 -OS
B
b d.4 03 <i <«
F/G. J. Line>feaver-B«r/t diagrams o/ i«èi/ra/e cflrèoxy/arion. Pane/ /l: carfeoxy/a//o« o/
7"/T. Pane/ B: carfco;r>7ah'o« o/pro-/T2<S. Apparen/ /f„ va/wei a5 ca/cu/afed/rom //ie /n/eriec-
h'on po/n/j were i mM /or 7"P7 and 6 //M /or pro-P72S. SymboAs: • - • , in r/ie presence o/
ammonium su/p/ia/e,- O—O, /n r/ie afesence o/ammonium su/p/ia/e
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If the pro-fragment was added as a peptide not covalently bound to a carboxy-
latable substrate, the carboxylation thereof was only slightly affected and am-
monium sulphate remained active as a stimulator of carboxylase activity. It was
also demonstrated that in order to substantially decrease the KM*'''' for carboxy-
lase, the propeptide has to be covalently linked to a peptide substrate (table IV).
Therefore the effect of (NH^SC^ seems to be dependent solely on the absence
of the pro-sequence. It has been demonstrated by observations from Knobloch
and Suttie (22) and from Ulrich et al. (20) that in the presence of the pro-sequen-
ce the efficiency of carboxylation of peptide substrates is considerably improved
especially when covalently bound to the peptide substrates, and that this impro-
vement is due to a decrease of the K^ ' ' rather than an increase of the V„„""*.
It has been suggested on several occasions, that the pro-sequence and (NH^SC^
would have similar effects on carboxylase, namely a conformational change by
which Glu-containing substrates would be accommodated better (or quicker) on
the active site of the enzyme. Our kinetic data are not consistent with this sug-
gestion: the fact that (NHJ2SO4 strongly increased the V„,„*'''', whereas the pro-
sequence remained restricted to a decrease of the K,/'''' indicates that these
stimulators must work via different mechanisms.
Second peptide or
protein present
None
Pro-Pt28 (40 uM)
Propeptide (40 uM)
Endogenous substrate
Kinetic
j^app
- (NHASO,
5.5
6.1
4.7
3.2
: constants for
(mM)
+ (NH„),SO,,
4.6
4.5
4.6
3.1
FLEEL carboxylation
- (NH^SO,
0.12
0.26
0.31
0.10
(nmol/ml)
+(NH,),SO<
0.77
0.82
0.94
0.57
/V. Appare/if Ai'nertc co/is(an/5 /or FLEEL carj>oxy/a/ion in fne presence o/ a second
pepfide or protein. Standard reatïion mü'fures conta/ned consfan? amou/ifs o/ ei'f/ier pro-P72#
or propepr/de (;ƒ added) and varying concenfrafi'ons o/ FL££L. Carftoxy/a/ed pro-P72S
remained Aound /o fne microro/na/ pro/e/'ns a/rer /r/cn/oroacefic acid preapiVa/i'on and was
separated/ro/n tarooxy/a/ed FL££Z. /»>' cenfri/uga/ion (5 min, iOOO J: g). For comparison, parf
o/ /ne cjcper/'ffien/ was repeared »virn m/crosomes /rom war/ari'n-/reafed anima/s (/asr /ine). /n
/ne /aKer case no pro-con/ain/ng pep//de was added and fne react/on mtrtwres confained fne
same amon«l o/ microsoma/ pro/eins as /nose in wn/cn we used norma/ m/croso/nes
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Improved efficiency by minimized escape of C
In the preceding paragraphs we have seen two classes of compounds capable of
increasing the efficiency of the carboxylation reaction: organic solvents (mainly
affecting solid-phase carboxylase) and (NH4)jSO4 (mainly affecting detergent-
solubilized carboxylase). During our studies it turned out, however, that a third
factor negatively affected the efficiency of the carboxylation reaction: the escape
of '^CO, from our reaction mixtures. Moreover we introduced a procedure by
which the incorporated '''CO2 may be expressed as nanomoles COj bound, which
enabled us to calculate the efficiency of the carboxylation reaction for each
substrate used. The procedures were published in a recent paper, which also
describes the carboxylating enzyme system as it is presently used in our lab. For
that reason it is printed integrally at the end of this chapter.
Conclusions
Our attempts to purify y-glutamylcarboxylase using classical purification tech-
niques have lead to two forms of partially purified carboxylase, one is bound to
a solid-phase, the other one is soluble. Although we did not succeed in purifying
the enzyme to homogeneity, these preparations have been helpful in optimizing
the conditions for carboxylase activity. This was accomplished with a number of
compounds of which (NH.j)2SO4 is still frequently used in our lab and elsewhere.
We have initiated the development of carboxylase in the bovine system and
have also contributed to the development and testing of affinity ligands, such as
the peptide homologous to the propeptide and a 59-residue recombinant peptide
homologous to the propeptide sequence and Gla-domain of human factor IX.
This is described in more detail in chapter 6. With these affinity ligands the
purification of carboxylase to homogeneity has finally been accomplished by
Wu and Stafford (2) and by Berkner and Suttie (23).
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Vitamin K-dependent carboxylase : minimized
escape of COj from solution may prolong linearity
of the reaction rate
Berry A. M. Soute, Ron Budé, Herman Buitenhuis and Cees Vermeer
Abstract
Escape of "''CC^ from the reaction mixture into the gas phase may seriously
affect the accuracy of in vitro measurement of vitamin K-dependent carboxylase
activity (and probably that of other carboxylases as well). In this paper we
describe the effect of a) the volume of the test tubes in which the reaction is
performed, b) the addition of an excess of NaH'^ CC^ in parallel with standard
amounts of NaH'^CO,, and c) the incubation temperature. In this way optimal
conditions are defined and used for the carboxylation of various peptide and
protein substrates. It is shown that both a presequence and an internal recogni-
tion site contribute to the effective recognition of a substrate by carboxylase.
The maximal efficiency of carboxylation was 1-2% with substrates lacking both
signals and 20-50% if only one was present. This indicates the need for develo-
ping peptide substrates containing both recognition signals for vitamin K-depen-
dent carboxylase.
Introduction
It is well known that CO, (and not HCO," ) is the active component in the
vitamin K-dependent carboxylation of peptide-bound glutamate into ycarboxy-
glutamate residues (24). To measure the carboxylation reaction in vitro,
NaH'^COj is added to the reaction mixture, so that radiolabeled products are
formed (25). The optimal pH for the reaction was found between 7.2 and 7.4
(15,26) and at this pH the equilibrium exists
2H* + "COj* - H* + H"CCV - H2O + " C O ^ [i]
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Provided that the reaction is performed in closed tubes, the '^CC^will be distri-
buted between the solution and the gas phase on top of it according to
• i '*CO^*"CO^ .,-,,-,,, .,,..p„ [ii]
The distribution of '^COj over the liquid and the gas phase is predicted by
Henry's Law, which can be expressed as
= k . V ^ , [iii]
where « is the number of moles, V ^ represents the volume of the gas phase,
and A: is a constant, which is still dependent on the ionic strength and tempera-
ture. The gas phase does not take part in de carboxylation reaction, which means
that escape of '^COj from the reaction mixtures will decrease the effective
concentration of '^COj. Similar equilibria exist for the atmospheric '^ CC^, but
these have been established in the buffers long before the start of the carboxyla-
tion reaction. Therefore the ''COj concentration in the buffers (1-2 mM) may be
regarded as constant. NaH'^CO,, however, is added to the mixtures shortly
before or in parallel with vitamin K, with which the in vitro carboxylation is
initiated. Any loss of '^CO, will decrease the ratio between the concentration of
'"CO2 and that of '"CO2 and hence decrease the apparent carboxylation rate. To
properly interpret the results obtained in the in vitro carboxylation reaction, it is
important that the ratio between ' " C C ^ and ' ^CC^ remains constant through-
out the reaction. Second, the loss of '*CO2 from solution must be minimized,
because it will decrease the sensitivity of the carboxylase assay. Taking into
account these considerations we have worked out the optimal conditions for
vitamin K-dependent carboxylase and we show how this system may be applied
for the carboxylation of a number of peptide substrates.
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Materials and methods
. Dithiothreitol (DTT) and 3([3-cholamidopropyl]dimethylammo-
nio)-1-propane sulphonate (CHAPS) were purchased from Sigma (St. Louis,
MO) and NaH'"CO, (56 Ci/mol) was from the Radiochemical Centre (Amers-
ham, UK). Vitamin K, (Konakion®) was obtained from Hoffmann-LaRoche
(Basel, Switzerland) and reduced to the hydroquinone form (KHj) by incubating
6 mM vitamin K quinone in the presence of 150 mM DTT at pH 8.5 and 37 °C
overnight in a light-protected tube. All other chemicals were of analytical grade
or better.
Pe/rtufes a/irf proteins. The pentapeptide Phe-Leu-Glu-Glu-Leu (FLEEL) was
from Vega Biochemical Co (Tucson, AZ) and pro-PT28 (consisting of the amino
acid residues -18 to +10 of bovine descarboxyprothrombin) was prepared as
described by Ulrich et al (20) and was kindly supplied to us by Dr. B.Furie
(Tufts University, Boston). Decarboxylated osteocalcin (d-osteocalcin) was
prepared and purified from bovine bones as in (27) and t-Boc-Glu-Glu-Val was a
kind gift from Drs. F.Azerad and F.Acher (Université R.Descartes, Paris, Fran-
ce). Salt-washed microsomes were prepared from normal cow liver as described
earlier (26).
Carioxyfase assay. Standard reaction mixtures (0.125 ml) contained 2 mg of
microsomal proteins, 0.4 % (w/v) CHAPS, 0.15 M NaCl, 50 mM Tris-HCl (pH
7.4), 1 M (NH^SO.,, 6 mM DTT, 0.1 mM KR,, 1.5 pCi NaH' tOj and 4 mM
FLEEL. Incubation periods and temperatures are indicated in the text. Incubati-
ons were stopped by adding 75 pi 1 M NaOH to the reaction mixtures. At the
various time points two samples were taken from each tube: 10 pi was transfer-
red into 100 pi Tris-HCl (pH 10.2) and diluted 100-fold with distilled water and
10 pi of this solution was counted as such. The other sample (150 pi) was
transferred into a vial containing 1 ml of 5% (w/v) trichloroacetic acid. Trace
amounts of nonbound label were removed by shortly heating the sample and
peptide- or protein-bound '*CC>2 was quantitated in a Beekman LS 1301 liquid
scintillation counter. Formula-989 (Dupont de Nemours, Dreieich, FRG) was
used as a scintillation liquid for all samples. All data are given as the means of
triplicate experiments and blank values (less than 200 dpm) are subtracted
throughout this paper.
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Results -ja?
As can be seen from Eq. [iii] the loss of '"COj into the gas phase may be de-
creased by reducing either V ^ or k. The limits to which Vg„ may be reduced
are set by practice, and therefore we have investigated the extent to which the
efficiency of the '^COj incorporation could be improved by a reduction of the
tube volume. Standard reaction mixtures (0.125 ml) were pipetted in tubes of
varying capacity (7, 1.5 and 0.15 ml respectively) and subsequently incubated at
25 °C. The disappearance of '*CO2 from solution is shown in figure 1A. In the
large, wide vessels an equilibrium between '^COj „<, and '"CO2 g^  was reached
after about 40 min and at that stage not more than 40% of the original label was
left in solution. In the midsize tubes (which were also narrower) the equilibrium
state was reached after about 1 h. The final concentration of '"CCX a, was 55%
of the original value. In the small tubes the loss of '"CC^ from solution was less
than 5%. In parallel tubes we also measured the vitamin K-dependent incorpo-
ration of '^COj into the pentapeptide substrate FLEEL (figure IB).
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In the largest vessels the carboxylation rate declined during the first 40 min and
remained constant for 1 h thereafter. Also in the midsize tubes the curve became
linear only after the '''COj distribution had reached its equilibrium. Only in the
smallest tubes the initial curvature was negligible and a straight line could be
drawn from the origin. It is also clear that the slopes of the linear parts of the
three curves in figure IB are different. Probably this is a reflection of the diffe-
rent '''COj /^ CC>2 ratios at that phase of the reaction. From these results we have
concluded that optimal results were obtained in the smallest tubes only. In all
other cases the incorporated '^ COj will give rise to an underestimation of the
real amount of carboxylation events.
A second possibility to avoid loss of '''COj in the gas phase would be to de-
crease k in Eq. [iii], either by decreasing the incubation temperature or by
increasing the ionic strength. Because the optimal conditions for the carboxylase
assay already include an unusual high ionic strength we have chosen to focus
our attention to decreasing the incubation temperature. Several other groups
have chosen this strategy (15,28). The relation between incubation temperature
and the "*COj distribution was investigated in large vessels only, and the results
are shown in figures 2A and 2B. It is clear that at increasing temperature both
the equilibrium levels of '^CO, ^ and the time interval required to reach these
levels decrease. In this case the peptide carboxylation was also studied in a
parallel experiment and again it was clear that linear reaction rates could only be
obtained after the distribution of '*CO, had reached its equilibrium (figures 2C
and 2D).
During the first phase of the reaction the curves were nonlinear at all tempera-
tures investigated. It may be concluded, therefore, that decreasing the volume of
the gas phase over the reaction mixtures is the most effective way to minimize
degassing of the reaction mixtures. Only the smallest tubes Eq. [ii] may be
neglected.
If a mixture of labelled and nonlabelled NaHCO, is added to the reaction mix-
tures in concentrations which are high relative to the amount of ''COjaq origina-
ting from the atmosphere, the '''COj /'"CO, ratio will not markedly change
during the course of the incubation. In that case the incorporation of '^COj is
expected to be constant from the onset of the reaction, irrespective of the capa-
city of the tubes in which it is performed. This was confirmed in an experiment
in which we added increasing amounts of NaH'^CO, to standard reaction mixtu-
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res. Incubations were performed in large vessels at 20" C. As is shown in figure
3 the loss of '"COj is independent of the NaH'^CO, concentration in the mixtu-
res. Linear carboxylation rates were only achieved at relatively high bicarbonate
concentrations, however.
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To measure the enzyme stability the carboxylation reaction was performed in
small tubes containing standard reaction mixtures supplemented with 10 mM
NaH'^COj. Time course experiments were performed at seven different tempe-
ratures. Figure 4B shows the initial phase of the reaction and it is clear that the
highest reaction rates were obtained at the highest temperatures. A disadvantage,
however, is that the enzyme is labile at these temperatures. This is demonstrated
in figure 4A. At lower incubation temperatures the linearity of the time courses
was substantially prolonged, resulting in very high levels of total COj fixation
after 24-48 h. Like the other experiments described in this paper the experiment
shown in figure 4 was performed with salt-washed microsomes from normal
cow liver. Similar results (data not shown) were obtained, however, with salt-
washed microsomes from warfarin-treated cows and with partly purified car-
boxylase, prepared from these two types of microsomes in the way described by
Soute et al. (29). Hence the stability of all four carboxylase-containing prepara-
tions were closely similar. From these results we also concluded that the
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maximal level of COj incorporation was achieved between 10 and 15 °C after an
incubation period of 48 h.
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Under these conditions we have measured the degree to which a number of
substrates were carboxylated. The substrates chosen were FLEEL, t-Boc-Glu-
Glu-Val, pro PT28 and d-osteocalcin and the results are shown in table I. It is
obvious that the tri- and pentapeptides are very poor substrates: the efficiency
with which they are carboxylated is low, and high concentrations are required to
see any carboxylation at all. The two polypeptide substrates pro-PT28 and d-
osteocalcin, on the other hand, were carboxylated to a reasonable extent: in the
case of d-osteocalcin even more than 1 mol of Gla was formed per mole of
substrate.
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Substrate
FLEEL
t-Boc-Glu-Glu-Val
pro-PT28
d-Osteocalcin
Gla residues for-
med (residue/
molecule)
0.02
0.04
0.42
1.47
Efficiency of
carboxylation (%
of theoretical
maximum)
1
2
21
49
ƒ. Vitamin K-depemfen/ ca/*oxyto/iow o/ various si/*sfra/es. Note: Standard
tonta/n/ng fZ.££Z. (4 mM), r-Boc-G/u-G/w-Va/ (J mMj, pro-/>72S (4/<M,), or d-
O5/eota/dn (4 //M,) were sup/?/e/we/ifed wiVn J2 mAf Wa//''COj and /ntufatfed /n swia// rubes a/
70 "C /or 72 n. 77ie tonten/ra/Zo/w o/ f/ie var;'oi« 5u/?5/ra/e5 represen/ r/ieir A^^ "'"'' va/wej. T/ie
ajci'mwm o/ G/a /orma/;'on is //iree rei/dues per mo/et«/e <?ƒ os/eoca/cin a«d /wo
per mo/etw/e m //ie o/ner
Discussion
Kinetic constants are generally defined at 25 °C and most enzymatic reactions
are therefore performed at that temperature. A prerequisite for a correct inter-
pretation of the results, however, is that measurements are made during a phase
at which the reaction rates are constant. Due to the fact that vitamin K-depen-
dent carboxylase is rather labile at 25 °C, all data should thus be obtained during
the first hour of incubation. Unfortunately, in the same period equilibrium [ii] is
established, so that the "''CO, /'^COj ratio decreases continuously. Hence linear
reaction rates (expressed as '''CO, incorporated) may not be expected.
In this paper we describe two ways to approximate linearity of the curves during
the first hour of incubation at 25 °C. This first method consists of using small
test tubes with a capacity barely more than the volume of the reaction mixtures.
If the tubes are tightly stoppered, the volume of the gas phase is minimized, and
the loss of '*CC>2 is negligible. This technique will give the highest amount of
'•"COj fixation, but the total COj concentration is of the same order of magnitude
as the KM'"' value. Hence the assay is sensitive to unwanted fluctuations. In
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general the increase of NaH'^COj concentrations to values as high as 10 times
the K^^'' is not possible because of the costs and safety regulations. The second
technique is the addition of an excess (32 mM) of nonlabelled NaHCO, to the
reaction mixtures. In the latter case not only '''COj, but also '^COj will redistri-
bute itself between the liquid and the gas phase. Hence the ratio between the
'•*CC>2 and the '^COj concentrations will remain nearly constant, even if relative-
ly large incubation vessels are used. Because the final bicarbonate concentration
in solution remains far above the K^^'' (0.4 mM (24)), the escape of COj will
hardly affect the rate of carboxylation. An additional advantage of using an
excess of '^COj is that the extent of carboxylation may be expressed on a molar
base (29). A disadvantage, however, is that the total amount of radiolabel incor-
porated will remain rather low.
For many types of experiments a temperature of 25 °C is not an absolute requi-
rement, so that the experiments may be performed at lower temperatures (e.g. 10
or 15 °C). Under these conditions carboxylase is surprisingly stable, and a linear
reaction rate may be maintained for over 24 h. The reason why carboxylase
activity rapidly decreases at 25 °C is presently unknown, but it has been descri-
bed that in a more purified form (like solid-phase carboxylase (7,28)) the enzyme
is far more stable.
From these data it may be concluded that a maximal incorporation of COj into a
suitable substrate is achieved in small tubes, at a high bicarbonate concentration
at 10 or 15 °C. Under these conditions we have compared the efficiency of
carboxylation of a number of substrates, and it appeared that the low molecular
weight peptides were poorly carboxylated. The importance of the pro-sequence
becomes clear from the fact that the extent of carboxylation of pro-PT28 is over
20-fold higher than that of the pentapeptide. This is consistent with earlier
observations, which showed that the KM"™" for pro-PT28 is about 100-fold lower
than that of FLEEL (21). Yet pro-PT28 is not fully carboxylated, possibly be-
cause it lacks the "internal recognition site". The latter sequence consists of the
amino acid residues Glu-X-X-X-Glu-X-Cys, and its presence in all mature
mammalian Gla-containing proteins was initially discovered by Price et al. (30).
Decarboxylated osteocalcin contains this internal recognition site, and although
it lacks the pro-sequence, it is a good substrate for carboxylase (27). Under the
conditions mentioned above, even 1.5 mol of CO2 could be incorporated per
mole of substrate. It is to be expected, therefore, that substantial improvements
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may be achieved by constructing polypeptides which contain both the pro-se-
quence and the internal recognition sequence. Whether these substrates will be
fully carboxylatable in vitro remains to be awaited, however.
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Vitamin K : Its role as a coenzyme in the
car boxy lation reaction
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Introduction i * I ?
On a molecular level many details of the carboxylation reaction still have to be
clarified. In principle the chemical possibilities for the addition of a COj-mole-
cule to the y-carbon in a substrate-bound Glu-residue may proceed either via a)
activation of oxygen, b) activation of COj or c) activation of glutamic acid.
Since it has been shown that both superoxide dismutase and catalase did not
inhibit carboxylation (1,2), oxygen activation seems not likely to occur. It has
been established by Jones et al. (3) that the active species in the carboxylation
reaction presumably is COj and not HCO,, but a COs-carrier role for vitamin K
hydroquinone has not been demonstrated (4). Although activation of COj by a
radical exchange reaction has been proposed by Gallop et al. (5), most evidence
strongly supports a start of a carboxylation event by labilization of a y-hydro-
gen. Many investigators have suggested that hydrogen removal precedes addition
of COj (6,7). Moreover, Azerad et al. (8) and Dubois et al. (9) have established
that the enzymatic y-abstraction step is stereospecific and corresponds to the
elimination of the pro-S hydrogen of glutamic acid. This justifies the expectation
that COj-addition also occurs in a stereospecific way. Both radical formation
followed by a one-electron reduction and proton abstraction have been proposed
as the pathway leading to a carbanion (7,10).
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A carboxylation event would then be completed by the electrophilic attack of
this carbanion by COj. The precise reaction mechanism by which this complica-
ted system proceeds needs further investigation, preferably in purified systems.
Although it is not clear at this moment how epoxide formation and y-hydrogen
abstraction are coupled, there is general consensus about the way in which the
vitamin itself is metabolized in the liver during and after the reaction. The active
cofactor for carboxylase is vitamin K hydroquinone (KH2), and all data presently
available indicate that the oxidation of (KH,) to vitamin K epoxide (KO) provi-
des the energy required for the carboxylation of Glu residues (11,12). Subsequent-
ly KO is reduced by the action of at least one reductase (see Chapter 1). In this
way vitamin K is efficiently recycled, and it may be calculated from the diffe-
rence between daily vitamin K intake and urinary Gla-excretion that the vitamin
is re-used several thousand times before it is degraded via lactone and glucuro-
nide formation (13).
Recycling of vitamin K
The involvement of y-glutamylcarboxylase in the vitamin K-cycle has been
unequivocally demonstrated and all enzymes participating in the recycling of
vitamin K have been identified in liver tissue. Inspection of a wide variety of
tissues has revealed that y-glutamylcarboxylase is distributed in tissues other
than the liver. In the recent past our group has contributed significantly to the
discovery of extra-hepatic tissues and cell lines (14-16), and it is now generally
agreed that y-glutamylcarboxylase belongs to the standard machinery of most
cell types. Whether the same holds true for the reductases involved in the vita-
min K-cycle is not clear, however. It has been reported by Price et al (17) that
the effect of warfarin on the y-carboxylation of circulating osteocalcin could not
be counteracted by high doses of vitamin K. One possible explanation for this
phenomenon is that the warfarin-insensitive NADH-dependent reductase is
inactive or absent in bone cells. The hypothesis was supported by Ulrich et al.
(18) who reported that the NADH-dependent K reductase activity was absent in
the osteoblast-like osteosarcoma cell line UMR 106. As early as in 1982 we
have described another extra-hepatic carboxylating system from human placenta
in which dithiol-dependent reductase activity could not be demonstrated. The
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importance of this reductase becomes clear when the carboxylation reaction in
vitro is started with vitamin K quinone as a cofactor, since only the reduced
cofactor is able to catalyse the carboxylation reaction. The results presented in
table I clearly demonstrate the presence of substantial amounts of carboxylase in
placental microsomes. The K M ^ for KHj was comparable with that in human
and bovine liver systems. However, if vitamin K quinone was used as a cofactor
the placental microsomes had no activity whereas normal activity was found in
the hepatic systems. Also replacement of dithiothreitol by other reducing agents
like NAD(P)H or p-mercaptoethanol did not stimulate the vitamin K-dependent
carboxylation reaction. : ,,:: ;.:, ; , •-.,-. . -n-fi .-d h-: .••.••. •; •.-•*.'
Carboxylase
(dpm.min '.mg')
K„ for vitamin KH2
(MM)
KM for vitamin K
(uM)
Bovine liver
31
10
13
Source of carboxylase
Human liver Human placenta
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Obviously the detection of reductase activity via the K quinone + carboxylase
route is an indirect test, but it should be kept in mind that the direct measure-
ment of reductase activity was not possible at that time. Therefore it is not clear
whether the absence of all vitamin K reductase activity is a real reflection of the
situation in vivo or merely a result of our inability to detect the enzyme activity.
Alternative explanations for the data presented are that either the placental
reductase is inactivated or separated from carboxylase during the preparation and
solubilization of the microsomes. At this moment direct tests for both KO and K
reductase are operational in our lab, and it would be interesting to repeat these
early experiments using the new and sensitive techniques. A physiological result
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of the absence of reductase in placenta would be that all vitamin K entering the
placenta is converted into KO. Direct evidence for a placental barrier for vitamin
K has been obtained by Hamuly&k et al. (19) using radiolabelled phylloquinone
in rats. In addition, Shearer et al. (20) have demonstrated the presence of vitamin
K, in plasma of neonates, although the levels were 2 orders of magnitude lower
than those in maternal plasma. Since KO is more hydrophillic than is the quino-
ne form this conversion might facilitate the vitamin K transport over the placen-
ta. As long as no placental Gla-proteins have been identified, it even cannot be
excluded that the conversion of vitamin K quinone into KO is the main function
of placental carboxylase. ;, -..?., : ,; - i. = ,, :•* ,^:n:.,,», ....•..., m,.,,,,».
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In nature two forms of vitamin K are found, both characterized by a functional
naphtoquinone ring and an aliphatic side chain. The main difference between
vitamin K, (phylloquinone) and vitamin Kj (menaquinone) is the composition of
their side chains (see chapter 1). Vitamin K, is mainly found in green plants
(21,22) whereas the menaquinones are produced by the intestinal flora (23). The
extent to which each of the K vitamins contributes to the carboxylation of blood
coagulation factors is still a matter of dispute. It has been shown that 92% of
the vitamin K store in liver consists of menaquinones (24). Yet a significant
effect on blood coagulation parameters was found in human volunteers after a
short period of reduced nutritional vitamin K intake (25,26). No changes had
occurred in the faecal menaquinone concentrations during the experiment. These
results suggest that menaquinones are of minor importance for the production of
coagulation factors. On the other hand vitamin Kj is successfully used in Japan
for preventing haemorrhagic disease in newborns (27,28). Various menaquinones
have been tested in early systems, showing maximal activity for MK-3 or MK-4
(29-34). The activity of vitamin K, was only slightly lower (29-32). During the last
15 years in vitro carboxylating systems have been substantially improved (35,36)
resulting in a more accurate comparison of apparent kinetic constants of the
various vitamins. In this way we have established the in vitro activity of phyl-
loquinone and various menaquinones. It was found that the cofactor activity of
the menaquinones varied with the length of the aliphatic side chain with an
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optimum at MK-3. Menadione was not active at all, which is consistent with
data reported by others (16-19). Menaquinones containing more than 10 isoprene
subunits were not tested, but if our results may be extrapolated to the higher
menaquinones, it is doubtful whether these forms of vitamin K are of physiolo-
gical relevance. The activities of both MK-3 and MK-4 were comparable to that
of phylloquinone. Menaquinones with shorter side chains were characterized by
a high KM*^, those with longer side chains by low V,^ ,*™" values. In human liver
and plasma the most abundant menaquinones are the menaquinones 7 and 8
whereas the menaquinones 9 and 10 are generally found in slightly lower
amounts (24). Because in vitro all these forms are less active than phylloquinone
is, their physiological importance remains unclear. Since no data exist about the
menaquinone absorption from the large intestine in humans, the source of liver
menaquinones remains to be established. More information will be obtained
from in vivo experiments with a vitamin K-deficient rat model system recently
developed in our lab. Experiments on this subject are in progress at this time.
K,
MK-1
MK-2
MK-3
MK-4
MK-5
MK-6
MK-7
MK-8
MK-9
MK-10
(MM)
12.3
30.0
9.7
5.8
3.6
2.5
1.6
1.9
1.4
1.4
1.4
V "PP
* max
(Hmol CO, bound/h)
25.4
4.0
24.9
30.5
24.7
22.2
19.6
18.0
15.8
14.0
13.0
V »PP
max
( % )
100.0
15.9
98.1
120.0
96.7
87.7
77.0
70.7
62.0
55.8
51.2
7"aWe / / /fi/iific conrfa/i/s o/ /ne/iaauinones 7 to i0. Vifa/ni/M were added ro //ie
i/i a fn'ro/i - so/Mfti'fced /o/-/n, and f/ie j/u7ia/ reac/ion ra/es were dere/vm/ied a//er
o/ //ie mü7nre.s/or 0, /0 and 20 mi/wres a/ 25 °C.
It has been confirmed that all metabolites of both phylloquinone and menaqui-
none (in this case MK-4) were active as a cofactor in the carboxylase reaction.
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All kinetic data is summarized in table III and it was demonstrated that the
KM*" value for K, was three times higher than that for MK-4, whereas the
V^,/" value was closely similar.
K,H,
K,
K,0
K,H,
K2
KjO
KM""
(f»M)
13.3
12.3
11.3
4.2
3.8
3.7
max
(umol CO, bound/h)
35.3
25.4
16.2
36.9
25.1
17.4
V »w>
max
( % )
100
72
46
100
68
47
7aWe /// . Kinertc constante o/ vttami/j Jf, and Jf^ . K/YamjVw were added ro f/ie reat7/on
1/1 a /ri/on - ro/ufo/7/zed /or/n, a«d f/ie /n/fi'a/ reacft'on rato were deferm/ned a/rer
o/ ;/ie mu/wrej /or 0, 70 a«d 20 /mnuto ar 25 "C. V„„"™' « expressed /« rwo
/</?io/ CO^ /?o«nd per /lour and as a percenrai'e o/ r/ie Ar,//; - i//m«/ared reac//on.
No difference was found in the relative amount of carboxylation obtained with
the various metabolites of vitamin K, and MK-4. Another observation was that
in reaction mixtures containing solubilized microsomes, independent of the
starting metabolite form, both phylloquinone and menaquinone reached an
equilibrium after about 15 min. Hence, irrespective whether the carboxylase
reaction was started with KHj, K or KO, these metabolites were found in a
constant ratio after this incubation period. These observations were made at 20
°C and in the equilibrium stage the reaction mixtures contained 2 % KO, 30 %
KHj and 70 % K quinone (figure 1). The observation that equilibria were not
reached before 15 minutes is inconsistent with a linear carboxylation rate for K
and KO found at 25 °C. During the initial phase of the K- and KO-stimulated
carboxylation reaction, KHj cannot be present in excess. Instead it will increase
during the first 20 minutes from zero to the equilibrium value. Yet linear time
curves were found. A plausible explanation may be that only a small fraction of
the vitamin K added to the reaction mixture is directly available for the car-
boxylase/reductase complex, and that the KHj formed during the first minutes of
the reaction is not distributed uniformly over the phospholipid micelles, but
remains concentrated on or around the carboxylating enzyme system. In this
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way high local concentrations of KHj would be generated without notably
affecting the total vitamin K pool. The rapid oxidation of KHj was not only
found in solubilized microsomes but also in reaction mixtures containing puri-
fied carboxylase (kindly supplied by Drs. Wu and Stafford). However, reaction
mixtures from which carboxylase was omitted were far more stable. These data
should be taken into account when KHj is thought to be added in excess to a
carboxylating reaction mixture, and they probably explain why several authors
have found only very short periods of linear carboxylation (37).
0 I 10 IS
Incubation time (min)
F/G. / . /t/ifl/ysjs o/Me vitom/f! tf//,, # awrf AfO con^/i/ra/ion during /Ae
se reactions. /I? J/^m'/i/ f/me Z/i/m'a/s f/ie /e/a//ve fonfe/i/rtih'o/M £>ƒ AT//2.
de/erm/nfrf />>» r/A>LC 77ie da/a are represented as ftoe /or/naf/on o/ AT,//j (//^
and /T,0 (/?#. 2C;. 5far//ng ma/er/a/ a/ r/me zero /'i respet/Zve/y AL,W_, (O-O), /
A ,^ AT; (/ïg. 2B)
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Allosteric interaction between propeptide-binding site and vitamin
K-binding site on carboxylase
Recently we were confronted with two Devon Rex cats exhibiting an unexplai-
ned bleeding problem. With plasma and liver samples from affected cats we
could not only explain the defect by postulating a mutation of the propeptide-
binding site, but we also demonstrated the allosteric interaction between the
propeptide- and the vitamin K-binding sites on carboxylase in unaffected cats.
This observation was confirmed in the well characterized rat and bovine sys-
tems. At the time of writing this thesis the paper reporting these data is still in
press, which is the reason of integrally reproducing it in this chapter.
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Conclusions
All enzymes of the vitamin K cycle are active in our cell-free liver system.
After addition of KHj to the reaction mixtures, it is rapidly oxidized until after
about 15 min a steady state is reached in which not more than 30 % of the
original amount of KHj is left. This conversion even takes place if the number
of carboxylation events is reduced to a minimum, e.g. by omitting a carboxyla-
table substrate in the reaction mixture. Also the presence of DTT is of no influ-
ence on the auto-oxidation of KHj. Therefore the actual concentration of KHj
may only be a fraction of the original value and may influence linear reaction
velocity. On the other hand we have found that the binding of propeptide-con-
taining substrates gives rise to the formation of a high affinity site for KHj on
carboxylase, resulting in a decrease of the K ^ for KH2 by at least one order of
magnitude. Since the decrease of both the actual KHj concentration and its KM*™"
are expected to have opposite effects, these data may explain why in the presen-
ce of propeptide-containing substrates, linearity of the carboxylation reaction
was observed for several hours.
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Congenital deficiency of all vitamin K-dependent
blood coagulation factors due to a defective vita-
min K-dependent carboxylase in Devon Rex cats
Berry A.M. Soute, Magda M.W. Ulrich, A. David J. Watson, Jill E. Maddison,
Rob H.M. Ebberink and Cees Vermeer
Abstract
Two Devon Rex cats from the same litter, which had no evidence of liver
disease, malabsorption of vitamin K or chronic ingestion of coumarin derivati-
ves, were found to have plasma deficiencies of factors II, VII, IX and X. Oral
treatment with vitamin K, resulted in the normalization of these coagulation
factors. After taking liver biopsies it was demonstrated that the coagulation
abnormality was accompanied by a defective y-glutamylcarboxylase, which had
a decreased affinity for both vitamin K hydroquinone and propeptide. This
observation prompted us to study in a well defined in vitro system the possible
allosteric interaction between the propeptide binding site and the vitamin K
hydroquinone binding site on carboxylase. It was shown that by the binding of a
propeptide-containing substrate to y-glutamylcarboxylase the apparent K ,^ for
vitamin K hydroquinone is decreased about 20-fold. On the basis of these in
vitro data the observed defect in the Devon Rex cats can be fully explained.
Introduction
Vitamin K hydroquinone (KHj) is an essential cofactor in the posttranslational
proces-sing of a number of proteins including the coagulation factors II, VII, IX,
and X. The vitamin K-dependent step is the conversion of the first 10-12 ami-
noterminal glutamate residues into y-carboxyglutamate (Gla) residues. During
this reaction, which is mediated by the microsomal enzyme Y-glutamylcarboxy-
lase (37), KHj is oxidized into vitamin K 2,3-epoxide (KO). At least one, but
probably several, reductases are involved in the subsequent recycling of KO into
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(38). This sequence of events is generally known as the 'vitamin K cycle'.
Besides vitamin K deficiency there are two major reasons why Gla-containing
proteins may occur in an undercarboxylated form. Firstly, the vitamin K cycle
may be interrupted by the action of 4-hydroxycoumarin derivatives, which are
potent inhibitors of the enzyme KO-reductase (39). The blockade of this enzyme
hampers the recycling of KO, leading to an increased circulating KO concentra-
tion, and rapid exhaustion of the KHj store. This results in an accumulation of
non-carboxylated precursor proteins in the endoplasmic reticulum and, if the
blockade is continued, in the cellular secretion of maturated Gla-proteins in a
non- or undercarboxylated form (the so-called 'descarboxyproteins'). Whether or
not the descarboxyproteins are secreted depends on the dose and the duration of
coumarin intake, as well as on the species (40).
A second reason for undercarboxylation of Gla-proteins is a poor recognition of
the precursor proteins by carboxylase. The so-called 'pro-sequence' in these
precursors consists of 18 amino acid residues directly preceding the amino
terminus of the mature proteins, and has been demonstrated to play a major role
in their affinity for carboxylase (41,42). Mutations in the pro-sequence may lead
to impaired substrate recognition and hence to poor substrate carboxylation, both
in vivo and in vitro (43,44). Blood coagulation disorders of this type are rare,
however (45).
Recently we encountered with two Devon Rex cats from the same litter, which
were affected by a bleeding tendency (46). Blood coagulation factor analysis
demonstrated substantially decreased levels of factors II, VII, IX, and X, whe-
reas the plasma concentration of factors V, VIII, XI, and XII were normal.
There was no evidence for exposure to coumarin derivatives, liver disease or fat
malassimilation. Yet oral treatment with vitamin K, resulted in normalization of
all vitamin K-dependent coagulation factor levels. Inspection of the family
history of the cats gave evidence that the defect was inherited as an autosomal
trait (46).
We have further investigated these cats, and our results indicate that the low
procoagulant activity is the result of a mutation in the vitamin K-dependent
carboxylase, leading to poor recognition of the pro-sequence and hence to a
poor carboxylation of the various coagulation factors. A model explaining why
this defect may be corrected by an increased vitamin K intake is discussed.
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Materials and methods.
. Vitamin K, (Konakion®) was obtained from Hoffmann-La Roche
(Basle, Switzerland) and vitamin K hydroquinone (KH^) was prepared by incu-
bating 6 mM vitamin K quinone in the presence of 150 mM dithiothreitol (DTT)
at pH 8.5 and 37 °C overnight in a light-protected tube. Vitamin K epoxide
(KO) was prepared according to the method of Tishler et al. (47). The chromo-
genic substrates S 2238 and S2337 were obtained from Kabi Diagnostica (Stock-
holm, Sweden). Russell's viper venom, Echis carinatus venom, DTT and 3-((3-
cholamidopropyl)-dimethylammonio)-l-propane sulphonate (CHAPS) were from
Sigma (Saint Louis, MO). The pentapeptide Phe-Leu-Glu-Glu-Leu (FLEEL) was
purchased from Vega Biochemical Co. (Tucson, AZ), NaH' tOj (56 Ci/mol)
and Formula 989 from New England Nuclear (Dreieich, F.R.G). ProFIXPT28
and propeptide were kind gifts from drs. B.C. and B. Furie (Tufts University,
Boston, MA). ProPT28, proPT28(FA-16) and proPTFLEEV were prepared at
Applied Biosystems (Maarssen, The Netherlands), proFIX59 was a kind gift
from dr. D.W. Stafford (University of North Carolina, Chapel Hill, NC). The
structures of these substrates are given in Fig. 1. Osteocalcin was prepared from
bovine bone, and thermally decarboxylated as described earlier (48). All chemi-
cals were of analytical grade or better.
£;tperime/ito/ a/tima/s. Blood required for the various tests was taken by
venipuncture and collected into 0.1 volume of 3.8% sodium citrate. The blood
sampling from two normal and both affected cats was performed before and
after a single, oral dose of 5 mg of vitamin K,. Liver biopsies were taken from
the same cats before vitamin K administration only. Vitamin K-deficiency was
generated in male Lewis rats (12 weeks old) by feeding them a vitamin K-defi-
cient diet (Hope Farms, Woerden, The Netherlands) for one week prior to sacri-
fice.
Car^ojcytose assay. Salt washed microsomes from normal and affected cats
and from normal and vitamin K deficient rats were prepared from liver accor-
ding to earlier described methods (49). Standard reaction mixtures (0.125 ml)
contained: 1 mg of microsomal proteins, 0.1% (w/v) CHAPS, 0.5 M NaCl, 25
mM Tris/HCl (pH 7.5), a carboxylatable substrate (concentration as indicated),
1.5 uCi NaH'^CO, and either vitamin K, KO or KH, (as indicated). When pro-
peptide-containing substrates were used, no (NH4)jSO4 was added to the reaction
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mixture. Incubations were performed for 30 min at 20 °C. For kinetic studies,
the reaction mixture without peptide or KHj was preincubated at 20 °C for 3
min and equal amounts were added at 20 s intervals to tubes containing varying
amounts of peptide or KHj. Kinetic data were calculated from time courses
obtained for at least five different substrate concentrations after incubations at 0,
5, 10, 20 and 30 min. All reactions were stopped by the addition of 50 pi of 1
M NaOH. Non-bound NaH'^COj was removed by adding 1 ml of 5% (w/v) tri-
chloroacetic acid and boiling for 5 minutes. Samples were counted in Formula
989 using a Beekman LS 1801 liquid scintillation counter. Data are expressed as
pmol COj fixed per min and per mg of microsomal proteins. r. • : r i, •
/CO-rerfuctese assaji. For the in vitro test, standard reaction mixtures were
incubated under similar conditions as described for the carboxylase assay. Ali-
quots were taken after 2.5, 5 and 10 min, extracted with isopropanol/hexane and
analyzed for KO and K by HPLC using a Lichrosorb RP 18 reversed phase
column (Chrompack) (50). Data are expressed as pmol K formed per min and per
mg of microsomal proteins. The in vivo KO-reductase activity was deduced
from circulating plasma KO levels, which were determined according to the
method of Shearer (51).
Coagufaft'ort assays. Prothrombin and factor X concentrations were deter-
mined with a one stage assay (52) in which prothrombin- and factor X-deficient
bovine plasma were used as a reagent, respectively. The total amounts of plasma
prothrombin + descarboxyprothrombin were determined in a slightly modified
two-stage assay initially described by Kirchhoff et al. (53). In this assay, which
is based on thrombin generation by Echis carinatus venom, plasma samples (25
pi) were diluted in 420 pi of a buffer containing 175 mM NaCl, 5 mM CaClj
and 0.5 mg/ml human serum albumin, and supplemented with 5 pi of a solution
containing 0.5 mg/ml E. carinatus venom. The samples were preincubated for 10
min at 37 °C, after which 50 pi of a 1.5 mM solution of the chromogenic sub-
strate S2238 were added. The rate of thrombin generation was monitored by the
absorbance at 405 ran and compared with a reference curve. Descarboxy-
prothrombin concentrations were calculated from the difference between the
two-stage and the one-stage prothrombin determinations. Descarboxyfactor X
concentrations were determined in a similar way but using Russell's viper
venom (5 pi, 0.2 mg/ml) for the two-stage generation of factor Xa and S2337 as
a chromogenic substrate (54).
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assays. Protein concentrations were determined according to the proce-
dure described by Sedmak and Grossberg (55).
Results
Effect of vitamin K administration on prothrombin and factor X concen-
trations.
Citrated plasma from normal and affected cats was taken before, and 12 and 24
h after vitamin K treatment. In the affected cats the circulating prothrombin
levels before treatment were about 10% of those in the control cats. In these
samples the two-stage assay was even slightly, but not significantly, lower than
the one-stage values (table I, lanes 2 and 3). Hence no descarboxyprothrombin
could be detected in this way. Twelve h after vitamin K administration to the
affected cats their plasma prothrombin concentration had increased to the normal
levels, and remained constant for at least another 12 h period. Also in these
samples the differences between the one-stage and the two-stage assays were
small and insignificant.
Time
dose
0
12
24
(h) after oral
of K
Coagulation factor concentration
(% of control rats)
Prothrombin
one-stage
10
89
99
two-stage
8
111
106
Factor
one-stage
5
115
92
X
two-stage
9
134
117
/. Ejjjfecf o/ vitamin AC aaVni/iis/ra/io/i on Mood coagu/a/ion /actors in norma/ am/
ajjjfecfed Deco» /?ex ca/s. Ow s/age and /wo j/age pra/nrom/x'n and /at/or X determination ;n
ci7ra/ed p/asma be/we, and 72 and 24 n a//er /ne admin/s/ration o/ an ora/ dose <?ƒ 5 mg
W/am/'n AT (ATonafa'on,). /!// da/a are /ne means o/ /r/p//ca/e eApen'men/5 in eacn o/ /ne ajjfec/ed
caM, and /ne}> are expressed as a percen/age o/para//e/ da/a ofe/a/ned ('n /ne con/ro/ am'ma/5
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Similar results were obtained with factor X (table I, lanes 4 and 5): in the affec-
ted cats the factor X concentration before treatment was less than 10% of nor-
mal and descarboxyfactor X was insubstantial (if any). Vitamin K administration
resulted in a strong increase of the factor X concentration (both in the one-stage
and in the two-stage assay) up to levels which were comparable with those in
the control cats.
Characterization of carboxylase/reductase content in normal and affected
cats.
Because the bleeding problem in the affected cats was clearly related to vitamin
K, we have investigated whether it could be ascribed to an alteration of one of
the enzymes of the vitamin K cycle. Firstly we have tested the ratio between the
plasma KO and K concentration before and 12 h after vitamin K administration.
In normal mammalian liver any KO formed is readily reduced by the enzyme
KO-reductase, and no KO is detectable in blood plasma. It is well known,
however, that in the case of a decreased KO-reductase activity substantial
amounts of KO are set free in the blood stream, especially after the administra-
tion of high doses of vitamin K (56). No elevated KO concentrations were found,
however (data not shown). Subsequently we have analyzed the various liver
biopsies for their carboxylase and reductase content. The results of these in vitro
experiments are summarized in table II. In agreement with the in vivo
measurements, no difference was found between the KO-reductase activity in
affected and that in control cats. The KHj-dependent carboxylase in the affected
cats seemed to be strongly impaired, however. The routine carboxylase assay is
performed at 4 mM of the pentapeptide FLEEL, which serves as a carboxylata-
ble substrate. Under these conditions the enzyme activity in the affected cats
was not more than 16% of that in the control ones. Hence the problem seemed
to be related to yglutamylcarboxylase, not to KO-reductase. It also seemed
interesting to know whether the relatively low carboxylase activity would be
accompanied by increased levels of non-carboxylated precursor proteins. The
fact that at least seven of these precursor proteins, each of them in varying
stages of maturation, are expected to be present in the liver microsomes places
severe constraints to their direct quantification. However, the pool of uncar-
boxylated proteins generally forms an 'endogenous substrate' for carboxylase
during the in vitro carboxylation reaction, and by having the carboxylation
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reaction proceed in the absence of exogenous substrate, a rough estimate about
the amount of precursor proteins may be obtained. No indication for elevated
amounts of endogenous substrate was found in the affected cats, however (table
II, line 3).
Hepatic marker tested
KO-reductase (pmol K formed/min
y-Glutamylcarboxylase
(pmol COj bound/min)
Endogenous precursor proteins
(pmol CO; bound)
Affected cats
120 ± 18
11.2 ±3.8
11.4 ±2.2
Normal cats
100 ± 15
73 ± 14
21.6 ±3.1
ƒƒ. Comparison o/ vitamin Jf-dependenf proteins in norma/ and ajQfecfed" Devon /?ex
ca/s. /!// reac7ionj were per/ormed under jfa«rfarrf conrf/7/ons. y-G/wfawy/car/wxy/ase wa5
<7i/anr///ed /ro/w f/ie /«/Via/ react/on ra/e in f/ie presence o/ 4 mW o/ /ne penfapepr/de FL££Z,
rne /n/tvosowia/ to«/e«r o/ endogenoHS precursor profeins was ej/iffia/ed /rom fne a/not/M o/
COj incorpora/ed dun>ig i>ic«/?a/io/! /or 7 /i in /Ae absence o/ ejco^eno«5 iMès/ra/e. 77ie dató
are presen/ed as //ie wea/w o/ /np//ca/e measuremen/s /« eat/i o/ e/7/ier fwo
or nt'o nor/na/ ta/s.
Comparison of the apparent kinetic parameters for substrates and cofactors
of y-glutamylcarboxylase.
In order to further identify the nature of the abnormality in the affected car-
boxylase, we have measured the apparent kinetic constants for several substrates
involved in the carboxylation reaction. The results are summarized in table III.
The KM"'"'' and the V„„"" for KHj were measured in the presence of an excess of
COj and 10 mM of the pentapeptide FLEEL, and it is clear that in normal and
affected animals the K^*^ values for this substrate were closely similar. Consis-
tent with the data shown in table II, the V„,„'"' for KHj in the affected system
was found to be about 5.5 fold lower than that in the control one. We also
compared the kinetic constants for a propeptide-deficient (FLEEL) and a propep-
tide-containing substrate (proPT28), obviously these tests were performed in the
presence of an excess of KH2 (0.1 mM) and COj. It turned out that in carboxy-
lating systems from normal cats the K^^ for the propeptide-containing substrate
was 2300 fold lower than that for FLEEL. This is consistent with earlier obser-
vations in bovine systems (41). In the affected cats, however, the effect of the
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pro-sequence on the K ^ was less prominent and resulted in not more than a
115-fold difference. In parallel, the differences in the V„„*"" values increased
from 5.5 fold when using the propeptide-deficient FLEEL to nearly 14-fold with
the substrate proPT28. This obviously amplifies the difference between normal
and affected cats. On the basis of these data we have formulated the hypothesis
that the coagulopathy observed in the affected cats was probably due to a muta-
tion in the hepatic y-glutamylcarboxylase, leading to an impaired recognition of
the pro-sequence in nascent blood coagulation factor precursors. To explain why
in vivo the production of the coagulation factors was restored after vitamin K
administration, we decided to investigate the possibility of an allosteric interac-
tion between the propeptide-binding site and the KHj-binding site on normal,
non-affected y-glutamylcarboxylase. If such an interaction could be demonstra-
ted in normal carboxylase, this would at least make plausible that a mutation in
the propeptide-binding site may lead to a different vitamin K requirement.
Firstly because the limited amounts of Devon Rex liver available did not allow
us to address this hypothesis in the same species, and secondly because the
question has a general character, not related to species, we decided to perform
our subsequent studies in the well-characterized rat and bovine liver systems.
Cofactor or
substrate tested
FLEEL
ProPT28
Animal
normal
affected
normal
affected
normal
affected
K "PP
(MM)
25 ± 5.0
17 ± 3.5
6700 ± 1200
4000 ± 1050
2.9 ± 0.7
35 ± 6
V "PP
* max
(pmol/min)
77.5 ± 16.9
14.0 ± 4.2
72.1 ± 13.8
13.0 ± 4.7
3.1 ±0.5
0.23 ±0.1
ƒƒƒ. Comparison o/ apparent fcinetic constants o/ nepa/ic enzymes /ro/n norma/ am/
' cats. 77ie Awr/c- twisfa/jfs were ca/t'M/afed fry ///e rtOfl-Z/war /easf sai/ares ret7i/;/fltte
(59) /« w/i/di we used //ie in/Via/ reaction ra/es a/ //ve aT/ferenf sufos/ra/e 6o«ce«fra//onj
ranging /rom 0.25 to 4 »mes f/ie AT,/*'' va/«e o/ (/ie compound <es/ed. TAe a"ara /or AT/j were
/e^ed" in //ie presente o/ /0 niA/ FL££Z.. i4// a<3/a presented are r/ie means f± 5.£.AfJ o/
fr/p//ta?e ej:per(men/s ('n eacn o/ e/r/ier nvo norma/ or rwo aj^ecfea' anima/s.
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Apparent Michaelis constants for KHj using either propeptide-containing or
propeptide-lacking substrates.
The KM*^ values for KHj were studied in ten carboxylating enzyme systems
which differed from each other by the nature of the carboxylatable peptide
substrates. The substrates used in this experiment are those given in figure 1,
and they were added to the reaction mixtures in excess: 10 mM FLEEL, 20 uM
d-osteocalcin, 20 uM proPT28, 1 mM proPT28(FA-16), 20 pM proFIXPT28, 20
uM proFIX59 or 20 uM proFTFLEEV. Moreover, in two cases the K,/"" values
for KHj were assessed by a combination of carboxylatable substrate + propepti-
de (20 uM).
1
2
3
4
5
6
7
e
proPT28
proPT28[FA-16]
proFIXPT28
pioFIXS9
proPTFLEEV
propeptide
d-osteocalcin
-18 -1 10 20 30 40
1 1 1 1 1 1
HVFLAPQQARSLLQRVRRANTFLEEVRK
HVALAPQOARSLLQRVRRANTFLEEVRK
AVFLDHENANKILNRPKRANTFLEEVRK
AVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECIEEKCSFEEAREVFENTERTNEF
HVFLAPOOARSLLQRVRRFLEEVRK
HVFLAPQQARSLLQRVRR
FLEEL
F/G. / Primary sfrucfure o/ fne pepftde^ «serf as carftoxytoteMe sufcx/ra/es in <«e vitamin K-
carftoxy/ase reac/ion. 77ie nw/nfrering /ram -75 to +40 re/ers to fne ami/io acid
ce in numa/i p/eprofnromfci'n. Sn/w/rate / fpra/T2S) w a jynf/iefic pep/ide £</n/7ar to rne
ami/to acid seoM^nce -75 to +/0 o/ /iMman destarftorypro//iroffiWn. 5ufts/ra/e 2
I'J »/n/7ar to pro/T2,5 excep//or r/ie extna«ge o/Z'/ie" into /1/a. 5«fesrrafe
is based on /ne propep/ide (7<S ami/io acids) o//actor /X a/id f/ie /ïrs/ 70
amino acid residues o/ /iwman descarAoxypro/nromfcin. 5wfcsfrafe 4 ^proF/X59) is a 59 residue
recwnfcinan/ pepfide con/aining f/ie propepride and f/ie co/np/efe /lon-carftoxy/a/ed G/a-do/nain
o/numan /actor /X. Suftsfrafe 5 fp/o/TFi.££V) is a synf/ie/ic pepnde composed o/ f/ie propep-
fide o/ /iwman pror/iromftin and f/ie pen/apepfide FL££K. Su/bsfrafe 6 fpropep/idej is siwi/ar to
fne residues -/8 to -7 in nu/nan preprof/iromWn. Tnc seoMe/ice o/ sufes/rató 7 fFL££L) is
/o«nd in severa/ coa^w/a/ion /actors (e.g. k m a n /actor V77). 5«isfra/e 8 Cd-osfeoca/cin) was
prepared fry f/ier/na/ decarooxy/a/ion o/fro vine os/eoca/cin.
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In those cases in which we used propeptide-lacking substrates, the KH, concen-
trations varied from 25 to 400 uM, whereas they ranged from 0.32 to 10 uM if
the carboxylatable substrates contained the pro-sequence. It turned out that in
the presence of the propeptide-lacking substrates (FLEEL and d-osteocalcin) the
K M ^ values for KHj were rather high (127 and 30 uM, respectively, see table
IV, lines 2 and 3). The addition of non-bound propeptide to the various reaction
mixtures did not significantly change these data (table IV, lines 4 and 5), which
is consistent with earlier observations of Cheung et al. (57). These authors failed
to check, however, the effect of substrates in which the propeptide is covalently
bound to the carboxylatable Glu-domain. Our data clearly demonstrate, that in
reaction mixtures supplemented with propeptide-containing substrates the KV''
for KHj values were considerably lower than those obtained in the presence of
substrates not covalently bound to the propeptide, and ranged from 0.8 to 3.7
uM (table IV, lines 6-10).
We have concluded, therefore, that the binding of a propeptide-containing sub-
strate to carboxylase results in a decrease of the K^ ' ' for KHj. The effect is
only seen if the propeptide and the carboxylatable sequence are covalently
linked via a peptide bond. A second conclusion which may be drawn from these
experiments is that, if added in excess (10 times their K^ concentration), both
proPT28 and proPT28(FA-16) had the same effect on the K , ^ value for vita-
min KHU. This strongly indicates that not the mutation, but the occupation of the
substrate-binding place is the factor determining the enzyme's K^*'''' for KHj.
The apparent interaction between the substrate binding place and the KHj bin-
ding place was not restricted to the rat, because similar results were obtained in
a carboxylating system derived from bovine liver. We also measured the K^^
for CO2 in the presence of substrates either containing or lacking the pro-se-
quence, but this constant was independent of the type of substrate used (data not
shown).
Apparent kinetic constants for vitamin KH, in carboxylase from vitamin K
deficient rats.
During vitamin K deficiency the carboxylation process comes to a halt, resulting
in the accumulation of precursor proteins in the liver. At least part of these
precursor proteins still contain the propeptide, and are tightly bound to y-glu-
tamylcarboxylase (58). In the in vitro carboxylation reaction this mixture of
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immature proteins may serve as a pool of endogenous substrate for carboxylase.
Comparison between carboxylase from vitamin K deficient and that from vita-
min K sufficient animals thus provided us with an additional tool to test the
hypothesis that the K„"^ of carboxylase for KHj is influenced by the binding of
the enzyme with a propeptide-containing substrate. It turned out that in the
presence of exogenous substrates lacking the pro-sequence, carboxylase from
vitamin K deficient animals had a 10-15 fold lower K M ^ for KH, than had
carboxylase from sufficient rats (table IV, lines 1-3). In the presence of exoge-
nous substrates containing the pro-sequence the values of the KM*"' for KHj
were comparable in both types of carboxylase (table IV, lines 6-10). It seems
therefore, that the endogenous precursor proteins bring about the same confor-
mational changes in carboxylase as do the propeptide-containing substrates.
Substrate added
1. None
2. FLEEL
3. d-osteocalcin
4. FLEEL + propeptide
5. d-osteocalcin + propeptide
6. proPT28
7. proFIX59
8. proFIXPT28
9. proPTFLEEV
10. proPT28(FA - 16)
K„"* for KHj
K-sufficient rats
127.0 ±20.00
30.0 ± 5.00
154.0 ± 23.00
25.0 ± 4.50
0.8 ± 0.14
4.2 ± 0.55
0.9 ± 0.16
1.1 ± 0.20
1.2 ± 0.25
of carboxylase from
K-deficient rats
8.0 ± 1.50
11.0 ± 2.40
3.7 ± 0.95
N.D.
3.2 ± 0.90
1.6 ±0.25
2.7 ± 0.80
1.1 ±0.24
1.8 ±0.30
1.8 ±0.27
/V. Sa/ carftoxy/a.se: AC„°" /or KW, depends on (ype o/ sufts/ra/e «serf. 77ie
Afin va/nes nrrf (.«/cw/a/ed />>' /ne /io/!-//near teas/ .s<7tta/"e.s /et7in/^ue (59,) in VWIIC/I we used
KW? eoncen/ra/io/u ranging /rom 0.J2 ro 400 ^M. Pep/i'de subs/rates were used in /ne /o//o-
w/ng fonccn/ra/jonj: d-otfroca/an, 20 ^Af; proPr2S, 20 ^M, proF/XP7"2S, 20 ^A/,- proF/X59,
20 ^M; pro/TFL££K. 20 /<M; FZ.EEZ., 70 niM ; proPr2SfFA-76j, 7 mAf and propep/ide, 70
/<Af. r/ie dala f± 5.£.M.j are presented ai /ne means o/lrip/ica/e measuremen/s in eatn of/wo
eifner aj^etfed or norma/ rars. N.D. stonds/or no/ de/ermi'ned.
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Discussion
The Devon Rex cats which were subject of the investigations reported in this
paper were clearly affected by a coagulopathy caused by reduced levels of all
vitamin K-dependent blood coagulation factors. The fact that this defect could
be totally corrected by pharmacological doses of vitamin K, suggested an abnor-
mality on the level of either vitamin K metabolism or vitamin K-dependent post-
translational processing of the various coagulation factors. Investigation of the
affected cats excluded hepatic disease or fat malassimilation, leaving the in-
gestion of a coumarin-type rodenticide (which is not uncommon in cats) as the
most likely explanation for the observed phenomena. However, this assumption
was contradicted by the fact that the high vitamin K requirement remained
during long periods of observation of the animals and by the absence of KO in
the plasma. Therefore we have analyzed the hepatic enzymes involved in the
vitamin K cycle, and found that KO-reductase (the target enzyme for coumarin
derivatives) activity in the affected cats was comparable to that in normal ones.
This observation definitely excludes the possibility of coumarin ingestion. On
the other hand it was shown that the abnormality involved y-glutamylcarboxy-
lase, and all in vitro data available suggest that this enzyme has undergone a
mutation resulting in decreased affinity for the pro-sequence of its natural sub-
strates. This would also explain why no evidence was obtained for elevated
levels of the hepatic pool of non-carboxylated precursor proteins complexed to
carboxylase. Since descarboxyproteins were neither found in plasma, the fate of
the non-carboxylated proteins remains obscure, however.
The question why a mutation in the substrate binding site leads to an increased
in vivo requirement for vitamin K in the affected animals may be explained by
the in vitro observation that in normal mammalian carboxylase the binding of
propeptide-containing substrates induce a high affinity binding site for the active
cofactor KH,. A mutation at the precursor protein binding site of the vitamin K-
dependent carboxylase may thus lead to a decreased affinity for KHj, resulting
in an increased dissociation constant for KHj. Under these conditions the supply
of vitamin K may be too low for a full carboxylation of the Gla-containing
coagulation factors, which explains why the affected animals are apparently
vitamin K deficient at a normal dietary intake of the vitamin. As soon as phar-
macological doses of vitamin K are administered, the amount of enzyme/KHj
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complexes is increased so that normal carboxylation of the coagulation factors
will occur. It has been shown earlier that non-bound propeptide decreases the
KM*^ for small Glu-containing substrates, probably by increasing the affinity of
the enzyme for peptide substrates (57). Our data strongly suggest that, if the
propeptide is covalently linked to the Glu-containing substrates, it also modifies
the affinity of carboxylase for its cofactor KHj.
At this time there is no material available to confirm the above hypothesis.
Therefore it is important that more Devon Rex cats are screened for the blood
coagulation disorder described here, and identified for further research. This
would give a better insight of the extent to which the defect has spread among
the breed, and its mode of inheritance. Additionally, the breeding of affected
animals may improve the accessibility of the altered carboxylase for experimen-
tal analysis.
References to Chapter 4
1 Esnouf, M. P., Green, M. R., Hill, H. A., Irvine, G. B., Walter, S. J. (1978) Biochem. J.
174, 345-348
2. Larson, A. E., Suttie, J. W. (1978) Proc. Natl. Acad. Sci. t/S/1 75, 5413-5416
3. Jones, J. P., Gardner, E. J., Cooper, T. G., Olson, R. E. (1977) J. Biol. Chem. 252,
7738-7742
4. Olson, R. E., Suttie, J. W. (1977) Vitam. Horm. 35, 59-108
5. Gallop, P. M., Friedman, P. A., Henson, E. (1980) in: Vitamin K Metabolism and
Vitamin K-Dependent Proteins (Suttie, J. W.,ed.) pp.408-412. Baltimore: University
Park Press
6. Friedman, P. A., Shia, M. A., Gallop, P. M , Griep, A. E. (1979) Proc. Natl. Acad. Sci.
t/S/t 76,3126-3129
7. McTigue, J. J., Suttie, J. W. (1983) J. Biol. Chem. 258, 12129-12131
8. Azerad, R., Decottignies-Le Maréchal, P., Ducrocq, C , Righini-Tapie, A., Vidal-Cros,
A., Bory. S., Dubois, J., Guudry, M.. Marquet, A. (1988) in: Current Advances in
Vitamin K Research ( Suttie, J. W. ed.), pp. 17-23, Elsevier, New York
9. Dubois, J., Gaudry, M., Bory, S., Azerad, R., Marquet, A. (1983) J. Biol. Chem. 258,,
7897-7899
10. Sadowski, J. A., Schnoes, H. K., Suttie, J. W. (1977) Biochemistry 16, 3856-3863
11. Sutie, J. W. (1980) CRC Crit. Rev. Biochem. 8,191-223
12. Vermeer, C. (1986) New. Compr. biochem. 13, 87-101
13. Suttie, J. W., Preusch, P. C , McTigue, J. J. (1983) in: Posttranslational Covalent Modi-
fications of Proteins (Johnson, B. C , ed.) pp. 253-279, Academic Press, New York.
14. Vermeer, C , Hendrix, H., Daemen, M. (1982) FEBS Lett. 148, 317-320
15. De Boer-van den Berg, M. A. G., Verstijnen, C. P. H. J., Vermeer, C. (1986) J. Invest.
Dermatol. 87, 377-380
16. De Boer-van den Berg, M. A. G., Uitendaal, M. P., Vermeer, C. (1987) Mol. Cell.
Biochem. 75, 71-76
96
17. Price, P. A., Williamson, M. K., Haba, T., Dell, R. B., Jee, W. S. S. (1982) Proc. Natl.
Acad. Sci. 79, 7734-7738
18. Ulrich, M. M. W., Knapen, M. H. J., Herrmann-Erlee, M. P. M., Vermeer, C. (1988)
Thromb. Res. SO, 27-32
19. Hamulyék, K., de Boer-van den Berg, M. A. G., Thijssen, H. H. W., Hemker, H. C ,
Vermeer, C. (1987) Brit. J.Haematol. 65, 335-338
20. Shearer, M. J., Barkham, P., Ralim, S., Stimmler, L. (1982) Lancet ii, 460-463
21. Shearer, M. J., Allan, V., Haroon, Y., Barkhan, P. (1980) in: Vitamin K Metabolism and
Vitamin K-Dependent Proteins (Suttie, J.W., ed.) pp. 317-327, University Park Press,
Baltimore, M.D.
22. Langenberg, J. P. (1985) Thesis, Leiden.
23. Bentley, R., Meganathan, R. (1982). Microbiol. Rev. 46, 241-280
24. Shearer, M. J., McCarthy, P. T., Crampton, O. E., Mattock, M. B. (1987). In: Current
Advances in Vitamin K research (Suttie, J.W., ed.) pp. 437-453, Elsevier Science
Publishers, New York.
25. Suttie, J. W., Kindberg, C. G., Greger, J. L., Bang, N. U. (1987). In: Current Advances
in Vitamin K research (Suttie, J.W., ed.) pp. 465-476, Elsevier Science Publishers, New
York.
26. Suttie, J. W., Mummah-Schendel, L. L., Shah, D. V., Lyle, B. J., Greger, J. L. (1988).
Am. J. Clin. Nutr. 47, 475-480
27. Fujimura, Y., Okubo, Y., Sakai, T., Sugimoto, M., Takase, T., Yoshioka, A., Fukui, H.,
(1984). Haemostasis 14, 211-217
28. Suzuki, S., Kanagawa, K., Maki, M., Shirahawa, K., Terao, T. (1984). Monatsschr.
Kinderheilkd. 132, 290-292
29. Yen, C. S., Mack, D. O. (1980). Proc. Soc. Exp. Biol. Med. 165, 306-308
30. Olson, R. E., Houser, R. M., Searcey, M., Gardner, E. J., Scheinbuks, J., Rao, G. N. S.,
Jones, J. P., Hall, A. L. (1978). Fed. Proc. 37, 2610-2614
31. Gardner, E. J. (1977). Fed. Proc. 36, 307 (Abstr.)
32. Jones, J. P., Fausto, A., Houser, R. M., Gardner, E. J., Olson, R. E. (1976). Biochem.
Biophys. Res. Commun. 72, 589-597
33. Friedman, P. A., Shia, M. (1976). Biochem. Biophys. Res. Commun. 70, 647-654
34. Newton-Nash, D. K., Sadowski, J. A. (1983). Fed. Proc. 42, 923 (Abstr.)
35. Vermeer, C , Soute, B. A. M. (1987). In: Current Advances in Vit. K research (Suttie, J.
W., ed.) pp. 25-39, Elsevier Science Publishers, New York.
36. Soute, B. A. M., Budé, R., Buitenhuis, H. C , Vermeer, C. (1989). Anal. Biochem. 182,
207-211
37. Vermeer, C. (1990) Biochem. J. 266: 625-636
38. Fasco, M. J., Hildebrandt, E. F., Suttie, J. W. (1982) J. Biol. Chem. 257, 11210-11212
39. Willingham, A. K., Matschiner, J. T. (1974) Biochem. J, 140, 435-441
40. Carlisle, T. L., Shah, D. V., Schlegel, R., Suttie, J. W. (1975) Proc. Soc. Exptl. Biol.
Med. 148, 140-144
41. Ulrich, M. M. W., Furie, B., Jacobs, M. R., Vermeer, C , Furie, B. C. (1988) J. Biol.
Chem. 263, 9697-9702
42. Knobloch, J. E., Suttie, J. W. (1987) J. Biol. Chem. 262, 15334-15337.
43. Jorgensen, M. J., Cantor, A. B., Furie, B. C , Brown, C. L., Shoemaker, C. B., Furie, B.
(1987) Cell, 48, 185-191
44. Hubbard, B., Jacobs, M., Ulrich, M. M. W., Walsh, C , Furie, B., Furie, B. C. (1989) J.
Biol. Chem. 264, 14145-14150
97
45. Ware, J., Diuguid, D. L., Liebman, H. A., Rabiet, M.-J., Kasper, C. K., Furie, B. C ,
Furie, B., Stafford, D. W. (1989) J. Biol .Chem. 264, 11401-11406
46. Maddison, J. E., Watson, A. D. J., Eade, I. G., Exner, T. (1990) J. Am. Vet. Med. Ass.
197, 1495-1497
47. Tishler, M., Freser, L. T., Wendler, N. L. (1940) J. Am. Chem. Soc. 62, 2866-2871
48. Vermeer, C , Soute, B. A. M., Hendrix, H., de Boer-van den Berg, M. A. G. (1984)
FEBS Lett. 165, 16-20
49. Soute, B. A. M., Ulrich, M. M. W., Vermeer, C. (1987) Thromb. Haemostas. 57, 77-81.
50. Thijssen, H. (1987) Biochem. Pharm. 36, 2753-2757
51. Shearer, M. J. (1986) in: Vitamins. HPLC of small molecules, a practical approach. Lim
C K (ed). IRL Press, Oxford, 1986: 157-219
52. Vermeer, C , Soute, B. A. M., Hemker, H. C. (1978) Thromb. Res. 12, 713-716
53. Kirchhof, B. R. J., Vermeer, C , Hemker, H. C. (1978) Thromb. Res. 13, 219-232
54. Lindhout, M. J., Kop-Klaassen, B. H. M., Hemker, H. C. (1978) Biochim Biophys Acta
533, 327-341
55. Sedmak, J. J., Grossberg, S. E. (1977) Analyt. Biochem. 79, 544-552
56. Bechtold, H., Trenk, D., Meinertz, T., Rowland. M., Jiihnchen, E. (1983) Brit. J. Clin.
Pharmacol. 16, 683-689
57. Cheung, A., Engelke, J. A., Sanders, C , Suttie, J. W. (1989) Arch. Biochem. Biophys.
274, 574-581
58. De Metz, M., Vermeer, C , Soute, B. A. M., van Scharrenburg, G. J. M., Slotboom, A.
J., Hemker, H. C. (1981) FEBS Lett. 123, 215-218
59. Cleland, W. W. (1979) Methods in Enzymology 63, 103-138
98
CHAPTER 5
Enzymes involved in the recycling of vitamin K
Based on:
- Vermeer, C , Soute, B.A.M., Aalten, M., Knapen, M.H.J., and Thijssen,
H.H.W. (1988). Vitamin K reductases in normal and in warfarin-resistant rats.
Biochem. Pharmacol. 37, 2876-2878.
- Soute, B.A.M., Groenen-van Dooren, M.M.C.L., Holmgren, A., Lundström,
J., and Vermeer, C. (1992). Stimulation of the dithiol-dependent reductases in
the vitamin K-cycle by the thioredoxin system: strong synergistic effects with
protein disulphide-isomerase. Biochem. J. 281, 255-259.
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Introduction
Reduced vitamin K (KHj) is an obligatory cofactor in the carboxylation reaction,
in which it is converted into the epoxide form (KO). Since body pools of vita-
min K are extremely low, efficient recycling of the vitamin is an essential
physiological requirement. The dietary intake of the vitamin is solely in the
quinone form, because of the rapid oxidation by air of an eventually reduced
intermediate in foods. Therefore mechanisms for efficient reduction/recycling
must be present in the microsomal fraction to meet the needs of the enzyme
carboxylase. Although it has never been proven unequivocally, it is generally
assumed that the reduction of KO into KHj occurs via the quinone form (1).
Several enzymes have been identified capable of reducing either vitamin K, KO
or both. The presence of at least two NAD(P)H-dependent quinone reductases
has been reported in the literature; one found in the cytoplasm, the other in the
microsomal fraction (2-4). Fasco and Principe (5) demonstrated the occurrence of
an exclusively dithiol dependent activity capable of producing KH, both from
vitamin K and KO. Whether these reducing steps are exerted by one or two
enzymes is still a matter of investigation. It was suggested by Fasco and Lee (6)
that the dithiol driven activities are located at separate catalytic sites and that an
essential disulfide supplies the reducing equivalents for both reduction steps.
Thijssen and Baars (7) recently demonstrated the existence of a microsomal
warfarin receptor located at these dithiol-dependent reductases. The in vitro
activity of the dithiol-dependent reductases is readily detectable in the presence
of synthetic dithiols like dithiothreitol, but the in vivo cofactor is unknown at
this time.
As has already been mentioned earlier both dithiol-dependent reductases and not
the NAD(P)H-dependent ones (8) are strongly inhibited by coumarin derivatives,
which is a clear difference with the dithiol-dependent and NAD(P)H-dependent
enzyme systems. In the case of intoxication the dithiol-dependent pathway
cannot be used and therefore the second route, via the relatively warfarin-insen-
sitive NAD(P)H reductases, can overcome the warfarin block. A prerequisite in
that case is that high amounts of vitamin K are available. Warfarin-binding
studies in an experimental animal (rat) model system already revealed that nor-
mal microsomes bind warfarin more tightly and in larger amounts than those
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from warfarin-resistant rats of a Welsh strain (9,10). In warfarin-resistant rats of a
different strain we have focused our attention to the likelihood that both dithiol-
dependent reductase activities are exerted by one and the same enzyme.
Dithiol-dependent reductases in normal and in warfarin-resistant
rats
The conversion of vitamin K quinone (K) into KH, may be accomplished either
by a dithiol-dependent reductase or by a NADH-dependent enzyme. The dithiol-
dependent reductions of KO and K are extremely sensitive to the action of oral
anticoagulants such as warfarin (8). KHj-dependent carboxylase activity as such
can be assessed by reducing vitamin K into KHj in a chemical way before it is
added to the reaction mixtures. The activity of the two K reductases, on the
other hand, is frequently determined in an indirect way, namely by starting the
carboxylation reaction with either K + DTT or with K + NADH. A direct mea-
surement of the K reductases by establishing the production of KH2 is less
reliable because the hydroquinone is unstable and is rapidly re-oxidized into its
quinone form by traces of oxygen.
F/G. i. War/ari/i-jnniMion o/ (K +
depinrfenf car^oxy/ase. 77me course «rpe-
r/me«te frefween 0 and 50 m;n were per/br-
mea" a/ eat/i war/ar/n concenfra/ion. 77ie
im'fia/ carfrory/a/ion rate was ca/cu/afed
and «pressed as a percen/age <?ƒ //ie non-
inniMed reaction. 700% acfi'v/ry corres-
po/ids to 24J0 dpm/m/n /« switepf/We ra/s
( • - • ^ and to 2970 dp/n/znin in war/an'n re-
raw (O-O/
5 10 is
[ Warfarin] (|iM)
Most studies up till now concerning warfarin resistance in rats have been perfor-
med with animals of the Welsh resistant strain (HW). It has been demonstrated
(10,11) that the resistance in these animals originates from a strongly reduced
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inhibitory effect of warfarin on the dithiol-dependent reductase activities (both
KO and K reductase). A second warfarin-resistant strain (HS), which had deve-
loped in Scotland independent of the Welsh strain, was described by Greaves
and Ayres (12). It was demonstrated by Thijssen (13) that in HS rats the in vitro
sensitivity of KO reductase for warfarin inhibition was comparable to that in
normal rats but that the inhibitory effect was reversible. We have compared the
reductase activities in wild-type and in warfarin-resistant HS rats. In our Scottish
resistant strain we observed that the dithiol-dependent reductase(s) were inhibi-
ted by warfarin to a similar extent as were the wild-type enzymes (figure l).The
in vitro sensitivity for warfarin was measured in the hepatic (K + DTT)-depen-
dent carboxylase assay, and the warfarin-resistant animals were compared with
normal Wistar rats. Whereas the wild-type K-reductase bound irreversibly to
warfarin, the drug was rapidly washed off from the mutant enzyme strain with
tris-buffered saline (figure 2)
1 2 3 4
Number of washing cycles
F/G. 2. EjQfec/ o/ was/iing o/ microtomes.
/tor/na/ ft/oied /raw,) and
(open fears,) rars were
/or fne prepara/zon o/ microtomes.
5/ep 7 represente fne non-was/ied reso/uW-
//zerf m/croso/nes. 7\w was/i/ng cyc/es w;>n
a /ow-sa// owjj'er (s/eps 2 ana" J,) were /o/-
/owed oy a n/gn-sa// was/i fs/ep 4) and fne
CAT + D77>dependen/ carooxy/ase acf;V;'ry
was measured and expressed as a percen-
tage o/ //KM I/I non-/rea/ed an/ma/s.
Like in the Welsh resistant strain, also in the Scottish strain an alteration was
found both in KO-reductase (13) as well as in the dithiol-dependent K-reductase.
Hence this is the second case in which a mutation leading to warfarin resistance
results in an apparent identical mutation in both dithiol-dependent reductases.
The probability of simultaneous mutations in two separate genes is extremely
low, the chance that simultaneous mutations have taken place in two different
strains must be regarded as nil. Therefore we postulate that both dithiol-depen-
dent steps in the vitamin K-cycle are mediated by the same enzyme.
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Natural cofactors for the dithiol-dependent reductase v *uin? i r
A second point of interest was the origin of the reducing equivalents required
for the reduction of KO into KHj. In an earlier paper from this group it has
been demonstrated that in vitro the protein thioredoxin may play a role in the
hydrogen transport to KO-reductase (14). We have elaborated on those findings,
and postulate a model in which the oxidation of cysteine residues into cystine
(mediated by the enzyme protein disulphide isomerase) is coupled to the reduc-
tion of KO. In this model two posttranslational models are coupled, and obtain
their energy from two successive steps in the oxidation of hydrogen. Additional-
ly it explains why the formation of KO and the formation of Gla are not cou-
pled stoichiometrically: if more cystines than Gla residues are formed (which is
probably usual), the recycling of vitamin K must proceed at a higher speed than
is required for Gla formation. This provides a rational explanation for the obser-
vation that epoxidation and carboxylation are rapidly uncoupled in vitro. Obvi-
ously our hypothesis will have to be tested thoroughly. Rather than regarding
them as conclusive, we hope that the data obtained thus far will be a starting
point for future investigations. For that reason the key paper is reproduced in its
complete form.
Conclusions
Both reduction steps in the vitamin K-cycle may be accomplished by dithiol-
dependent reductases. Their identical kinetic behaviour towards DTT and inhi-
bition by several compounds (warfarin, lapachol, sulfaquinoxaline) together with
the mutation pattern in two independent cases of warfarin resistance strongly
supports the idea that both reduction steps are exerted by the same enzyme. In
vitro this enzyme may use synthetic dithiols as a reducing cofactor. We have
shown that in vitro dithiothreitol may successfully be replaced by a combination
of thioredoxin and protein disulphide isomerase. Under these conditions both
NAD(P)H and reduced RNAase may serve as reducing cofactors. On the basis
of these results it is proposed that the hydrogens which are set free during the
formation of disulphide bonds in a posttranslational modification are oxidized
via the vitamin K-cycle, and thus provide the energy required for a second
posttranslational modification: the conversion of Glu residues into Gla residues.
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Stimulation of the dithiol-dependent reductases in
the vitamin K-cycIe by the thioredoxin system:
strong synergistic effects with Protein Disulphide-
Isomerase
Berry A.M. Soute, Monique M.C.L. Groenen-van Dooren, Arne Holmgren,
Johanna Lundström and Cees Vermeer.
Abstract
It has been shown previously that the thioredoxin system (thioredoxin + thiore-
doxin-reductase + NADPH) may replace dithiothreitol (DTT) as a cofactor for
vitamin KO- and K-reductase in salt-washed detergent-solubilized bovine liver
microsomes. Here we demonstrate that the system can be improved further by
adding protein disulphide-isomerase (PDI) to the components mentioned above.
Moreover, NADPH may be replaced by reduced RNAase as a hydrogen donor.
In our in vitro system the various protein cofactors were required at concentra-
tions of 2-5 orders of magnitude lower than that of DTT, whereas the maximal
reaction rate was about 3-fold higher. PDI stimulated the thioredoxin-driven
reaction about 10-fold with an apparent K^ value of 8 uM. These data suggest
that in the in vitro system the formation of disulphide bonds is somehow linked
to the vitamin K-dependent carboxylation of glutamate residues. In vivo both
disulphide formation and vitamin K-dependent carboxylation are post-trans-
lational modifications taking place at the luminal side of the endoplasmic reti-
culum of mammalian secretory cells. The possibility that the reactions are also
coupled in vivo is discussed.
Introduction
Most secretory proteins undergo extensive post-translational processing before
they are secreted into the extracellular environment. Although more than 100
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posttranslational modifications are presently known (15), most of these reactions
have been studied in less detail than transcription and translation, the earlier
steps in protein biosynthesis. In this paper we focus our attention on two of
these post-translational modifications: the conversion of glutamate (Glu) into
gammacarboxyglutamate (Gla) residues, and the formation of the disulphide
bonds.
The formation of Gla-residues is accomplished during a carboxylation reaction,
which is catalyzed by the microsomal enzyme y-glutamylcarboxylase (hereafter
termed: carboxylase). Vitamin K hydroquinone (KHj) functions as a cofactor in
this reaction (16,17). The oxidation of KHj into an epoxide (KO) provides the
energy required for the carboxylation step. In two successive reduction steps
(figure 1) KO is subsequently recycled into KHj. In vitro the synthetic dithi-
othreitol (DTT) as well as reduced thioredoxin may serve as a reducing cofactor
for KO- and K-reductase (14,18).
DTT-(SH)2 DTT-Sj
DTT-
F/G. i . TAe vitamin AC cycfe.
Enzymes azfa/}\s/>i,g
arc.- /a,
vifami/i AT
f,- 2,
rednc/cwe. 'G/M' .stands /or
- or profe/'n-fcoMnd G/u
DTT-(SH)j
In its reduced form thioredoxin (12,000 Da) is a powerful protein disulphide-
reductase and acts as a hydrogen donor for the enzymatic reduction of ribonu-
cleotides and methionine sulphoxide (19,20). Dihydrolipoic acid (21) and dihydro-
lipoamide (H.H.W. Thijssen, personal communication) also have reductase
cofactor activity. The origin and the nature of the physiological reduction system
is still a matter of debate, however (22).
Nascent polypeptide chains entering the lumen of the endoplasmic reticulum
contain free SH-groups, which are transformed into native disulphide bonds by
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net oxidat ion and the suggested catalytic action of an enzyme called protein
disulphide isomerase (PDI, E C 5.3.4.1, for a review see (21)). PDI is a 57 ,000
Da acidic protein in the lumen of the endoplasmic ret iculum possessing two
thioredoxin-l ike domains with the active site sequence Trp-Cys-Gly-His -Cys .
Recent ly it was demonstra ted that the thioredoxin-like domains of oxidized PDI
are substrates for N A D P H and mammal ian thioredoxin-reductase (TR; E C
1.6.4.5), and that PDI has thioredoxin-like activity in the reduct ion of insulin
disulphides (23). PDI and thioredoxin thus share a similar mechan i sm of act ion,
summar ized in equat ions (1) and (2):
PDI-Sj + NADPH + H+ 22 > PDI-(SH);, + NADP+ (1)
PDI-(SH>2 + insulin-S, spontaneous > PDI-Sj + insulin-(SH)2 (2)
In equat ion (1) TR stands for thioredoxin-reductase. PDI-S2 is also readily
reduced by reduced thioredoxin. Hence PDI has a higher redox potential and is
a much weaker reductant than is thioredoxin (23). This suggests that PDI is redu-
ced by SH-groups in the nascent proteins according to equat ion (3):
PDI-S j + protein-(SH)2 ' ^ PDI-(SH)2 + prote in-Sj (3)
Obviously the PDI-bound sulphydryl groups should be oxidized somehow, but
nothing is known about the nature and origin of the oxidizing cofactor(s) invol-
ved (24).
The c o m m o n aspects for the vitamin K-dependent carboxylat ion and the disulp-
hide bond formation are:
1. Both reactions take place at the luminal side of the rough endoplasmic reti-
cu lum (similarity of location).
2. Both reactions occur during the early steps of post-translational modif icat ion
(similarity in t ime).
3. Both involve thiol-disulphide exchange reactions, but their redox cofactors
have remained obscure despite substantial amounts of research (similarity of
prob lem) .
Because of all these similarities we have investigated in an in vitro system
whether these two reactions are coupled, so that the disulphide bond formation
provides the reducing equivalents required for the reduction of K O and K, i.e.
whether the reducing equivalents produced during the formation of the cyst ine
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bonds may be oxidized via the vitamin K cycle. The results of these investiga-
tions are presented in this paper.
Materials and methods
A/aterw/s. Vitamin K, was obtained from Merck (Darmstadt, Germany) and
converted to its epoxide form (KO) according to the procedure of Fieser et al.
(25). The various forms of vitamin K were added to the reaction mixtures as an
ethanol solution. NaH'*CO, (55 Ci/mol) was from Amersham International
(Amersham, Bucks., U.K.) and the pentapeptide Phe-Leu-Glu-Glu-Leu (FLEEL)
from Vega Biochemical Co. (Tucson, AZ, U.S.A.). DTT, CHAPS, lipoamide
(reduced form), and glutathione (reduced form) were purchased from Sigma (St.
Louis, MO, U.S.A.). All other chemicals were of analytical grade or better.
Proteins. The following proteins were prepared from bovine tissues according
to previously described methods: PDI (23), thioredoxin (26), TR (27,28). Glutare-
doxin was prepared from E.coli (29). E. coli thioredoxin and TR (19) were from
Imco (Stockholm, Sweden). Glutathione-reductase (from yeast; EC 1.6.4.2) was
purchased from Boehringer Mannheim (Germany) and insulin (from pig pan-
creas) and RNAase (from bovine pancreas; EC 3.1.27.5), were from Sigma.
RNAase was reduced in 100 mg quantities by incubating the enzyme for 30 min
in the presence of 200 mM DTT and 8 M urea in buffer C (Tris-buffered saline
at pH 8.5) and 37 °C. After removal of the DTT and urea by size exclusion
chromatography in buffer C on a PD 10 column (Pharmacia) the samples were
flushed with nitrogen gas and kept in sealed tubes at 4 °C until use. Salt-was-
hed, detergent-solubilized microsomes were used as a source of the carboxyla-
se/reductase complex (30). After the extensive washing procedure, the PDI con-
tent of these microsomes was determined using the micromethod of insulin
reduction (see below) and turned out to be 3.5 uM. The microsomes contained
neither thioredoxin nor TR in detectable amounts (by Western blot analysis).
Various assays. Vitamin K-directed carboxylase activity was determined as
described earlier (31), but with some modifications to allow for a maximal acti-
vity of the PDI/thioredoxin system. Reaction mixtures contained 25 mM
Tris/HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.4% (w/v) CHAPS, 0.1 mM
vitamin K quinone, 5 uCi of NaH'^CO, and 1 mg of microsomal proteins; the
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incubation temperature was 20 °C. Reducing cofactors were added as indicated.
Initial reaction rates were calculated from time courses obtained after incubati-
ons for 0, 5, 10, 20, and 30 min. Each experimental point was determined in
duplicate, and blank values (no vitamin K added) were subtracted throughout.
KO-reductase was assayed in 0.25 ml reaction mixtures of a similar compo-
sition as described for carboxylase, but the samples were preincubated at 20 °C
for 3 min and the reaction was started by adding KO instead of K. Aliquots (50
pi) were taken after incubation for 2.5, 5, and 10 min; during this period the
reaction rates were linear. Vitamin K metabolites were extracted from the reac-
tion mixtures and analyzed by HPLC as described by de Boer-van den Berg et
al. (32).
Kinetic data were calculated by the non-linear least-squares technique (33), in
which we used the initial reaction rates at 6-8 different substrate concentrations,
ranging from 0.25 to 4 times the apparent K ,^ value of the compound tested.
The data are presented as the means ± S.E.M. of three independent experiments.
The enzymatic activities of PDI, thioredoxin, TR and glutaredoxin were
tested by methods described previously (23,28). Protein concentrations were
assessed according to Sedmak & Grossberg (34).
Results
Co/actors /or viVam/n A-<fe;;in<fen; car6oxyfa.se. In a first set of experiments
we have compared synthetic DTT with seven natural reducing agents for their
ability to stimulate the vitamin K-dependent carboxylase reaction in vitro (Table
I). A low but distinct activity was found in the presence of NADH and NADPH,
but the reaction was insensitive to warfarin up to concentrations as high as 100
uM. In contrast, the reactions stimulated by the other cofactors were all highly
sensitive to inhibition by warfarin, with apparent Kj values below 1 uM. This
demonstrates once more that the NAD(P)H-dependent reduction of K is accom-
plished via an alternative pathway (35), which will not be discussed in this paper.
From Table I it appears that DTT, thioredoxin and lipoamide are all three ca-
pable of stimulating the K-dependent carboxylase reaction, but that thioredoxin
differs from the other two cofactors by its low apparent K^. Therefore we
regard thioredoxin as a good candidate for being a natural cofactorfor the reduc-
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tases involved in the vitamin K cycle. Maximal activity was only obtained in the
presence of the NADPH-dependent enzyme TR, suggesting that in our system
oxidized thioredoxin is recycled via this pathway.
Compound added
1. DTT
2. NADH
3. NADPH
4. Glutathione
5. Thioredoxin + TR + NADPH
6. Glutaredoxin
7. PDI
8. PDI + TR + NADPH
9. Lipoamide
(mM)
0.8 ± 0.2
1.5 ±0.3
1.1 ±0.3
n.d.
0.022 ± 0.005
n.d.
n.d.
n.d.
0.6 ±0.1
max
(relative rate)
100 ± 18
7± 2
8± 3
n.d.
32 ± 7
n.d.
n.d.
10 ± 2
21 ± 4
I. wereagenfj as co/acfors /or A-dependen/ carèoxytose. A
/fle itonda/rf cond/7/ort.s deitr/fcerf ;n Mafer/a/i anrf Mer/iOffr. flo//i
and PD/ were reiferf I/I //ie presente o/an e*cess o/ 77? f0.2 ^M; and /VADP// (4
(up ro 24 ;/M) wa5 a/so /es/ed /n f/ie absence o/ //iese compownds. G/n/aredttAï/1
tontenfrar/'on: 65 ^M) was assayed in r/ie presente o/an excess «ƒ g/M/ar/i/wie f4 mM,
//i/o/je-redMttose f/0 /i^/m/j, and NADPW (4 mM). 7"/ie e#ecr o/ PD/ was t7jecA:ed in rne
presente o/ 4 mM /VAD/*//. OA/da/ion o/ r/ie pro/c/n d/7ni'o/£ was re/arded />y /«e presente o/
/0 ^M D7T ;n a// reatfi'on miA-fwres. B0//1 //n'oredoAin and T/? were/ro/w £. to/i. N.d. s/ands
/o/- no/ de/ecfaWe.
co/ac/ors /or (Vitamin /f + /AioreJoArj«)-</spcnrf««r corftoxy/ase.
Because the maximal reaction rate of the DTT-stimulated reaction was still 3-
fold higher than that of the thioredoxin-catalysed one, we investigated whether
the latter reaction could be stimulated further by one of the other cofactors
mentioned above. As is shown in Table II only PDI had a measurable effect,
and it is notable that the combination of PDI + thioredoxin resulted in a 3-fold
higher reaction rate than was obtained with DTT. The apparent K^ (8 uM) for
PDI was about 12-fold higher than the concentration of endogenous PDI (0.7
uM, see Materials and Methods) in our reaction mixtures, which explains the
stimulatory role of added PDI. We have also compared the characteristics of a
109
system containing thioredoxin and TR from E. coli with a system in which all
cofactors were of bovine origin.
Compound added
1. N o n e ' • : /
2. DTT
3. Glutathione
4. Glutaredoxin
5. Lipoamide
6. PDI
(mM)
_
0.8 ±0.3
—
n.d.
0.008 ± 0.002
V "PP
* max
(relative rate)
32 ± 5
100 ±24
29 ± 4
30 ± 3
36 ± 7
335 ± 66
/. Stimulo/ion o/ (tfji'oredoxin + )^-</epen</en/ caréoxytose. A//
conta/ned //wredan/i (0.2 mAf), 7/? (0.2 ^MJ and NAD/W (4 mAf). Fwr//ier derai/s are as
deifn'èed /« //ie /egend Jo 7aWe /.
As can be seen from Table III, the apparent K ,^ values for thioredoxin and PDI
were similar in both systems, whereas in the homologous system that for TR
was slightly (4-fold) higher than in the heterologous system. This may be due to
the rather high sensitivity of mammalian thioredoxin/TR systems to irreversible
inactivation by molecular oxygen (36), or to the fact that bovine TR has a broa-
der substrate specificity than the E. coli enzyme (19).
Reaction component
Thioredoxin
Thioredoxin reductase
PDI
KM"'* (JIM) in system
E.coli
20 ± 6
0.019 ± 0.006
8.1 ± 1.8
with Trx/TR from
calf thymus
21 ± 5
0.081 ±0.012
7.9 ± 2.4
//ƒ. Apparai/ K„ /or co/ac/ors o/ vttamin K-<fepe/ufeRf carèorytose A//
were per/ormed under sfa/jdard tondi7/on5. 7VJC 5/a/ic/s /or r/i/'oreaarin. /ƒ added ƒ/» ejrcew
conce«/ra//on o/ r/ie variows reac/ion component wai 70 //mej f/ie Af« va/«e. Fur?«er
are as dejcr/7>ed in r/ie /e#end ro TaA/e /.
In all experiments mentioned thus far NADPH was used as a hydrogen donor
for the PDI-containing systems; the physiological reductant of PDI is probably
not NADPH but more likely a reduced protein. Therefore we have measured the
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kinetic properties of the (PDI + thioredoxin)-driven carboxylase reaction in the
presence of either NADPH or reduced RNAase (Table IV).
System used
DTT
Trx/TR + NADPH
Trx/TTR + PDI + NADPH
Trx/TR + reduced RNAase
Trx/TR + PDI + reduced RNAase
'"CO2 incorporated (dpm)
5,419 ±1,877
2,864 ±724 : , '
16,320 ±4,518
92 ±25
12,941 ± 2,932
/V. /?e<fuce<f flM4ase as a co/ac/or /or JC-depe/idenf carfroxy/ase. A// /'/icttAa//onj were
ed /or 30 m/n under s/andard condi(/o/i;, and //ie rej«//5 are ej;pre«ed as dp/n incor-
porated per wig o/ mitrosoma/ profe/ns. £acn ejtper/menfa/ po/n/ was de/erwj/wed 1/1 fr/p//ca/e,
and rne va/«ei are means ± S.£.A/. 7>J: sfands /or rn/oredo.wn. 77ie various reacf/on compo-
nents were used in /ne /o//ow/ng to/ice/i/ra/ion^: Z)7T, 4 mM; £. co/i /yiioredoxin, 0.2 mM; £.
to// 77?, 0.2 ^Af; PD/, 24 ^M; NADP//, 4 /nM,- reduced KM4aje, 0 2 «W. Furt/ier de/ai/s are
as destr/fced 1/1 /ne /egends /o TaWes / and //.
No differences between the two systems were observed, except that the RNA-
ase-directed reaction could be blocked completely by 100 uM warfarin, whereas
in the presence of NADPH the inhibition by warfarin was only 92%. The resi-
dual activity probably originated from the warfarin-insensitive NADPH-depen-
dent K reductase mentioned earlier in this paper.
Co/actors /or /C0-ra/«c/ase. The reductases of the vitamin K cycle may be
tested directly by extraction of the various K metabolites from the reaction
mixtures, followed by HPLC analysis. At rate-limiting concentrations of the
various cofactors this method was not sufficiently accurate to yield reproducible
kinetic data. Therefore we have measured the effect of the various cofactors for
KO reductase under non-limiting conditions only. The results are summarized in
Table V, and demonstrate the same tendency as was found for K-dependent
carboxylase: PDI alone is not a cofactor for the enzyme, the cofactor activity of
(thioredoxin + TR) is 30-40% that of DTT, and the combination of thioredoxin,
thioredoxin-reductase and PDI may stimulate the reaction to a level which is
several fold higher than that reached with DTT alone. Like in the case of K-
dependent carboxylase, the data obtained with thioredoxin and TR from E. coli
were slightly better than those obtained with the all-bovine system.
I l l
Cofactor(s)
DTT
PDI
Trx
Trx
Trx + PDI
Trx + PDI
Source of Trx/TR
.. .
—
E. coli
bovine thymus
E. coli
bovine thymus
Rate of K.0 reduction
(pmol K.mg'\min"')
25.6 ± 3.2
0
13.6 ± 2.9
9.7 ± 2.7
57.1 ± 14.8
49.8 ±11.5
77iWe V. Co/ac/or ac/ivu} o/ various m/wcta/ite /or K0 rerfuc/ase. A
per/ormerf u/ider s/aridard cortd/7/ons; //ie co/ice/i/ra/io/is o///ie var/ons twwporte/i/s
were /O r/mes //ie £„""' va/ues/ou/id/or //ie tf-depe/ide/i/ car/wry/a/zon reac/ion. 77ie
are expressed" as pwio/ /f/ormed per mg o/ /nicrojoma/ pro/ejns per mj/i. £ac/i experwien/a/
po/n/ was de/erm/ned I/I /rip//ca/e, and //ie va/ues are means ± S.E.M. 7r;t s/ands /or //i/ore-
r/n. Fur//ier de/a/7s are as /« //ie /egend /o Taft/e /.
Discussion
Despite considerable efforts neither KO-reductase nor vitamin K reductase have
yet been purified to homogeneity. Therefore we have used the rather crude
system of salt-washed detergent-solubilized microsomes for all experiments
described in this paper. It was shown that under these experimental conditions
the combination of reduced RNAase, PDI and thioredoxin/TR is superior to
DTT in providing the reducing equivalents required in the vitamin K cycle. This
is demonstrated by the fact that the apparent K ,^ values for these compounds are
between 2 and 5 orders of magnitude lower than that for DTT, whereas the
maximal reaction rate is about 3 fold higher. These conclusions hold true for
homologous systems in which all proteins are of bovine origin, but also for
systems in which thioredoxin and thioredoxin-reductase are from E. coli. Advan-
tages of the latter proteins are that they are commercially available, and that
they are less sensitive to inactivation by thiol oxidation with molecular oxygen
(19). Our data clearly demonstrate that in an in vitro system the process of
disulphide bond formation may be coupled to the reductive steps in the vitamin
K cycle. All reaction components required for this coupling are natural com-
pounds, the occurrence of which in the endoplasmic reticulum has been demon-
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strated (37-39). However, the way in which this coupling is brought about re-
mains uncertain.
The fact that reduced thioredoxin is the only reaction component displaying
cofactor activity for KO and K reductase seems to support the reaction pathway
shown in figure 2A. This is consistent with results from Gardill and Suttie (40),
who demonstrated that E.coli thioredoxin may be used as an affinity ligand for
the partial purification of KO-reductase. On the other hand it is likely that PDI
is involved in disulphide bond formation in the way shown in figure 2B, and it
is tempting to speculate about the possibility that both processes are directly
coupled (i.e. X = PDI and Y = thioredoxin). However, such a sequence of
events is not in line with the respective redox potentials of the proteins invol-
ved, thioredoxin being a much stronger reductant than is PDI (23,41). This was
previously also concluded from experiments in which mixtures containing
equimolar concentrations of reduced thioredoxin and oxidized PDI were incuba-
ted, and in which an equilibrium was reached after 90% of the thioredoxin and
10% of the PDI were in the oxidized state (36). It should be realized, however,
that in the optimal carboxylating system the apparent K„ for PDI is about 3-fold
lower than that for thioredoxin (Table III), and that the concentration of PDI in
the lumen of the endoplasmic reticulum is very high (21). Under these conditi-
ons, and provided that most of the PDI occurs in the reduced state, it cannot be
excluded that sufficient amounts of thioredoxin are reduced to allow for its
involvement in the vitamin K cycle. The likelihood of such a mechanism being
operational in vivo therefore depends on the ratio between the luminal concen-
trations of PDI and thioredoxin in the endoplasmic reticulum. But although with
the aid of immunohistochemical techniques the occurrence of thioredoxin in the
lumen of the endoplasmic reticulum has been demonstrated unequivocally (39),
its local concentration is not known at this time.
An alternative explanation for our data is that in the in vitro system thioredoxin
(a powerful protein disulphide reductase) is required to reduce critical disulphi-
des on the carboxylase, which have artificially formed during the microsome
preparation and which inactivate the enzyme. Additionally, both thioredoxin and
PDI may be active as reductants supplying electrons during the reduction of KO.
This explanation implies that in vivo PDI-(SH)2 may even function as the only
cofactor for KO-reductase. It is well known that the synthesis of Gla (carboxyla-
se activity) and the formation of KO (epoxidase activity) only proceed at equi-
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molar rates at saturating concentrations of CO2 and carboxylatable substrate (42).
Most probably these conditions are not met in vivo, and it is an intriguing to
speculate why the recycling of vitamin K may be uncoupled from the carboxy-
lase activity, and may exceed by far the rate of Gla formation. A putative rela-
tion between disul-phide bond formation and the reductive steps in the vitamin
K cycle readily explains the necessity of such an uncoupling, however; in vivo
the number of disulphide bonds formed during protein synthesis will probably
exceed that of Gla-residues; hence the oxidation rate of KHj must be higher
than the protein carboxylation rate.
An alternative explanation for the putative involvement of PDI in the vitamin K
cycle would be that the enzyme has a structural role. In our model all proteins
involved in the carboxylation reaction (PDI, TR, thioredoxin and the enzymes of
the vitamin K cycle) must be aligned in a complex protein/ phospholipid aggre-
gate, which is disrupted by the preparation procedure for the microsomes and by
the detergent used in the assay. It is known that PDI is the (3-subunit of prolyl
hydroxylase, where it serves as a structural component (43), and it might have a
similar role in the carboxylase/reductase complex. This hypothesis requires
further confirmation, however. Experimental systems should be developed, in
which it is possible to demonstrate whether the model proposed in figure 2
occurs in vivo. If the coupling between disulphide bond formation and vitamin
K recycling proves to be a physiological route, an explanation will also have to
be found for the mechanism of disulphide bond formation during periods of oral
anticoagulant treatment.
B
Y • (SH) j ^ - » . PDI • S j - . , -
HJI - (SH) 2 * ^ ^ »
F/G. 2. Ojcidorerfuctóseï «nvo/ved in //re rerfuc/io/i o/ KO and AC (A) and possi'We redo*
earners /or /ne oxida/ion o/ pro/ein-èownd c.ys<eine SW groups (B). B0//1 reactions 4 and 5
may ottur spo/i/a/ieoMs/y, />«/ are ca/a/yzed />v 7"/?. X and y stand /or /rypo/nef/ca/ redo*
fo/tiftors, nof >>ef /de«////ed. 77ie pass/M/ry rnaf //ie receding o/PD/ « diret7/y to«p/ed fo
o/ /ni'oredo-c/n and v/7a/n/n /^ is discussed ;n //ie rearr.
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The conclusions which can be drawn thus far are that for in vitro studies the
PDI/thioredoxin system is an improvement over the commonly used synthetic
dithiols like DTT. Maximal activity is only obtained if both proteins (PDI as
well as thioredoxin/TR) are present in the reaction mixture, but the precise
mechanism by which they participate in the reduction of KO and K is presently
uncertain. The PDI/thioredoxin system is a good candidate to be the physiolo-
gical 'cofactor' providing the reducing equivalents required in the vitamin K
cycle, but whether these dithiol proteins are involved in the vitamin K cycle in
vivo remains to be proven.
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Introduction
Since the discovery of the enzyme y-glutamylcarboxylase extensive investigati-
ons have been carried out to understand substrate recognition requirements and
to develop good substrates for the in vitro assay of the enzyme. In the first car-
boxylating enzyme systems the pool of endogenous precursor proteins, accumu-
lated during in vivo warfarin treatment or vitamin K-deficiency, served as a
substrate for carboxylase (I). However, because of the poor possibilities to
quantitate the endogenous substrate and the number of carboxylation events,
these systems were less useful for kinetic studies. The development of synthetic
exogenous peptides gave new impulses to the study of the enzymology of the
system (2,3). The first generation of artificial substrates invariably consisted of
short peptides homologous to the N-termini of the Gla-containing plasma pro-
teins. Examples are the pentapeptide Phe-Leu-Glu-Glu-Val, corresponding to
residues 5 to 9 of the bovine prothrombin precursor, and Phe-Leu-Glu-Glu-Leu,
corresponding to residues 5 to 9 in the human FVII precursor (2,4). They have
been of great value in elucidating molecular details of the carboxylase reaction
and have facilitated efforts to partially purify the enzyme. However, their high
KM"'''' (2-8 mM), their low efficiency of carboxylation (5) and their inability to
carboxylate adjacent glutamic acid residues made it less probable that they were
comparable with the endogenous substrates (6). The reason for their suitability as
substrates in the carboxylation reaction is probably the fact that they can be
used in very high concentrations (5-10 mM). In the late 1980's substrates were
developed which contain the carboxylase recognition (or "pro") sequence (7,8).
Because of their high affinity for carboxylase these so-called second generation
substrates have played a crucial role in the purification of the enzyme.
Vitamin K-dependent carboxylation of Poly-L-Glutamate
The "vitamin K-dependent" plasma proteins contain a number of Gla-Gla se-
quences which have formed the base for the first synthetic substrates. Peptides
with Glu-Glu sequences are in general better substrates than those containing
only one Glu-residue and also the residue preceding the Glu-Glu sequence
seems to be relevant for substrate activity (9). We have investigated whether
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sequence homology with Gla-containing coagulation factors is a prerequisite for
proper carboxylation. Therefore three poly-L-glutamate preparations of varying
chain length were used as substrates for bovine liver 7-glutamylcarboxylase. The
quality of these substrates (as measured by their apparent kinetic constants) was
compared to that of TFT (the tripeptide Boc-Glu-Glu-Val) and FLEEL (the
pentapeptide Phe-Leu-Glu-Glu-Leu) two other well known substrates for vitamin
K-dependent carboxylase and to that of free glutamic acid and N-t-Boc-Glu-
aBE. All experiments were performed both in the presence and in the absence
of (NHJjSOv The effect of the latter component was checked because it has
been reported to stimulate the carboxylation of various synthetic substrates (10).
As is shown in table I all three poly-Glu preparations could serve as a substrate
for carboxylase, and the amount of CO2 incorporated increased with increasing
molecular weight of the substrate.
Substrate
Glutamic acid
N-t-Boc-Glu-aBE
TPT
FLEEL
Poly-Glu5.,o
Poiy-Glu.o.50
Poly-Glu,o.ioo
Concentration
(raM)
50
25
1
1
1
1
1
"CO;
+(NH^S<
8.1
22.5
384.9
449.1
122.8
214.8
793.7
incorporated (pmol)
D< -(NH^SO,
. . .
6.7
77.0
80.2
14.9
45.9
206.3
ƒ. Ca/*oxy/tf/io/i o / various sufofra/es. A// reaction mix/uz-es were /ncuÜJa/ed/or iO /n/n
af 20 °C M/uter itantfani conrf/f/o/w.
The stimulation by (NH^SC^ was 4-9 fold, which is comparable to that with
the pentapeptide FLEEL. As is shown in table II, the apparent K^"^ values were
closely similar for all three poly-Glu preparations. On the other hand, the
maximal reaction rates increased at increasing peptide chain length in such a
way that the ratio between V^„*" and molecular weight was more or less con-
stant. An explanation for this phenomenon might be that carboxylation only
takes place at isolated, widely separated positions of the poly-Glu chain, and
that the longitudinal movement of carboxylase along the polypeptide chain is
much faster than the association/dissociation of the enzyme and its substrate.
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Presently we have no arguments to support this hypothesis, however. From these
experiments we have concluded that the presence of a specific aminoacid se-
quence for a Glu-containing peptide to be used as a substrate for vitamin K-
dependent carboxylase is not required. It seems as if the only restriction is that
both the a-carboxyl and the amino group form part of a peptide bond. As may
be calculated all poly-Glu substrates were carboxylated with a very low efficien-
cy: less than one Gla-residue was formed per 2000 Glu-residues per h.
Substrate
Poly-Gluj.,„
Poly-Glu,o.,o
Apparent kinetic constants for
tion
KM""" (mM) V
1.5
1.8
1.1
poly-Glu carboxyla-
„,„ """(pmol min ' )
1.66
3.24
8.08
//. /lp/jaren/ A:irte/i'c coniYön/i /or po/y-G/w carftoxy/a/ion J'« /Ae prese/ice o/
SO^. 5ra/irfar</ reac7/w( /nirfttre.v conto/nec/ varyz'ng amoMflW o/ e/7/ier po/y-G/Wj.^,,
po/y-G/H,„.„, or po/^-G/ttjo.,,,,. /mf/a/ car/raxyteio/i rato were de/erffiined a/ter />icMfear/o« o/
r/ie van'r;M.v /nijr/wws /«r 0, 5, 70, 20 and iO mi>i«rw a/ 20 "C. T/ie K^,""" « eAprewed 05
"CO, iwforporafed per mi«.
Vitamin K-dependent carboxylation of descarboxy-coagulation
factors
Another group of substrates lacking the prosequence is formed by the "natural
substrates". Anticoagulant treatment of cattle and humans results in the excretion
of descarboxy forms of the vitamin K-dependent coagulation factors. In contrast
to earlier expectations several authors reported these descarboxy proteins either
to have no substrate activity at all, or be very poor substrates (11,12). KM""" values
have been found in the range of those for the peptides mentioned above, i.e. far
beyond normal plasma levels. Therefore descarboxy proteins are not likely to
function as substrates for carboxylase in vivo, ^rom the cDNA sequences of
vitamin K-dependent plasma proteins it was predicted that the primary gene
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products of these proteins contain a propeptide (13). In recent years this propep-
tide has shown to function as a recognition site for the enzyme y-glutamylcar-
boxylase (14,15). The presence of this y-carboxylation recognition site was first
detected in the propeptide of FIX (16), and with site-specific mutagenesis the
significance of the propeptide for carboxylation has been shown (16,17,18). Based
upon this knowledge various peptides containing the propeptide have been
constructed (7,8), which all were characterized by K^"'''' values of at least three
orders of magnitude lower than those for the peptides not containing a prose-
quence. In a collaborative project with Transgene (Strasbourg) recombinant
descarboxy FIX was constructed, containing the propeptide necessary for y-
carboxylation. It was shown that these large protein substrates could be carboxy-
lated efficiently ( K M ^ = 0.12 uM) in vitro and that when analysed by PAGE in
SDS, the carboxylated product was similar to normal plasma FIX. FIX proco-
agulant activity was not found and could neither be expected because:
a) the strongly reducing conditions during the carboxylation reaction will
rapidly destroy all disulphide bonds in the precursor protein and
b) the propeptide, which remains attached to the carboxylated product, has
been reported to prevent normal procoagulant activity (17).
If the production of biologically active FIX via expression in eukaryotic cell
lines turns out not to be successful, the in vitro carboxylation method might be
an alternative approach to produce biologically active FIX from incompletely
carboxylated recombinant material. In that case it should be checked whether by
the replacement of DTT by the PDI/thioredoxin system (19) the disulphide bonds
will remain intact. Also the propeptide will have to be removed, e.g. by the
recently purified microsomal liver endopeptidase (20).
A recent paper of our group on this subject is reproduced at the end of this
chapter.
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In vitro y-carboxylation of a 59-residue recombinant peptide in-
cluding the propeptide and the y-carboxyglutamic acid domain of
coagulation factor IX
Since it has become apparent that a major part of the signal, necessary for car-
boxylase to recognize the substrate, resides in the propeptide of the vitamin K-
dependent coagulation factors, the importance of the propeptide in carboxylation
has been documented by the use of synthetic peptides. However, until three
years ago the best peptide substrate reported was proPT28 that was carboxylated
in vitro to only 45% of the theoretical value. The short synthetic peptides used
failed to include the complete Gla domain (array of glutamic acid residues that
are normally carboxylated).
There is evidence indicating that sequences other than the propeptide are impor-
tant in enzyme recognition. Decarboxylated bone Gla protein (21) and fragment
13-29 of prothrombin (22) were found to be good in vitro substrates for carboxy-
lase. The role of residues other than the propeptide in recognition by the car-
boxylase is still not resolved, and there may be other, as yet unrecognized,
signals that are necessary for processes like translocation of the substrate across
the carboxylase enzyme or release of the substrate from the enzyme. Answers to
these questions may require the use of still longer peptides. Therefore the pro-
duction in Escherichia coli of a fusion protein from which a 59-residue peptide
has been isolated has been started by Wu and Stafford. The peptide included the
propeptide and all of the glutamic acid residues of factor IX which are normally
carboxylated. In addition peptides with mutations identical to FIXj^ D ^ (**"
ginine to glutamine at -4) or FlXc^ hndge (arginine to serine at -1) as well as a
peptide with both mutations in the propeptide sequence have been prepared and
the effect of the mutations on in vitro carboxylation has been examined. The 59-
amino acid peptide is an efficient substrate for in vitro y-carboxylation (see
table I). Its KM*** (0.55 uM) is several thousand-fold lower than that of the
commonly used substrate FLEEL and about 5 times lower than proPT28 or
proFIX28 (7.8). The difference with the latter two substrates indicates that besi-
des the propeptide sequence, part of the binding site for the carboxylase resides
in the Gla-domain itself. This is consistent with the suggestion of Price et al. (23)
that a sequence similarity (Gla-X-X-X-Gla-X-Cys at the positions +17 to +23)
together with an essential sulfhydryl group in the carboxylase which forms a
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disulphide bond with the substrate during carboxylation, play an additional role
in the substrate selection by carboxylase.
Substrate
FIXGla
FIXQ-4
FIXS-1
FIXQ/S
V w
max(cpm/min)
1015
1455
1403
1504
K M * »
(uM)
0.55
0.87
0.70
0.74
V "PP/K *PP
(cpm/min/uM)
1845
1672
2004
2032
/. Enzyme Ati'/iefic s/utfïes o/ //ie F/JfG/a pepride a/i</ /Are* m u M /orwis. 77iree
\ V^"*' and V^°™"//:^ were determ/ned />>• L/fleweavÉT-BwrA: and Eadie-
p/o/s. F/XG/a .s/a/ias /or a iP-residwe peprüfe i/ic/iu/ing f/ie propeptóe a/id //ie
F/X G/a do/na/n ;n to flon-carboxy/ated' /or/n; F/XQ-4 H //ie /nwton//orrn ;'n H'/I/C/I
w t/ian^ed /n/o ^/«/awi/«e a/ -4; F/X5-7 IJ //ie mw/an//orm in w/ii'tn arg/ni/ic « c/ian-
/ -7;
In addition, FIXGla is the first peptide substrate that is carboxylated in vitro to
more than one Gla/molecule (6-11 gammacarboxyglutamic acids/molecule).
These high levels of carboxylation were obtained after prolonged incubation (48
h at 10 °C). The extent of carboxylation was calculated from the specific activity
of the radioactive COj and the concentration of the peptide. Enzyme kinetic
studies revealed no significant difference in V^^/K^"^ values between normal
and mutant substrates. Maximum COj incorporation was achieved with the
double mutant. Several mutations have been described in which the cleavage of
the propeptide from factor IX is hampered. Two of these mutants, factor IXj„
Dimas (24) and factor IXcambridge (25), have been reported to be undercarboxylated to
the same extent (7 Gla/molecule). From our study, we propose that the highly
conserved residues arginine -1 and arginine -4 are not important for y-carboxy-
lation but function as the recognition site for the propeptidase. The presence of
both arginine residues appears to be critical for the cleavage of propeptide by
the enzyme propeptidase as both factor IXj^ oimas arid factor IXcambndge retain
their propeptide, which probably explains their dysfunction. Bone matrix protein,
which contains a propeptide-like sequence with a single arginine corresponding
to the -1 position of other vitamin K-dependent coagulation proteins, is not
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cleaved, and the propeptide-like domain is retained in the mature protein. Re-
cently Kawabata & Davie (20) have purified a microsomal endopeptidase the
activity of which for proteolytic cleavage was dependent on arginine residues
located at the -1 and -4 position. This finding supports the hypothesis that both
arginine residues are only important for the cleavage of the propeptide and not
for carboxylation.
From these data we conclude that 1) FIXGla and the mutants described above
are excellent substrates for studying the mechanism of gamma-carboxylase, 2)
Although arginines at positions -4 and -1 are highly conserved in the propeptide
sequence of all the vitamin K-dependent proteins, neither is critical for y-car-
boxylation.
Conclusions
During the last decade our knowledge about the substrates in the vitamin K-
dependent carboxylation reaction has been substantially increased. A number of
peptide substrates similar to the Gla-containing sequences in some coagulation
factors have been synthesized, except that Gla had been replaced by Glu. K ^
values of these substrates were all in the millimolar range which meant that they
were poorly recognized by the enzyme. The presence of a y-carboxylation
recognition site seemed to be required for efficient in vitro carboxylation. The
construction of the propeptide and peptide substrates containing the propeptide
demonstrated that a carboxylation recognition site indeed was critical for effi-
cient carboxylation. Not only the understanding of the mechanism of y-gluta-
mylcarboxylation has been facilitated with the propeptide but finally Wu et al.
(26) and Berkner et al. (27) have succeeded in the purification of carboxylase ma-
king use of the tight binding of enzyme and propeptide.
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In vitro carboxylation of a blood coagulation ***'
factor IX precursor produced by recombinant
DNA technology , — — ,.,.•....-...•,,. .w..,
Berry A.M. Soute, Alain Balland, Thérèse Faure, Henri de la Salie, Cees Ver-
meer
Abstract
Blood coagulation factor IX (Christmas factor) is a plasma protein which is
required for normal haemostasis. A functional deficiency of factor IX results in
haemophilia B, a bleeding disorder which is generally treated by infusions of
factor IX concentrates prepared form pooled human plasma. The use of human
blood products is connected with the risk of transmitting viral agents responsible
for diseases such as hepatitis B and AIDS. Recombinant DNA techniques may
provide in the means to produce the required proteins without exposing the
patients to these risks and at lower costs. One of the problems which has to be
overcome before recombinant factor IX can be used for therapeutical purposes is
related to the vitamin K-dependent carboxylation of its 12 NHj-terminal gluta-
mate residues. In cell cultures this carboxylation, which is required to render the
protein its procoagulant activity, is far from complete, especially at high expres-
sion levels. In this paper we describe the in vitro carboxylation of non and/or
partly carboxylated recombinant factor IX produced by transformed Chinese
hamster ovary cells. The identity of the newly formed Gla residues was verified
and it could be demonstrated that all carboxyl groups had been incorporated into
the recombinant factor IX.
Introduction
The clinical use of proteins obtained by recombinant DNA technology may be
hampered due to the inability of certain hosts to correctly process molecules
normally subjected to post translational modifications. Some of these problems
125
have been solved by using eukaryotic cell lines as host. Recombinant factor IX
produced by baby hamster kidney cells (28), Chinese hamster ovary (CHO) cells
(29) and human hepatoma cells (30) is partially active, indicating at least some
correct post translational processing. After cleavage of the 28 amino acid signal
peptide, factor IX undergoes post translational modifications including glycosy-
lation, hydroxylation at aspartic acid residue 64 and the vitamin K-dependent y-
carboxylation of the first 12 glutamate residues of the mature protein (13,31,32).
This latter modification is thought to be directed by an 18 amino acid N-termi-
nal prosequence which is cleaved off before factor IX appears in the plasma (15-
17,33). It is generally accepted that the y-carboxylation is the limiting factor in
the expression of high levels of active recombinant factor IX. It has been do-
cumented that at high expression levels, recombinant factor IX secreted by CHO
cells has a very low specific activity due to inefficient y-carboxylation (29).
In principle two procedures may lead to an improved carboxylation of the
recombinant factor IX: a search for a cell line expressing high levels of the
enzymes of the vitamin K cycle (carboxylase, KO reductase and K reductase)
or, alternatively, the in vitro carboxylation of the insufficiently carboxylated pro-
teins. We have investigated the second possibility using a partly purified car-
boxylating enzyme system from cow liver and recombinant factor IX produced
by Chinese hamster ovary (CHO) cells.
Materials and methods
s. Vitamin K, was obtained from Hoffmann-La Roche (Switzerland)
and chemically reduced as described by de Metz et al. (34). Dithiothreitol and
CHAPS were from Sigma (USA) and NaH"CO, (40 Ci/mol) from Amersham
International (UK). Ultrogel AcA 34 was purchased from LKB (Sweden), hepa-
rin agarose (A4R) from IBF (France), and CNBr-activated Sepharose 4B from
Pharmacia (Sweden). Polyclonal, immunopurified antibodies against the various
human coagulation factors as well as against the proteins C an Z were kindly
supplied by Dr. R. Bertina (Leiden, The Netherlands). Atomlight (New England
Nuclear, FRG) was used as a scintillation liquid for radioactivity measurements.
All other chemicals were of the highest purity commercially available.
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Factor /AT assays. Factor IX antigen was monitored using an enzyme-linked
immuno-sorbent assay (Stago, France). Factor IX procoagulant activity was
determined with a cephalin-kaolin one-stage assay in the presence of deficient
plasma (35).
CW/ cu/fure conditions. A CHO transformed cell line (622.4) producing
recombinant factor IX is routinely grown in selective medium consisting of
oc2000 (Gibco, UK), supplemented with 10% dialysed foetal calf serum, glucose,
glutamine, hypoxanthine, thymidine, xanthine and mycophenolic acid (36). The
production of recombinant factor IX was performed in multichamber trays
(Nunc, Denmark) in non-selective medium, consisting of cx2000 supplemented
with 10% inactivated foetal calf serum and vitamin K, (50 ug/ml). Factor IX
secreted under these cell conditions had a procoagulant activity of 10-15% from
that of normal pooled plasma.
iParria/ /«/ri/ïca/ton o/ reco/nè/nan/ /actor 7X. Supernatant culture medium
of the 622.4 cells was adjusted to pH 6.0 with Mes-Tris buffer and loaded onto
a heparin agarose column (2 x 20 cm). The proteins were eluted at 20 ml/h with
a linear gradient from 0.1 to 1.5 M NaCl in 20 mM Mes-Tris buffer, pH 6.0 and
1 mM benzamidine. Fractions containing factor IX antigen were pooled and
purified further by chromatography on an Ultrogel AcA 34 column (1.5 x 100
cm) in buffer A (0.15 M NaCl, 20 mM Tris/HCl, pH 7.5). The fractions contai-
ning factor IX antigen were pooled and concentrated with an Amicon diaflo
system using a PM 30 membrane filter. The average yield of factor IX antigen
ranged from 55 to 65% of the crude cell supernatant and the purification was
about 50-fold. The proportion of biologically active molecules was about 13%.
Preparations thus obtained, contained 100 ug/ml of recombinant factor IX with a
purity of 1% and they were used for all experiments described in this paper.
Carftoxy/ase. Vitamin K-dependent carboxylase was prepared from normal
cow liver and partly purified as described by Soute et al. (5). Standard reaction
mixtures (0.125 ml) for in vitro carboxylation contained 0.25 mg of carboxylase,
2 ug of recombinant factor IX, 0.15 M NaCl, 1 M (NH^SO,,, 20 mM Tris/HCl,
pH 7.5, 8 mM MnCl^, 5 uCi NaH^COj, 4 mM dithiothreitol, 0.05% (w/v)
CHAPS, 0.4 mg/ml phosphatidylcholine, and 0.4 mM vitamin K hydroquinone.
Phosphatidylcholine was added as mixed micelles with cholate in a 1:1 (w/w)
ratio as described by de Metz et al. (37). The reaction mixtures were incubated at
25 °C for the indicated periods and the reaction was stopped by adding 1 ml of
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5% (w/v) trichloroacetic acid. After gentle boiling for 1 min the samples were
counted in Atomlight. In some cases the carboxylation reaction was not termi-
nated by adding trichloroacetic acid but by cooling the samples in ice, removal
of non-bound '^COj by gentle bubbling with '^ CC^ gas and dialysis against cold
buffer A.
Po/yacryfaiHÜfe ge/ efecfrop/ioresis. Analytical polyacrylamide gel electrop-
horesis was carried out in 10% slab gels in the presence of 0.1% sodium dode-
cyl sulphate using a Bio Rad Mini Protean II dual slab gel system. If ['*C]r-
factor IX was analyzed, reaction mixtures containing approximately 10,000 dpm
of labelled protein were adsorbed onto Sepharose-bound anti-factor IX, eluted
with 2 M KCNS and extensively dialysed. The samples were supplemented with
7.5 ug of non-labelled plasma-factor IX, concentrated to 100 pi and 40 pi ali-
quots were applied onto the gel. The gels were either stained with 0.25% Coom-
assie Brilliant Blue and destained with 30% methanol/10% acetic acid in distil-
led water or blotted electrophoretically on nitrocellulose paper (Bio Rad Trans-
Blot). Proteins were visualized on the nitrocellulose paper by staining with 0.1%
amidoblack and factor IX-related material was specifically stained with the
Western blot technique using horse radish peroxidase-labelled goat anti rabbit as
a second antibody. The presence of radiolabel was detected by slicing the nitro-
cellulose paper into 0.25 cm strips which were counted as such in a liquid
scintillation counter.
OfAer tec/tnifues. Protein-bound Gla-residues were determined after alkaline
hydrolysis of the samples with the HPLC technique described by Kuwada and
Katayama (38). The correct incorporation of '^COj into Glu-containing substrates
was checked by comparing the amount of radiolabel after acid and after alkaline
hydrolysis. Since Gla is acid-labile, a carboxyl group is rapidly lost under acidic
conditions. This carboxyl group may be either ^COj or '^COj. Because no
stereospecificity has been observed for the decarboxylation of Gla into Glu, a
theoretical loss of 50% of the label is expected, whereas Gla remains stable
under alkaline conditions. The number of Gla-residues present in several recom-
binant factor IX preparations was quantified using free Gla as a standard. As-
suming that all Gla-residues originated from the recombinant factor IX, the
mean Gla-content of the latter follows from the quotient of the concentrations of
protein-bound Gla and recombinant factor IX antigen.
Protein concentrations were measured according to Sedmak and Grossberg (39).
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A stable transformed Chinese hamster ovary (CHO) cell line constitutively ex-
pressing human factor IX has been established as was described elsewhere (36).
The sequencing of the purified protein showed that two recombinant species are
secreted by CHO cells. One is correctly processed and possesses the N-terminal
sequence expected for the mature protein. The other fraction corresponds to the
precursor form with an 18 amino acid extension at the NHj terminus. The
majority of recombinant proteins thus obtained present a deficiency in gamma-
carboxyglutamic acid content as was tested by direct Gla analysis (see below).
Purification of the recombinant factor IX secreted into the culture medium can
be performed using a protocol derived from conventional methods of plasma
fractionation (36). In this purification scheme the first step involves barium
citrate precipitation. During this process only molecules which are sufficiently
carboxylated are expected to be linked to barium ions. Such a treatment elimi-
nates incomplete or non-carboxylated recombinant molecules which would be
potential substrates for the carboxylase. We therefore performed a limited puri-
fication procedure (excluding the barium precipitation step) based on affinity
chromatography on heparin agarose previously developed to fractionate natural
coagulation factors (40). The recombinant factor IX molecules present in the
crude cell supernatant are totally adsorbed on heparin agarose and eluted in high
salt conditions with a yield ranging from 65 to 75%. After a second purification
step (size exclusion chromatography on an AcA 34 column), the preparation was
analyzed by polyacrylamide gel electrophoresis in SDS, followed by immuno-
blotting on nitrocellulose paper. As is shown in figure 1 the migration rate of
the majority of the antifactor IX-reaction material was slightly slower than that
of factor IX from human plasma. This difference is too large, however, to be
explained by an impaired cleavage of the leader sequence alone. Possibly the
high molecular weight material represents a form of factor IX which has been
excessively glycosylated. As stated above, the best results in our carboxylation
assays were obtained with recombinant factor IX preparations of limited purity
(about 1%) and this material was used for all experiments described below.
However, the vast excess of contaminating proteins in these preparations did not
allow us to detect the Gla-residues. In more purified recombinant factor IX
preparations (10-20% purity) the Gla-content was invariably found to be 3 re-
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sidues per molecule or less. Therefore, we assume that the majority of the
recombinant factor IX used in this paper also contained less than 3 Gla residues
per molecule.
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The recombinant factor IX was used as a substrate for vitamin K-dependent car-
boxylase and a time-course of its in vitro carboxylation is shown in figure 2A.
After a short lag-phase the reaction rate was constant for more than 1 h. From
the linear parts of the curves (15-75 min) obtained at various substrate concen-
trations we calculated the initial carboxylation rate, which was then plotted in a
Lineweaver-Burk diagram (figure 2B). This resulted in a straight line and from
the interception with the abscissa the KM*"" for recombinant factor IX could be
calculated to be 0.12 uM, which is lower than that of any other exogenous
substrate presently known. To make sure that the protein-bound '^COj had been
incorporated into the recombinant factor IX, three control experiments were
performed. Firstly is was verified that the incorporated label could be identified
as Gla. After completion of the in vitro carboxylation, aliquots from the reaction
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mixtures were submitted to either alkaline or acid hydrolysis as described in
Materials and Methods. The acid-induced loss of '''COj was calculated for all
recombinant factor IX concentrations shown in figure 2A and amounted to 56.3
± 4 . 1 % . . - . . . ..• ... .. .,• •,...,; , . , : , . . • - ;, ,.,;.; S ^ , , . ; i ' . . , • t ) W , I
a.
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After hydrolysis the samples were also analyzed by HPLC and it turned out that
after alkaline hydrolysis the '"C-label was exclusively found at the position of
Gla, whereas after acid hydrolysis the label eluted at the position of Glu (figure
3). Moreover, in the latter case the total amount of label recovered was about
50% from that after alkaline hydrolysis. From these results we concluded that
indeed Gla-residues had been formed during the carboxylation reaction.
A second control experiment was the immuno-adsorption of ['*C]r-factor IX to
immobilized antibodies. Polyclonal, immuno-purified antibodies against normal
human prothrombin, factor IX, factor X, factor VII, protein C and protein Z
were linked to CNBr-activated Sepharose (1 mg of protein per g Sepharose) and
it was verified that they were monospecific for each of the corresponding plas-
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ma proteins. The affinity of ['"C]r-factor IX (4,100 dpm per reaction mixture)
for each of these antibodies was measured by incubating the labelled product
with the Sepharose beads. The mixtures were subsequently centrifuged (5 min at
1,500 x g) and the supernatants and washed pellets were counted (Table I). In
all tubes a low amount of label was found to be associated with the Sepharose.
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This might be the result of non-specific adsorption of some precipitation (dena-
turation) of the material. The antibodies against factor IX, however, bound more
than 75% of the labelled proteins, thus indicating that the product of the car-
boxylation reaction consists of recombinant factor IX. Finally, the radiolabeled
product was analyzed on polyacrylamide gels (figure 4). Since the samples had
been supplemented with an excess of plasma factor IX (see Materials and
Methods), the immunoblot shows the presence of normal factor IX, whereas the
label indicates the position of in vitro carboxylated material. Obviously the two
bands coincide.
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From these data we concluded that the recombinant factor IX had indeed been
carboxylated, and we have tried to estimate the number of Gla residues formed
per molecule of recombinant factor IX. For these calculations it was assumed
that the concentration of non-labelled atmospheric COj in the reaction mixtures
was similar to that dissolved in distilled water and the various buffers (ap-
proximately 2 mM).
Immobilized antibody
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Prothrombin
Factor X
Factor IX
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Protein C
Protein Z
Carboxylated
bound
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28
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260
product (dpm)
non bound
3,532
3,299
856
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3,605
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an»fcod/es «ad Aeen added J/I excess.
Because standard reaction mixtures contain 1 mM of '^COj, the specific activity
of the label is reduced to about 15 Ci/mol. When using 2 ug (36 x 10* umole)
of recombinant factor IX, a maximal level of incorporation of 10* dpm (3 x 10"*
pmole) could be reached. From these data it follows that under optimal conditi-
ons about 8 moles of COj were incorporated per mole of recombinant factor IX.
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Obviously this figure is only a rough estimate, the height of which varies with
the estimated level of atmospheric COj present in the reaction mixtures. Never-
theless these calculations clearly show that at least several Gla residues are
formed per molecule of recombinant factor IX.
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Discussion
Factor IX undergoes several post translational modifications and an N-terminal
processing prior to secretion into the plasma as a mature protein. The factor IX
precursor, recently discovered by analysis of two inactive forms (factor IX
Oxford 3, factor IX Cambridge) isolated from haemophilic patients, carries an
N-terminal extension of 18 amino acid residues (15,17). In the case of factor IX
Cambridge, the natural mutation of the arginine residue at position -1 has been
shown to impair the y-carboxylation (15). The other vitamin K-dependent pro-
teins are also synthesized as precursors and although the exact size of the pro-
134
sequence has not been determined for each one, the comparison between publis-
hed cDNA sequences (41-45) shows clear homology in their respective propepüde
regions. •»•»
These observations suggest that this aminoterminal extension is important for
the post translational carboxylation and could act as the recognition site for car-
boxylase. Furthermore, several experiments manipulating the cDNA sequence by
either removing the prosequence or altering particular aminoacids within it have
been performed using both factor IX and protein C (16,33). In all cases studied,
alteration of the prosequence resulted in a decrease or the complete abolition of
the carboxylation reaction, •..••'iljub-;--! .^  n a w ? ^ ' ^i V-* Tfi!-j-?,vy,i Ü ;->£ '-•!^VÜÜ
We describe elsewhere (36) the purification and the characterisation of the re-
combinant factor IX used in this study, and demonstrate that at least two recom-
binant species are secreted by CHO cells: one corresponding to the mature
protein, the other being the precursor. The CHO cells thus present an enzymatic
deficiency which lead to the incomplete processing after Arg'. We can take
advantage of the presence of this precursor form synthesized in a mammalian
expression system as it should be a good substrate for the carboxylase. Indeed,
by analogy with our previous results showing that non-carboxylated plasma
prothrombin was not a substrate for the vitamin K-dependent carboxylase (22),
we can speculate that partially carboxylated or non-carboxylated mature recom-
binant factor IX would be equally disappointing. On the other hand, the precur-
sor form of human factor IX is probably the ideal target for carboxylase. At-
tempts to purify the recombinant factor IX before it was added to an in vitro
carboxylating enzyme system invariably lead to an increased ratio between
factor IX procoagulant activity and factor IX antigen. In parallel also the ability
of the preparation to serve as a substrate for carboxylase decreased considerably.
Explanations for this phenomenon may be that either the various purification
steps tend to select for normally carboxylated recombinant factor IX, or the
leader sequence is prone to proteolytic digestion, so that it is cleaved off during
the purification procedure.
In this study we have used therefore a partly purified recombinant factor IX
preparation and we have tested if it could be carboxylated in vitro. We have
shown that the incorporated '*CO2 is recovered in a protein which reacts with
monospecific antibodies against plasma factor IX (Table I) and which is found
exclusively at the position of factor IX after Western blot analysis (Fig. 4).
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Moreover the radiolabel is found in the HPLC peak corresponding to Gla resi-
dues. The present work shows that the post translational formation of Gla resi-
dues in recombinant factor IX may be increased in vitro by using partly purified
bovine liver carboxylase. It is probable that other recombinant proteins (e.g.
factor X, protein C) can also be processed in this way. At this stage of our
investigation an increase of procoagulant activity is not really expected for two
reasons. Firstly, the strongly reducing conditions, required for an efficient car-
boxylation reaction will rapidly destroy the disulphide bonds in the precursor
protein. The recent discovery that thioredoxin from E. coli may replace dithio-
threitol as a cofactor for the vitamin K reducing enzymes of bovine origin
shows that a system may be developed in which the disulphide bonds in protein
substrates for carboxylase remain intact (46), but the activity of this system will
have to be increased. In this respect it would be interesting to investigate if the
results could be improved by using thioredoxin from cow liver, thus creating an
all bovine enzyme system. Secondly, the propeptide still present on the molecule
probably interferes with the adequate activation of the zymogen. For example
Bentley et al. (17) have shown that factor IX Oxford 3, an inactive form of
factor IX carrying an 18 aminoacid N-terminal extension nevertheless possesses
the twelve normal Gla residues. In the event of producing a fully y-carboxylated
recombinant factor IX with attached prosequence, a putative "propeptide pepti-
dase" would have to be isolated and used to dissociate the fully carboxylated
factor IX from its propeptide. Certain transformed cell lines have been described
which produce recombinant factor IX lacking the propeptide and it will be
interesting to see whether these proteins can be carboxylated in vitro in the
presence of a synthetically prepared and hence not covalently bound propeptide.
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Summary and conclusions
During maturation, most secretory proteins undergo extensive post-translational
processing before they are secreted into the extracellular environment. One of
these post-translational modifications is the conversion of glutamate (Glu) into
y-carboxyglutamate (Gla) residues. The formation of Gla-residues is accomplis-
hed during a carboxylation reaction, which is catalyzed by the microsomal
enzyme y-glutamylcarboxylase, which is predominantly found in the membranes
of the rough endoplasmic reticulum. Vitamin K hydroquinone (KHj) functions
as an essential cofactor in this reaction. The oxidation of KHj into vitamin K
2,3-epoxide (KO) provides the energy required for y-carboxylation. In two
successive reduction steps KO is subsequently recycled into KHj. In this way
vitamin K may be re-used several thousand times before it is excreted. At least
one, but probably several, reductases are involved in the recycling process of
vitamin K. This sequence of events is generally known as the 'vitamin K cycle'.
In Chapter 1 of this thesis a review is presented of our current knowledge
concerning the y-glutamylcarboxylation reaction and the role of vitamin K in
this reaction.
Gla residues have only been demonstrated in a limited number of proteins, and
in these proteins they are found at well defined positions. The first protein
demonstrated to contain Gla was prothrombin, one of the blood coagulation
factors produced by the liver. Hence the first enzyme systems in which vitamin
K-dependent carboxylase could be tested in vitro were prepared from liver
homogenates. Later on it became clear that carboxylase is present in tissues
differing from each other as much as kidney, spleen, testis, lung, vessel wall and
bone. At least six Gla-containing proteins are involved in the blood coagulation
process and the presence of Gla in these proteins is a prerequisite for their
biological activity. Hence a sufficient supply of vitamin K is of vital importance
for normal haemostasis. Besides vitamin K deficiency the intake of 4-hydroxy-
coumarin derivatives may result in incompletely carboxylated Gla-proteins
entering the circulation in an undercarboxylated form. During coumarin treat-
ment the vitamin K cycle is interrupted by a blockade of the enzyme KO-reduc-
tase, leading to increased levels of circulating KO, and to a rapid exhaustion of
the KHj store. This results in an accumulation of non-carboxylated precursor
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proteins in the endoplasmic reticulum and, if the blockade is continued, in the
cellular secretion of maturated Gla-proteins in a non- or undercarboxylated form
(descarboxyproteins). Whether or not descarboxyproteins are secreted depends
on the dose and the duration of coumarin intake, as well as on the species. In
cattle and in humans descarboxyproteins are secreted into the bloodstream from
where they may be purified with conventional methods. In the early years of
carboxylation it was thought that descarboxyproteins would be the target sub-
strates for the enzyme y-glutamylcarboxylase. Hence the effect of carboxylation
was supposed to be detectable from an increase of the enzymatic activity of
descarboxyproteins. However, it is now known that by the absence of a recog-
nition-site descarboxyproteins fail to act as good substrates and therefore this
approach turned out not to be successful. The development of some sensitive
coagulation assays was the positive outcome of this period. Coagulation kinetics
initially worked out by Hemker et al. could be proven with these reagents. In
Chapter 2 the preparation and sensitivity of these reagents is described. Second-
ly we report an improved method for the separation and detection of descarboxy
and normal coagulation factors by HPLC.
In Chapter 3 the optimizing of an in vitro system for measuring vitamin K
dependent carboxylation is described. In the past years the purification of car-
boxylase has been the main goal of many investigators, since the lack of puri-
fied preparations has been a major limitation in understanding the mechanism of
carboxylation. Whereas most investigators use rat liver as a starting material for
preparing microsomes, in our lab the bovine system has always been the princi-
pal source for carboxylase. In our attempts to purify Y-glutamylcarboxylase from
bovine liver two methods have been developed leading to partially purified
preparations, one of which is bound to a solid-phase, the other one is soluble.
Although none of these methods resulted in a purified enzyme, the partially
purified carboxylase preparations have been helpful in defining optimal conditi-
ons for carboxylase activity. Remarkably this activity was enhanced by a num-
ber of organic solvents and by high concentrations of (NHJjSO.,.
In Chapter 4 we have focussed our attention on the cofactor of carboxylase:
vitamin K. During the formation of Gla-residues KH2 is converted into K
epoxide (KO). Under normal in vitro conditions dithiol-dependent reductases
will catalyse the recycling of vitamin K. However, during warfarin treatment
KO reductase is inhibited resulting in a retardation of the carboxylation reaction.
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Placental carboxylase differed from the liver systems because only vitamin K
hydroquinone and not vitamin K quinone could be used as a coenzyme for the
carboxylation reaction. Obviously, the dithiol-dependent K reductase was absent
in these preparations. In the second part of Chapter 4 attention is focused on the
two different forms of vitamin K found in nature: vitamin K, (phylloquinone)
and vitamin K2 (menaquinone). Both are characterized by a functional
naphtoquinone ring and an aliphatic side chain. Phylloquinone is mainly found
in green plants whereas the menaquinones are produced by the intestinal flora.
The extent to which each of the K vitamins contributes to the carboxylation of
blood coagulation factors is still a matter of investigation. Phylloquinone and
various menaquinones were compared for their ability to serve as a cofactor for
the hepatic vitamin K-dependent carboxylase. It was found that the cofactor
activity of the menaquinones varied with the length of the aliphatic side chain
and that it showed an optimum at MK-3. Under in vitro conditions both vitamin
K, and the Kj-vitamins were rapidly metabolized into a mixture of the quinone,
the hydroquinone and the epoxide form. The fact that at equilibrium the levels
of these three metabolites were independent of the starting material shows that
the vitamin K cycle is operational for vitamin K, as well as for Kj. Finally we
describe in this chapter the occurrence of an allosteric interaction between the
vitamin K binding site and the propeptide binding site on carboxylase. By this
mechanism the affinity for KHU of the enzyme/substrate complex is about 20-
fold higher than that of carboxylase alone.
In Chapter 5 we have investigated some aspects of the reductases involved in
the recycling of vitamin K. Both reduction steps in the vitamin K-cycle may be
accomplished by dithiol-dependent reductases. Whether this activity is exerted
by one or different enzymes is still a matter of investigation. However, the
mutation pattern found in two independent cases of warfarin resistance strongly
supports the idea that only one reductase is responsible for the recycling of
vitamin K. In vitro the synthetic dithiothreitol (DTT) as well as reduced thiore-
doxin may serve as reducing cofactor for KO- and K-reductase. It was shown
that in vitro the formation of disulphide bonds may be linked to the vitamin In-
dependent carboxylation of glutamate residues. In vivo both disulphide formati-
on and vitamin K-dependent carboxylation are post-translational modifications
taking place at the luminal side of the endoplasmic reticulum. It is possible that
also in vivo both reactions are coupled, which would explain the source of
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reducing equivalents necessary for carboxylation and the source of oxidating
equivalents necessary for the formation of a disulphide bond. A model in which
this hypothesis is worked out is presented at the end of this chapter.
In Chapter 6 data concerning substrates in the vitamin K-dependent carboxylase
reaction are described. During the last 15 years two types of substrates have
been developed: those containing and those lacking a pro-sequence of the natu-
ral Gla-proteins. Examples of the first type are FLEEL and FLEEV. All sub-
strates of this type are characterized by high K ^ values. The fact that poly-Glu
preparations are carboxylated at a comparable rate as are the pentapeptide sub-
strates demonstrated that a specific aminoacid sequence is not an essential
requirement for carboxylation. In vitro it has been shown that the carboxylation
of Glu-containing substrates is substantially enhanced when the substrates are
extended with the propeptide. The improvement turned out to be the result of a
decrease of the K^''''. Propeptide-containing substrates in the in vitro carboxy-
lase reaction are, for example, pro-PT28 and recombinant factor IX. The in vitro
carboxylation of the latter substrate, produced by transformed Chinese hamster
ovary cells, is described and the identity of the newly formed Gla residues is
verified. Finally a 59-amino acid peptide containing the propeptide sequence and
Gla-domain (residues -18 to 41) of human factor IX (FIXGla), is demonstrated
to be an efficient substrate for in vitro gamma-carboxylation. Its K^*" (0.55 uM)
is several thousand-fold lower than that for the commonly used substrate FLEEL
and about 5 times lower than that for proPT28 or proFIX28. It is the first pep-
tide substrate that is carboxylated in vitro to more than one Gla/molecule (6-11
Gla/molecule). In addition, peptides with mutations similar to those in FIXj^
Dimas or FlX^^dge as well as a peptide with both mutations in the propeptide
sequence have been prepared. Enzyme kinetic studies revealed no significant
difference in V ^ ^ T K ^ values between normal and mutant substrates, indica-
ting that arginines at positions -4 and -1, although highly conserved in the
propeptide sequence of all the vitamin K-dependent proteins, is not critical for
y-carboxylation.
The purification of y-glutamylcarboxylase has turned out to be more laborious
and complex than anyone had imagined. At this time purified, homogenous
carboxylase is available in at least three leading research groups, which means
that we are experiencing a turning point in science: behind us is a period in
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which carboxylase research was performed exclusively in non-purified systems.
By the availability of purified carboxylase this research area has finally come to
maturation. In front of us are scientific challenges such as the elucidation of the
detailed mechanism of the carboxylation reaction, the mechanism of termination
of Gla-formation as well as possible interactions between carboxylation and
other posttranslational modifications. We hope and expect that the Maastricht
group will continue to actively participate in this fascinating field of science.
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Samenvatting en conclusies
De meeste secretie-eiwitten ondergaan een aantal belangrijke post-translationele
modificaties tijdens hun synthese voordat ze door de cel uitgescheiden worden.
Een van deze veranderingen is de omzetting van glutaminezuurresiduen (Glu) in
y-carboxyglutaminezuurresiduen (Gla). De omzetting van Glu in Gla vindt plaats
tijdens een carboxyleringsreactie die wordt gekatalyseerd door het microsomale
enzym y-glutamylcarboxylase, dat voornamelijk in de membranen van het ruw
endoplasmatisch reticulum wordt gevonden. De gereduceerde vorm van vitamine
K (KHj) is een belangrijke cofactor bij deze reactie. De energie die nodig is
voor carboxylering wordt geleverd door de oxydatie van KHj tot vitamine K
epoxide (KO). In twee opeenvolgende reductiestappen wordt KO vervolgens
weer omgezet in KH2. Op deze manier kan vitamine K duizenden malen op-
nieuw worden gebruikt voordat het wordt uitgescheiden. Tenminste één maar
waarschijnlijk meerdere reductases zijn betrokken bij de recycling van vitamine
K. Dit hele proces staat bekend als de "vitamine K cyclus". In hoofdstuk 1 van
dit proefschrift wordt een overzicht gegeven van onze hedendaagse kennis over
de carboxylerings reactie en de rol die vitamine K daarin speelt.
Gla residuen zijn tot nu toe slechts aangetoond in een beperkt aantal eiwitten
waar zij op specifieke plaatsen worden gevonden. Prothrombine, één van de
stollingseiwitten die door de lever worden geproduceerd, was het eerste eiwit
waarin Gla werd aangetoond. Daarom werden lever homogenaten als uitgangs-
materiaal gebruikt voor de ontwikkeling van de eerste enzymsystemen waarin
vitamine K afhankelijke carboxylering kon worden gemeten. Het werd later
duidelijk dat carboxylase in veel weefsels gevonden wordt zoals o.a. in de nier,
milt, testes, long, vaatwand en bot. Tenminste zes Gla bevattende eiwitten zijn
betrokken bij het bloedstollingsproces, waarbij de aanwezigheid van Gla een be-
langrijke voorwaarde is voor hun biologische activiteit. Daarom is voldoende
aanvoer van vitamine K van essentieel belang voor een normaal bloedstollings-
proces. Behalve een tekort aan vitamine K kan ook de inname van 4-hydroxy-
coumarine derivaten leiden tot de uitscheiding van niet volledig gecarboxyleerde
Gla eiwitten. Tijdens coumarine behandeling wordt het enzym KO-reductase
geblokkeerd waardoor de vitamine K cyclus wordt onderbroken. Dit heeft tot
gevolg dat het circulerend KO niveau zal stijgen en de KHj voorraad snel zal
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afnemen. Dit zal leiden tot een ophoping van niet gecarboxyleerde eiwitten in
het endoplasmatisch reticulum en als de blokkade wordt voortgezet uiteindelijk
tot de uitscheiding van niet of gedeeltelijk gecarboxyleerde eiwitten (descar-
boxyeiwitten). Of deze descarboxyeiwitten al dan niet worden uitgescheiden
hangt af van de dosis en de duur van de coumarine behandeling evenals van de
behandelde species. Bij de koe en de mens worden descarboxyeiwitten in het
bloed uitgescheiden waaruit zij gezuiverd kunnen worden met gebruikelijke
zuiveringstechnieken. In de beginjaren van carboxylering werd aangenomen dat
deze descarboxyeiwitten als substraat konden dienen voor het enzym y-gluta-
mylcarboxylase en dat het carboxyleringsproces gevolgd kon worden door
meting van de toename van de biologische activiteit van de descarboxyeiwitten.
We weten nu echter dat door de afwezigheid van een herkenningsplaats descar-
boxyeiwitten geen goede substraten zijn en dat daardoor de destijds gevolgde
procedure niet succesvol kon zijn. De ontwikkeling van reagentia waarmee
gevoelige stollingsbepalingen werden opgezet kan beschouwd worden als een
nuttige zijlijn uit deze periode. Met behulp van deze reagentia kon de door
Hemker et al. gepostuleerde stollingskinetiek bewezen worden. In hoofdstuk 2
wordt de bereiding en de gevoeligheid van deze reagentia beschreven evenals
een verbeterde methode voor de scheiding en detectie van descarboxy- en nor-
male stollingsfactoren met behulp van HPLC.
In hoofdstuk 3 wordt de optimalisering van de vitamine K afhankelijke car-
boxylering in vitro beschreven. Omdat gezuiverd carboxylase een absolute nood-
zaak is om het carboxyleringsmechanisme te kunnen begrijpen, is de zuivering
van carboxylase in de afgelopen jaren het voornaamste doel geweest van veel
onderzoekers. Hoewel rattelever meestal gebruikt werd als uitgangsmateriaal
voor de bereiding van microsomen is dit in ons lab altijd lever van de koe
geweest. Onze pogingen om y-glutamylcarboxylase te zuiveren hebben geleid tot
de ontwikkeling van twee methoden voor de bereiding van gedeeltelijk gezuiver-
de preparaten. Het eerste preparaat is gebonden aan een vaste drager, het tweede
in oplossing. Hoewel geen van beide methoden een gezuiverd enzym hebben
opgeleverd, speelden beide preparaten wel een belangrijke rol bij de bepaling
van de optimale condities voor carboxylering en bij de ontdekking van een
aantal essentiële kenmerken, welke o.a. geleid hebben tot de uiteindelijke zuive-
ring van het enzym. Opmerkelijke bevindingen waren dat de carboxylaseactivi-
teit gestimuleerd werd door een aantal organische oplossingen en door hoge
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concentraties
In hoofdstuk 4 wordt de aandacht gericht op de cofactor voor carboxylase,
vitamine K. Tijdens de vorming van Gla residuen wordt KH2 omgezet in K
epoxide (KO). In vitro wordt onder normale condities de recycling van vitamine
K gekatalyseerd door dithiol-afhankelijke reductases. Na toediening van warfa-
rine echter wordt het KO-reductase geremd, wat een onderbreking van de K
cyclus en daardoor een onvolledige carboxyleringsreaktie tot gevolg heeft. Bij
carboxylase uit placenta werd gevonden dat alleen vitamine K hydroquinon en
niet vitamine K quinon als cofactor gebruikt kon worden in de carboxyleringsre-
aktie, in tegenstelling tot levercarboxylase. Waarschijnlijk komt dit door de
afwezigheid van het dithiol-afhankelijke K-reductase in deze preparaten. In het
tweede gedeelte van hoofdstuk 4 worden twee verschillende vormen van vita-
mine K bestudeerd die in de natuur gevonden worden: vitamine K, (phyllo-
quinon) en vitamine Kj (menaquinonen). Beide vormen worden gekenmerkt door
een functionele naftaquinon ring en een alifatische zijketen. Phylloquinon wordt
voornamelijk gevonden in groene planten, terwijl menaquinonen worden gepro-
duceerd door o.a. de bacteriën in de darm. De mate waarin beide vitamines K
een rol als cofactor spelen bij de carboxylering van de bloedstollingsfaktoren
wordt nog steeds onderzocht. De cofactoractiviteit van phylloquinon en een
aantal menaquinonen werd vergeleken in levercarboxylase. De cofaktoractiviteit
van de menaquinonen bleek afhankelijk van de lengte van de alifatische zijk-
eten en was optimaal bij menaquinon-3. In vitro werden zowel vitamine K, als
vitamine Kj snel omgezet in een mengsel van de quinon, de hydroquinon en de
epoxide vorm. Het feit dat in evenwichtstoestand de hoeveelheid van deze drie
metabolieten onafhankelijk was van het uitgangsvorm bewijst dat de vitamine K
cyclus zowel met vitamine K, als met vitamine Kj werkt. Tenslotte wordt in dit
hoofdstuk een allosterische interactie tussen de vitamine K bindingsplaats en de
propeptide bindingsplaats bij carboxylase beschreven. Hierbij werd gevonden dat
de affiniteit van KHj voor het enzym/substraatcomplex ongeveer 20 maal groter
was dan voor carboxylase alleen.
In hoofdstuk 5 worden enkele aspecten onderzocht van de reductases die betrok-
ken zijn bij de recycling van vitamine K. Beide reductie-stappen in de vitamine
K cyclus kunnen uitgevoerd worden door dithiol-afhankelijke reductases. Onder-
zocht wordt nog altijd of deze activiteit gekatalyseerd wordt door één of meer-
dere enzymen. Mutaties, gevonden in twee verschillende gevallen van warfarine
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resistentie, ondersteunen echter sterk de theorie dat slechts één reductase zorgt
voor recycling van vitamine K. In vitro kunnen zowel het synthetische dithio-
threitol (DTT) als gereduceerd thioredoxine optreden als reducerende cofactor
voor het KO- en K-reductase. In vitro werd aangetoond dat de vorming van
disulfide bruggen gekoppeld kan worden aan de vitamine K afhankelijke car-
boxylering van glutaminezuur residuen. In vivo zijn zowel de disulfide vorming
als de vitamine K afhankelijke carboxylering posttranslationele modificaties die
plaatsvinden aan de luminale zijde van het endoplasmatisch reticulum. Het is
mogelijk dat ook in vivo beide reacties gekoppeld zijn, waarmee dan ook een
verklaring gevonden zou zijn voor de herkomst van de reducerende equivalenten
die nodig zijn bij carboxylering en voor de herkomst van de oxiderende equiva-
lenten die nodig zijn voor de vorming van een disulfide band. Aan het eind van
dit hoofdstuk wordt een model gepresenteerd waarin deze hypothese uitgewerkt
is.
In hoofdstuk 6 worden enkele gegevens beschreven van substraten in de vita-
mine K afhankelijke carboxylerings reactie. In de afgelopen 15 jaar zijn er twee
soorten substraten ontwikkeld: substraten met en zonder de prosequentie zoals
die gevonden wordt in de natuurlijke Gla-eiwitten. Voorbeelden van het eerste
type zijn FLEEL en FLEEV. Alle substraten van dit type worden gekenmerkt
door hoge K^-waarden. Het feit dat poly-Glu preparaten dezelfde Kn/^-waar-
den hebben als de pentapeptides, laat zien dat een specifieke aminozuurvolgorde
geen essentiële voorwaarde is voor carboxylering. In vitro werd aangetoond dat
Glu-bevattende substraten betere substraten zijn wanneer zij een propeptide-
sequentie bevatten. Deze verbetering wordt veroorzaakt door een verlaging van
de K^P-waarde. Voorbeelden van substraten voor de in vitro reactie die een
propeptidesequentie bevatten zijn bijvoorbeeld pro-PT28 en recombinant factor
IX. De in vitro carboxylering van het laatstgenoemde substraat, geproduceerd
door een CHO cellijn, wordt beschreven evenals de identificatie van het ge-
vormde produkt. Tenslotte word aangetoond dat een peptide, bestaande uit 59
aminozuurresiduen met daarin de propeptide volgorde en het Gla-domein (resi-
duen -18 tot 41) van humaan factor IX (FIXGla), een goed substraat is voor
carboxylase in vitro. De K.,^ (0.55 uM) is enige duizenden malen lager dan die
van proPT28 en die van proFIX28. Het is het eerste peptidesubstraat waar in
vitro meer dan één Glu per molecule werd gecarboxyleerd (6-11 Gla's per
molecule). Tevens werden peptides gemaakt met mutaties gelijk aan die in
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Dimas en ïTQ^mbndge' ^n een peptide met beide mutaties in de prosequentie.
Kinetische studies toonden geen wezenlijke verschillen in V„„"^ en K ^ tussen
normale en gemuteerde substraten, waarmee wordt aangetoond dat arginines op
de posities -4 en -1 niet noodzakelijk zijn voor y-carboxylering.
De zuivering van y-glutamylcarboxylase is bewerkelijker en complexer gebleken
dan men zich in eerste instantie voor kon stellen. Op dit ogenblik is gezuiverd
carboxylase beschikbaar in tenminste drie leidende onderzoeksgroepen, hetgeen
betekent dat we nu op een keerpunt staan in het carboxylaseonderzoek: achter
ons ligt een periode waarin dit onderzoek uitsluitend werd uitgevoerd in on-
gezuiverde systemen. Door de beschikbaarheid van gezuiverd carboxylase is dit
onderzoeksgebied eindelijk naar volwassenheid gegroeid. Voor ons liggen we-
tenschappelijke uitdagingen, zoals de opheldering van het gedetailleerde me-
chanisme van de carboxyleringsreaktie, het mechanisme voor het stoppen van de
Gla-vorming nadat in een eiwit een strikt gedefinieerd aantal Gla-residuen is
gevormd, en ook de mogelijke interacties tussen carboxylase en andere post-
translationele modificaties. We hopen en verwachten dat de Maastrichtse groep
actief zal blijven deelnemen aan dit fascinerende onderzoeksgebied.
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